methusalem report 2010 final - universiteit hasselt · headed: samuel coenen (100% bap research...

Methusalem Report 2010

University of Antwerp Centre of Excellence: Vaccine & Infectious Disease Institute VAXINFECTIO

Hasselt University Center for Statistics CenStat

- Table of Contents -

2

- Methusalem Report 2010 -

3

Table of Contents

1 Methusalem Consortium ............................................................................................................................. 9

1.1 Composition of the Methusalem Consortium ...................................................................................... 9

1.2 Organisational structure of the Methusalem Consortium ................................................................. 11

1.3 Management structure of the Methusalem Consortium ................................................................... 13

1.4 The Methusalem Consortium within the University of Antwerp & Hasselt University ....................... 14

Vaxinfectio as formal Institute within the Faculty of Medicine (UA) .......................................................... 14

Recognition of Vaxinfectio research groups within the University of Antwerp .......................................... 15

Facilities (UA) ............................................................................................................................................ 15

Facilities (UHasselt) ................................................................................................................................... 16

2 Objectives of the Methusalem Consortium ............................................................................................... 17

3 Research Activities 2010 ........................................................................................................................... 19

4 Dissemination Activities ............................................................................................................................ 25

4.1 Scientific papers in peer reviewed journals ....................................................................................... 25

4.2 Yearbooks .......................................................................................................................................... 25

4.3 Workshops/Conferences/summer course ......................................................................................... 26

Methusalem Research Days ...................................................................................................................... 26

Valentijn Vaccinatiesymposium ................................................................................................................. 26

Scientific Chair in Evidence Based Vaccinology .......................................................................................... 26

ESAC Meetings .......................................................................................................................................... 27

GRACE Meetings/workshops ..................................................................................................................... 28

VHPB Meetings ......................................................................................................................................... 29

Summer Course in Vaccinology ................................................................................................................. 30

AUHA Research Days ................................................................................................................................. 31

4.4 Intellectual property rights ................................................................................................................ 32

5 Communication ......................................................................................................................................... 35

5.1 Press releases .................................................................................................................................... 35

5.2 Website ............................................................................................................................................. 38

5.3 Newsletters ....................................................................................................................................... 39

6 International and National Collaborations................................................................................................. 41


4

6.1 Strategic collaborations with other research groups & industry ........................................................ 41

National Collaborations ............................................................................................................................. 41

International Collaborations ...................................................................................................................... 44

6.2 Ad hoc collaboration with industry .................................................................................................... 51

6.3 Flanders Vaccine ................................................................................................................................ 52

7 External Research Funding ........................................................................................................................ 53

7.1 Overview of submitted projects 2010 ................................................................................................ 53

7.2 Overview of granted projects 2007‐2010 .......................................................................................... 56

7.3 Project proposals in the pipeline 2011 .............................................................................................. 74

7.4 Difficulties encountered with obtaining additional funding ............................................................... 75

8 Human Resources ..................................................................................................................................... 77

8.1 Overview of Methusalem Personnel .................................................................................................. 77

8.2 Opportunities for Postdoctoral Researchers ...................................................................................... 78

8.3 PhD students & PhDs obtained .......................................................................................................... 78

9 Budget & Investments ............................................................................................................................... 81

9.1 Overall budget 2008‐2014 ................................................................................................................. 81

9.2 Budget Vaxinfectio ............................................................................................................................ 81

Investments in expert personnel 2010 ...................................................................................................... 81

Investments in state‐of‐the‐art technologies, methodologies and equipment 2010 ................................. 81

Future Investments in state‐of‐the‐art technologies, methodologies and equipment ............................... 82

9.3 Budget CenStat .................................................................................................................................. 82

Investments in expert personnel 2008‐2009 ............................................................................................. 82

Future Investments ................................................................................................................................... 83

10 Annexes .................................................................................................................................................... 85

10.1 ANNEX I: Administrative Information ................................................................................................ 87

10.2 ANNEX II: Minutes of the meeting of the Board of Directors ............................................................. 89

10.3 ANNEX III: List of Papers, Books and Book chapters 2010 .................................................................. 93

10.4 ANNEX IV: Programme of the Methusalem Research Day n°3 (2010) ................................................ 99

10.5 ANNEX V: Extracts of the Flemish Government Directive ................................................................ 101

10.6 ANNEX VI: Personnel list anno 2010 ................................................................................................ 109


5


6


7

Methusalem Key Features Strengths

Multidisciplinary Consortium Vaxinfectio is recognised as Center of Excellence Vaxinfectio is recognised as WHO Collaborating Center on Vaccines and Infectious Diseases Employing 141 staff members of which 65 PhD students Over 200 papers published for the period 2008‐2010 of which 12 joint publications Vaxinfectio‐CenStat in 2010

Organisation of annual Methusalem Research Days Over 60 new project proposals submitted in 2010. More than M€20 of external funding obtained in 2010 Large number of EU‐funded projects Large number of industrial collaborations and industry‐funded projects Large number of national and international collaborations (over 35 countries)

Threats

Incompatibility of Methusalem Funding with other BOF Funding Future of Methusalem Funding Too few permanent staff employed jeopardizing future FP7, DG Sanco and other EU grant applications

Lack of mid‐level postdoctoral researchers leading to discontinuity of research Lack of (research) professorships at the Faculty of Medicine Lack of opportunity to be assigned as core facilities by the University of Antwerp Lack of space (labs/offices)

- Methusalem Key Features -

8


1 Methusalem Consortium

1.1 Composition of the Methusalem Consortium The Methusalem Consortium is an interuniversity collaboration between:

• The Vaccine & Infectious Disease Institute ‐ Vaxinfectio, University of Antwerp • The Centre for Statistics ‐ CenStat, Hasselt University

- Methusalem Consortium -

10

UNIVERSITY of ANTWERP Methusalem Team leader: Prof. Dr. Herman Goossens Research Unit: University of Antwerp, Vaccine & Infectious Disease Institute: VAXINFECTIO Chair: Prof Dr. Pierre Van Damme Vice‐chairs: Prof. Dr. Herman Goossens & Prof. Dr. Zwi Berneman Research & Innovation Manager (IOF): Dr. Vanessa Vankerckhoven Administrative coordinator: Gino Verwimp Administrative staff: Emmy Engelen & Sophie Nys Participating Research Units in the Institute: 1) Centre for the Evaluation of Vaccination (CEV), Faculty of Medicine.

Head: Pierre Van Damme (100% ZAP) ‐ Koen Van Herck (10% ZAP)

Collaborating unit: Research Unit Health Economics and Mathematical Modelling of Infectious Diseases (CHERMID) Head: Philippe Beutels (100% ZAPBOF) ‐ Niel Hens (50% ZAP) ‐ Olivier Lejeune (100% postdoc BAP) ‐ Andraud Mathieu (100% postdoc BAP)

2) Laboratory of Medical Microbiology, Faculty of Medicine. Head: Herman Goossens (100% ZAP) ‐ Greet Ieven (10% ZAP) ‐ Katherine Loens (80% postdoc BAP) ‐ Surbhi Malhotra (100% postdoc BAP) ‐ Arno Muller (100% postdoc BAP)

Collaborating unit: Research Unit Infectious Diseases (RUID) Headed: Samuel Coenen (100% BAP Research Leader) ‐ Sibyl Anthierens (80% postdoc BAP)

3) Laboratory of Experimental Hematology (LEH), Faculty of Medicine.

Head: Zwi Berneman (100% ZAP) ‐ Peter Ponsaerts (100% postdoc BAP) ‐ Wilfried Schroyens (10% ZAP) ‐ Nathalie Cools (100% postdoc BAP) ‐ Katrien Vermeulen (100% postdoc BAP) ‐ Bart Tambuyzer (100% postdoc BAP)

Collaborating unit: Centre for Cell Therapy and Regenerative Medicine (CCRM), University Hospital Antwerp (UZA) Head: Viggo Van Tendeloo (100% ZAPBOF) ‐ Evelien Smits (100% postdoc BAP)


HASSELT UNIVERSITY Methusalem Team leader: Prof. Dr. Geert Molenberghs Research Unit: Center for Statistics (CenStat), Department of Mathematics, Physics and Computer Sciences. Head: Geert Molenberghs (100% ZAP) - Marc Aerts (100% ZAP) - José Cortiñas (100% postdoc BAP) - Christel Faes (100% ZAP) - Niel Hens (50% ZAP) - Ziv Shkedy (100% ZAP)

1.2 Organisational structure of the Methusalem Consortium Centre for the Evaluation of Vaccination

VAXINFECTIO

Medical Microbiology

Vaccinology, Infectious Disease Epidemiology, Health Economics and

Modelling

CEVPierre Van Damme, MD, PhD

Director

Clinical /Vaccine Trials (CT)Head CT‐teamFroukje Kafeja, MD

CT PhysiciansIlse De Coster, MDAnnick Hens, MD

CT NursesAline BontenakelSerge Broodhaers

Annemie BruynseelsAnnelies Van Winckel

Project AdministratorNaïma Dighou

Study Coordinator

Q‐management

Leen Suykens, MSc

Infectious Diseases Epidemiology projects, Education and Training

Tessa Braeckman, MScGreet Hendrickx, MScElke Leuridan, MDHeidi Theeten, MD

Koen Van Herck, MD, PhD (10%)Alex Vorsters, MSc

PhD StudentsBeatrice de Vos, MD

Germaine Hanquet, MDVeronik Hutse, MScIsabel Micalessi, MScPieter Neels, MD

Martine Sabbe, MD

CHERMIDPhilippe Beutels, MSc, PhD

Director

Health Economics

PhD StudentsJoke Bilcke, MSc

Adriaan Blommaert, MSc (50%)Jessica Fraeyman, MSc, Visiting

Jeroen Luyten, MSc

Biostatistics and Modelling

Chair in Evidence Based Vaccinology

Niel Hens, MSc, PhD (50%)

Postdoctoral ResearchersMathieu Andraud, MSc, PhDOlivier Lejeune, MSc, PhD

PhD StudentsAdriaan Blommaert, MSc (50%)Nele Goeyvaerts, MSc, visitingBenson Ogunjimi, MSc, MD

Kim van de Kerckhove, MSc, visitingLander Willem, MSc

Project AdministrationSophie Nys (50%)

Project AdministrationEmmy EngelenGino Verwimp

Experimental Hematology

Research and Innovation ManagerVanessa Vankerckhoven, Msc, PhD

Project administrationEmmy EngelenSophie Nys

Gino Verwimp


Laboratory of Medical Microbiology

Vaxinfectio

Medical

Microbiology

LMM

Herman Goossens, MD, PhD

Director

Post Doctoral researchers & Part‐time ZAP

Sibyl Anthierens, MD, PhD (80%)

Samuel Coenen, MD, PhD (70% BAP / 30% ZAP)

Surbhi Malhotra, Msc, PhD (100% BAP)

Arno Muller, Msc, PhD (100% BAP)

Katherine Loens, Msc, PhD (80% BAP)

PhD students

Niels Adriaenssens, MD

Muriel Gazin, MSc

Katrien Latour, Msc

Fabienne Paasch, MSc

Liesbet Vanheirstraeten, MSc

Evelyn Vanhommerig, MSc

Jascha Vervoort, MSc

Ann Versporten, MSc

Peter Zarb, Msc

Technicians

Liesbeth Bryssinck

Sabine Chapelle

Christine Lammens

Gert Leten

Anouk Vanderstraeten

Greetje Vercauteren

Consultants

Nico Drapier (IT development)

Project Administration

Anne Struyven

Sophie Nys

Greet Van kerckhoven

Vaccinology, Health Economics and Modelling

Experimental

Hematology

Research and Innovation Manager

Vanessa Vankerckhoven


Emmy Engelen

Sophie Nys

Gino Verwimp


Laboratory of Experimental Hematology

1.3 Management structure of the Methusalem Consortium Director: Prof. Dr. Herman Goossens Board of Directors: Chair: H. Goossens, Vice‐chair: G. Molenberghs Composed of the heads of the 4 participating core research groups, the (part‐time) ZAP members (9), all postdocs (13), Research & Innovation Manager, administrative coordinator, one administrative officer Department of Research (ADOC) and the chairman of the Research Council. Total: 28 members. Meeting frequency: at least once per year Composition per (per 01/09/2010): 31 Present number Goossens Herman, Chair and Head LMM (UA) Molenberghs Geert, Vice‐chair and Head CenStat (UH) Van Damme Pierre, Head CEV (UA) Berneman Zwi, Head LEH (UA) Vankerckhoven Vanessa, Research & Innovation Manager (IOF) – (UA) Verwimp Gino, Administrative coordinator (UA) Spruyt Eric , Head Department of Research, ADOC (UA)


Emmy Engelen

Sophie Nys

Gino Verwimp

VAXINFECTIO

Medical

Microbiology

Vaccinology, Health

Economics and

Modelling

Experimental

Hematology

LEHZwi Berneman, MD, PhD

Director

ZAP

Wilfried Schroyens (10%)

Viggo Van Tendeloo (100% ZAPBOF)

PhD students

Sébastien Anguille, Msc

Eva Lion, Msc

Amber Nuyts, Msc

Kristien Reekmans, Msc

Ann Vandriessche, Msc

Technicians

Jasmijn Daans

Kevin Lenders

Charlotte Quisquater

Barbara Stein

Visiting professors

Ludo Muylle

Alain Gadisseur

Dirk Van Bockstaele

Ann Van de Velde

Marc Van der Planken

Post Doctoral researchers

Irene Bergwerf, Msc, PhD

Nathalie Cools, Msc, PhD

Peter Ponsaerts, Msc, PhD

Evelien Smits, Msc, PhD

Bart Tambuyzer, Msc, PhD

Katrien Vermeulen, Msc, PhD

Research and Innovation Manager

Vanessa Vankerckhoven, MSc, PhD


14

Peters Ann, Head Research Coordination (UH) Timmermans Jean‐Pierre, Chairman Research Council (UA) Janssen Paul, Chairman Research Council (UH) Aerts Marc (100% ZAP) (UH) Beutels Philippe (100% ZAPBOF) (UA) Faes Christel (100% ZAP) (UH) Hens Niel (100% ZAP) (UA/UH) Shkedy Ziv (100% ZAP) (UH) Van Tendeloo Viggo (100% ZAPBOF) (UA) Ieven Greet (10% ZAP) (UA) Schroyens Wilfried (10% ZAP) (UA) Van Herck Koen (10% ZAP) (UA) Andraud Mathieu (100% postdoc BAP) (UA) Anthierens Sibyl (80% postdoc BAP) (UA) Coenen Samuel (100% BAP) (UA) Cools Nathalie (100% postdoc BAP) (UA) Loens Katherine (80% postdoc BAP) (UA) Malhotra Surbhi (100% postdoc BAP) (UA) Muller Arno (100% postdoc BAP) (UA) Ponsaerts Peter (100% postdoc BAP) (UA) Smits Evelien (100% postdoc BAP) (UA) Tambuyzer Bart (100% postdoc BAP) (UA) Vermeulen Katrien (100% postdoc BAP) (UA) Board of Advisors: Chair: H. Goossens Composed of one administrative member ADOC and researchers with international recognition in the research field:

• Haruo Sugiyama, MD, PhD, Professor, Department of Functional Diagnostic Science Osaka University Graduate School of Medicine 1‐7, Yamada‐Oka, Suita City Osaka, Japan (confirmed);

• Ron Dagan, Professor of Pediatrics and Infectious Diseases, Ben Gurion University, and director of the pediatric infectious disease unit of Soroka University Medical Center and at Ben Gurion University, Beer‐Sheva, Israel (confirmed)

• Christopher C Butler, Professor and Head of Primary Care Medicine, Centre for Health Sciences Research, School of Medicine, Cardiff University (confirmed)

Meeting frequency: at least once per year

1.4 The Methusalem Consortium within the University of Antwerp & Hasselt University

Vaxinfectio as formal Institute within the Faculty of Medicine (UA) In 2007, the Vaccine and Infectious Disease Institute (Vaxinfectio), composed of three research units and three collaborating units (see 1.1), was founded within the University of Antwerp and more specifically within the Faculty of Medicine. As from October 2009, all staff members of the Institute belong to the Department Vaxinfectio within the Faculty of Medicine. Within this unit, sub‐units have been formed, based on the specific research units composing the department and their leading researchers:


15

• Vaxinfectio‐Laboratory of Medical Microbiology (lead by Prof. Dr. Herman Goossens) • Vaxinfectio‐Center for Evaluation of Vaccination (lead by Prof. Dr. Pierre Van Damme) • Vaxinfectio‐Laboratory of Experimental Hematology (lead by Prof. Dr. Zwi Berneman)

Recognition of Vaxinfectio research groups within the University of Antwerp Currently, all ongoing and past research projects are currently recorded in the central research database under the common denominator of the "Vaxinfectio" department ('vakgroep'). This database is managed by the Department of Research (ADOC) and is for Vaxinfectio accessible through the following link: (http://www.ua.ac.be/main.aspx?c=.ONDERZKDB&n=40309&id=UA120&tid=21097&showproj=1). As a consequence of the current reporting system, the 3 research groups and the 3 collaborating units that constitute the Methusalem Consortium on the UA side, cannot be traced on an individual basis in the research database made available by ADOC. However following a request for an update of the underlying database structure, Vaxinfectio submitted 4 abstracts, one abstract with a framework text for Vaxinfectio and 3 abstracts covering the research topics of the three core groups. The Faculty has decided that their organisational structure, which is composed of 11 departments ('vakgroepen') also counts for the research structure. This decision is rather unfortunate for various reasons. Firstly, it limits the visibility of the separate research groups in term of representing their specific identity (f.i. CEV a clinical trial platform). Secondly, it limits the opportunities in terms of applying for certain funding at the level of the Special Reseach Fund (BOF). Finally, it has an effect on the functional organisation of a research visitation at the level of the individual 'research team', which is legally required every 7 years. Therefore, action will be taken to the appropriate policy levels in order to remediate this situation.

Facilities (UA) Already at the start of the Methusalem funding in 2008, it became apparent that insufficient office and lab space was available to house all staff members that were part of the Consortium, in particular the staff of Vaxinfectio at the University of Antwerp. During the years 2008, 2009 and also 2010, the number of staff even further increased within Vaxinfectio. Chapter IVbis of the Directive of the Flemish Government states the rules on Methusalem Funding. In this Chapter, Article 14decies §4 clearly states that ‘The University provides the necessary rooms and basic facilities to the ZAP member and his/her research group’. After numerous consultations and discussions with the UA rector, the UA general manager and his staff, a few possibilities were proposed to improve the lack of space. Currently, office and lab space is available for all staff members of the different research units, albeit with insufficient expansion opportunities for several of the research units and the staff scattered over the University Campus and the University Hospital. Moreover, the CHERMID and LMM staff is currently mainly located in former labs that were used by the Department of Pharmacy. Indeed, the staff is currently located on different floors of three buildings (R, S and T) at the UA Campus Drie Eiken, as well as at the site of the University Hospital (UZA). The CEV staff can be found on the second floor of Building R. The CHERMID staff is located on the 4th floor of Building S, together with part of the staff of LMM. The lab of LMM is situated on the 3th floor of Building S. The RUID staff is located in Building R on the 3th floor. LEH has a lab in Building T and the remainder of the staff as well as the CCRM staff is located at UZA. The plans to regroup the Institute in one location have been cancelled for the moment. Instead, at the end of 2011 the staff of LMM will be joined on the 6th floor of Building S, together with the lab of LEH. The remainder of the LEH and CCRM staff will stay at UZA. The RUID staff will stay on the 3th floor of Building R. The CHERMID staff will be spread together with the CEV staff over the second floor of the R building and the 2nd floor of the S building.


16

Facilities (UHasselt) The Center for Statistics at Hasselt University (former Limburgs Universitair Centrum) was founded in May 1998 as a result of a growing applied statistics branch within the university. The scientific research conducted within the Center for Statistics (CenStat) is internationally renowned, both for its theoretical as well as for its applied component. Also the education and consultancy records are excellent. Over the years CenStat has collaborated with many (inter)national institutions within and outside UHasselt, of which a fruitful collaboration of more than a decade with CEV, UA and with the other Vaxinfectio institutes has led to its participation in the Methusalem Consortium. The Methusalem funding enables joining the expertise of Vaxinfectio and CenStat on a long term basis with shared appointments, enabling the consortium to play a pivotal role internationally. An ideal setting of what could become a more structural collaboration such as given by the unification of CenStat, UHasselt and the Biostatistical Centre at the Catholic University of Leuven in the Interuniversity Institute of Biostatistics and statistical Bioinformatics (I‐Biostat), anno 2008, strengthening both centres’ expertise in biostatistics, applied statistics and bioinformatics.


17

2 Objectives of the Methusalem Consortium The main basic research aim of the Consortium is to study microbiological, immunological, mathematical‐biological, statistical, economical, societal and epidemiological aspects of infectious diseases and vaccines. The constituting research teams of the Consortium will use the Methusalem funding to create a science platform with an aim (1) To structure and consolidate the existing pool of knowledge and expertise in their respective

disciplines with targeted investments in qualified personnel, state‐of‐the‐art equipment and sufficient operational resources, and

(2) To advance knowledge and expertise in the listed scientific fields with focus on multidisciplinarity and based on the highest quality standards, with a view to attract additional resources and to increase its scientific output.

- Objectives of the Methusalem Consortium -

18


3 Research Activities 2010

Figure 3.1: dynamics of the research within the Methusalem Consortium

Table 3.1 Overview of ongoing joint research activities

BASIC QUESTION CLINICAL RESEARCH BASIC RESEARCH PARTNERS

INVOLVED

A 1. Correlation of humoral

and cellular response in

vaccinees? Correlation with

protection?

2. Duration of cell‐

mediated immunological

(CMI) responses?

3. Immune tolerance

mechanisms in infectious

agents and tumours?

4. Mechanisms in non‐

response to vaccination

5. Immunoscence

1. Vaccine studies CEV

2. Long‐term follow‐up

studies CEV

3. Phase I therapeutic DC

vaccines in tumour, HIV

and CMV patients

4. Vaccine trials CEV

(hepatitis B, influenza)

5. Low influenza vaccine

response in elderly

1. Analyzing vaccine‐induced

T cell responses by multi‐

parametric flow cytometry

and in vitro restimulation

cytokine assays

2. Modelling vaccine‐induced

cellular responses as a

function of time

3. in vitro studies of dendritic

cells and their interation on

suppressor T‐cells

4. Analyzing genetic factors

in non‐responders

5. Analysis of the impact of

CMV infection on the

immune system of elderly

CEV, LEH,

CenStat

- Research Activities 2008-2009 -

20


INVOLVED

B 1. Role of TLR stimulation

in innate and adaptive

immunity to microbes and

tumours?

2. Role of TLR signalling and

the immune modulatory

effects of probiotic

lactobacilli

1. Therapeutic DC vaccine

trials

2. ‐

1. Effect of in vitro TLR3

signalling on the induction of

antiviral and anti‐tumoural T

cell responses.

2. Measuring TLR signalling

and effect of probiotics on

signalling, on transfected cell

lines and by ELISA.

LMM, LEH,

CenStat

C 1. Impact of vaccination on

pneumococcal carriage?

2. Impact of vaccination

programmes on

epidemiology of Hib,

rotavirus, pertussis and

meningococcus

1. oropharyngeal carriage

in (family contacts of)

infants during first year of

life

2. (molecular)

epidemiology in (family

contacts of) infants during

first year of life

1. & 2. Quantification of

penumococcal carriage,

serotyping by Quellung

reaction, strain typing by

multilocus sequence typing,

and antibiotic resistance

profiling by disk diffusion,

PCR and sequencing.

CEV, LMM,

CenStat

D Effect of using new

injection devices, adapted

administration route

and/or new adjuvant

formula on vaccine

efficacy?

Phase I trials using new

injection devices, new

administration routes or

new adjuvants with

existing vaccines

CMI analysis on vaccinees

Dendritic cells as nature’s

adjuvant

TLR ligands as adjuvants

LEH, CEV,

CenStat,

Artesis

E 1. Local immune response

in vaccinees?

2. HPV identification in

urine

1. Phase I HPV trial

2. Use of urine for HPV

screening as diagnostic or

for public health purposes

1. Analyzing CMI responses

in cervical secretions

2. Development of a urine

test based on HPV DNA

CEV, LEH,

LMM


21


INVOLVED

F 1. Neonatal/infant

immunity? Impact of

maternal antibodies?

2. Changes in the intestinal

microbiotome of infants

with asthma and effect of

prebiotics on the

development of asthma?

3. Differences in the

microbiotome of infants

with obesity vs non‐obesity

1. Longitudinal studies in

pregnant women and their

infants

2. Double blind placebo

controlled intervention

study on 200 neonates

3. Pilot study in 60 infants

1. Analysing humoral and

cellular immunity and

statistical modelling

2. Quantitative analysis of

faecal samples by phenotypic

methods and population

fingerprinting to

elucidate/type bacterial

species by denaturing

gradient gel electrophoresis.

3. Quantitative analysis of


methods and real‐time PCR

to detect differences in

bacterial genera and species.

CEV, LMM,

LEH, CenStat

G Kinetics of cellular‐

mediated immunity to

varicella zoster virus after

contact with a primary

case?

Longitudinal study in

contact persons of children

with primary varicella

infection

Analyzing vaccine‐induced T

cell responses by multi‐

parametric flow cytometry

and in vitro restimulation

cytokine assays

CEV, LEH,

CenStat

H Changes in the intestinal

microbiotome of patients

with irritable bowel

syndrome (IBS) and effect

of probiotics on IBS?

Clinical trial administering

probiotics to IBS patients

and healthy volunteers

Quantitative analysis of


methods and real‐time PCR

to detect differences in

bacterial genera and species.

LMM, Censtat


22


INVOLVED

I 1. Mechanisms of

resistance and phenotypic

tolerance selected by

amoxicillin therapy?

2. Mechanisms of

resistance and selection

dynamics of

fluoroquinolones (FQs),

ciprofloxacin and

levofloxacin exposure on

the human oropharyngeal

and gastrointestinal flora?

1. A randomized placebo‐

controlled prospective

study in patients with

community‐acquired lower

respiratory tract infections

conducted as part of the

ongoing FP6 project GRACE

and the ongoing FP7

project TheraEdge

2. A randomized placebo‐

controlled trial in healthy

volunteers

1. Quantitative analysis by

phenotypic methods of

changes in the oral

streptococcal flora and

genotypic methods to study

resistance mechanisms pre

and post‐amoxicillin therapy.

Analysing phenotypic

tolerance by spectrometric

quantification of elaborated

β‐lactamases and visualising

biofilm formation by FISH

analysis.

2. Quantitation of FQ‐

resistant Escherichia coli and

streptococci in faecal and

throat samples pre and post‐

therapy. Analysis of FQ‐

resistant mechanisms and

genetic relatedness of

isolates by PCR/sequencing,

SDS‐PAGE, growth inhibition

assays, and pulsed‐field gel

electrophoresis.

LMM, CEV,

CenStat

J Carriage and transmission

dynamics of (resistant)

bacteria?

Data from clinical trials in

section I

Deterministic dynamic

transmission models

CEV,

LMM,CenStat

K Mechanism of innate

immunity in the central

nervous system?

‐ Development of multimodal

imaging strategies to

monitor inflammation and

cellular implants/vaccines in

the central nervous system.

LEH, CenStat


23


INVOLVED

L 1. Best strategy to diagnose

M. pneumoniae and C.

pneumoniae LRTIs?

2. Development of an

evidence‐based

intervention package for a

more targeted antibiotic

policy in lower respiratory

tract infections (LRTI) in

primary care in Europe, and

to assess effectiveness of

the implementation of this

model

1. A prospective study in

patients with community‐

acquired lower respiratory

tract infections

2. Prospective case‐control

study in adults presenting

with LRTI at their GP

1. Evaluation of different

tests for the detection of

Mycoplasma pneumoniae

and C. pneumoniae in

patients with lower

respiratory tract infections

(LRTI)

2. Development diagnostic

models to differentiate

between 1) viral and

bacterial infections and 2)

CAP and other, construct a

simple algorithm that can be

applied in daily practice and

will enable the GP to discern

patients at risk for

complications from patients

with self‐limiting disease

with low risk for poor

outcome

LMM, CenStat

M Antmicrobial consumption

and resistance patterns in

Europe

Assess the quality of

antimicrobial consumption

in ambulatory care,

hospital care and nursing

homes, explain variation,

and measure effect of

interventions

Time series and

compositional analysis of

longitudinal antimicrobial

consumption data, and

identification of appropriate

outcome measures

LMM, CenStat

N Cell migration Prospective study in mice Differences healthy brain and

intoxicated groups

LEH, CenStat

O Dendritic cells in Multiple

Sclerosis

A prospective study in MS

patients

Evaluation of DCs and Treg in

MS

LEH, CenStat


24


INVOLVED

P 1. Predictiveness of social

contacts for disease

transmission

2. Mechanisms for

parvovirus B19

transmission

3. Alternative routes to

estimate MMR vaccination

coverage

4. Correlation between

indirect costs and disease

diagnosis

5. sero‐epidemiology of

vaccine‐preventable

infections

1. population survey

through contact booklets

registries and sero‐surveys

2. serological and

immunological analysis in

mother‐infant pairs

3. immunization coverage

survey analysis

4. use of available costing

information in health

ensurance databases

5. use of sero‐survey data

1. Using serological data and

social contact data to

estimate infectious disease

parameters

2. Estimating basic

immunological processes and

maternal risk for parvovirus

B19

3. Estimating trivalent

vaccination coverage from

trivariate current status data:

application for measles,

mumps and rubella

4. Estimating indirect costs

related to pneumococcal

infections

5. Seroepidemiology of

vaccine‐preventable

infections. Estimating the

reproduction number from

final size data

CEV/CHERMID,

CenStat

Please note that Table 3.1 gives an overview of the joint research activities, for a detailled overview of research projects; please consult Tables 7.1‐7.4.


4 Dissemination Activities

4.1 Scientific papers in peer reviewed journals Figure 3.1: Number of peer‐reviewed articles published from 2008 to 2010

Importantly, the Methusalem funding made an improved scientific collaboration with the University of Hasselt possible, which is clearly indicated by the increase in the number of joint publications, ie 4 in 2008 which increased to 10 in 2009 and 12 in 2010. An overview of published papers and papers in press is given in Annex III, next to an overview of books and book chapters published by the Methusalem Consortium.

4.2 Yearbooks European Surveillance of Antimicrobial Consumption (ESAC) Yearbooks ESAC Yearbook 2008 (ISBN 9789057282911) The ESAC yearbook 2008 covers the 1999‐2008 consumption data for antimicrobials for systemic use (ATC group J01), antimycotics for systemic use (ATC group J02) and additional specific substances i.e. the data available in the ESAC database which were collected by the ESAC Management Team in 2009. Of the 35 participating countries, 30 were able to deliver 2008 outpatient data, 19 hospital data and 3 total data covering both sectors for 2008. Malta could deliver for the first time 2007 outpaient data. Also, an overview is given of the in‐depth analyses on ambulatory care, hospital care, nursing homes, and socio‐economics. Additionally, for each of the countries that provided data a country sheet summarizing their data is available in the yearbook. A PDF version of the ESAC yearbook 2008 can be consulted on the ESAC website: www.esac.ua.ac.be

57

4

2622

94

64

10

26

1319

15

79

12

2632

22

13

0

10

20

30

40

50

60

70

80

90

Total Joint UA‐UH

CEV LMM LEH CenStat

2008

2009

2010

- Dissemination Activities -

26

4.3 Workshops/Conferences/summer course

Methusalem Research Days On October 13, 2010, the third joint scientific meeting of the Methusalem Consortium was held at the premises of the University of Hasselt. Three activities were organised. In the morning, a workshop was held on Linear Models, with a hands‐on session using the statistical programme R. During lunch time, the annual meeting of the Methusalem board of directors was held. The main purpose of this meeting was, similarly to last year, to present ongoing collaborative research between UA and UH and to seek new opportunities for the future. In the afternoon, there were a series of presentations on ongoing and future joint research collaborations within the Methusalem consortium Vaxinfectio‐CenStat, with an overview by the heads of each collaborating unit (LMM, CEV, LEH and CenStat), and with specific case presentations. A presentation was held by guest speaker Hilde Van Raemdonck from Flandersbio, presenting collaboration opportunities between academia and the bio industry in Flanders and beyond. The meeting was closed by UH Rector Luc De Schepper. This third Research Day attracted a total 61 participants. Interestingly, the Research Day did attract researchers outside the Methusalem Consortium, including LMPH (Laboratory of Microbiology, Parasitology, and Hygiene), ESOC (Epidemiology and Social Medicine), and AMBIOR (Applied Molecular Biology Research group). Also, a representative from Janssen Pharmaceutica and FlandersBio attended the third Methusalem Research Day. Next to a scientific meeting, both Methusalem Research Days also provided the ideal opportunity to bring together the different members of the Board of Directors. The minutes of the Board of Directors meeting can be found in Annex II. For the programme of the Methusalem Research Day see Annex III.

Valentijn Vaccinatiesymposium In 2010, the 8th edition of the Valentijn Vaccinatiesymposium, organised by CEV, were held. The purpose of these conferences is not as much to transfer scientific knowledge, but rather to offer high quality presentations on applied live topics. The programme for 2011 will for instance cover safety monitoring of vaccines in Belgium and Europe, with a focus on H1N1 influenza vaccines, as well as a safety update on HPV vaccination. Information on these conferences can be found on: www.ua.ac.be/valentijn. Since its start, the Valentijn Vaccinatiesymposium attracted more than 250 participants each year. In 2010 we welcomed the participation of HM Princess Mathilde, and of the head of the cabinet of the Flemish Ministry of Health&Welfare, who presented the minister’s point of view on the vaccination policy in Flanders.

Scientific Chair in Evidence Based Vaccinology Background: The need was felt among the researchers of both Vaxinfectio and CenStat to set up a more comprehensive research and education plan of action in the field of evidence based vaccinology, as part of the overall research plan of the Methusalem consortium. It was opted to establish a scientific chair, in order to make it possible to attract funding from various sources, including from private sector. The promotor of the Chair is Prof. Dr. Philippe Beutels, head of the Centre for Health Economics Research and Modelling Infectious Diseases (CHERMID); Prof. Dr. Pierre Van Damme, head of the Centre for the Evaluation of Vaccination (CEV) and President of Vaxinfectio, acts as co‐promotor of the Chair. The Scientific Chair in Evidence Based Vaccinology (EBV) was officially established by decision of the UA Board of Directors (Bestuurscollege) on December 9, 2008. Funding for the EBV Chair has meanwhile been secured from Wyeth for three years (60.000 EUR annually).


27

Holder of the EBV Chair: As of 1st February 2009, Prof. Dr. Niel Hens has been selected as holder of the Chair. He has been appointed as 50% Guest Professor, and combines this assignment with a position as lecturer/assistant professor at the University of Hasselt. He holds a PhD in science (mathematics) and an MSc in biostatistics and he has an excellent track record in terms of research and education. His doctoral research has been on the crossroads between the disciplines of medicine, mathematics and statistics. His curriculum lists several international awards, refereeing for international peer reviewed scientific journals, supervising PhD students, publications as first author, presentations at international conferences, workshops and symposia, as well as involvement in large (national and international) research projects. His appointment serves as a continuation of the intensive collaboration between UH and UA. Scientific objectives of the EBV Chair: The EBV Chair will support research into improved estimation methods to establish the effectiveness and cost‐effectiveness of vaccination programmes, including pneumococcal conjugate vaccine programmes, as well as medical education in evidence based vaccinology. The scientific aim of this Chair is to raise the level of scientific research in the area of evidence based vaccinology, in order to match the growing scientific interests from academics and industry, and in order to achieve a high level of independent research in this area. Activities to be developed by the EBV Chair:

• The further development and refinement of scientific research in evidence based vaccinology, comprising estimating the efficacy, effectiveness and cost‐effectiveness of vaccination programmes by infectious disease modelling.

• The establishment of various external scientific activities in the area of evidence based vaccinology (symposia, workshops, and conferences), in order to translate the results to the national and international public health community.

• The improvement of course modules on the subject area used in tertiary education. • Supervision of MSc and PhD dissertations in the field of evidence based vaccinology.

The inaugural lecture ‘Current Topics in Vaccinology: from Basic ``Who Infects Whom'' Research to Modelling H1N1 Flu’ was organised on September 23, 2009. Recently, Wyeth has been taken over by Pfizer in 2010. The latter company has ensured future funding of the scientific chair in Evidence‐based Vaccinology. A second academic session will be organized at the University of Antwerp on June 21, 2011.

ESAC Meetings ESAC (European Surveillance of Antimicrobial Consumption; www.esac.ua.ac.be) is an international network of national surveillance systems, collecting comparable and reliable antibiotic use data granted by ECDC (European Centre for Disease Prevention and Control; Grant Agreement GRANT/2007/001). Structure and modus operandi: The structure of ESAC includes the ESAC Management Team (MT), ESAC Scientific Advisory Board (SAB), ESAC Audit Committee (AC), and ESAC National Networks (NN). A multi‐disciplinary MT (with expertise in information technology, data management, microbiology, infectious diseases, epidemiology, ambulatory care medicine, hospital care medicine, pharmacology, and health economics) was installed at the Laboratory of Medical Microbiology, Vaccine & Infectious Disease Institute, University of Antwerp but also has members in Brussels, Dundee (UK) and Ljubljana


28

(Slovenia). This MT ensures day‐to‐day management and monitoring of the network activities. Participating countries have established NN consisting of relevant experts in the field of antimicrobial consumption. These networks are coordinated by Lead National Representatives (LNR). The SAB provides scientific support to the MT and liaises with ECDC as well as EU funded projects on antimicrobial use and resistance, whereas the AC monitors the progress of the project and helps resolve problems. ESAC Meetings: ESAC organizes subprojects meetings, at least one Scientific Advisory Board meeting per year where the strategy is discussed and approved, at least one Audit Committee meeting during which output is evaluated and one annual meeting during which the LNRs from the 35 participating countries (27 member states, 3 applicant countries and 5 others) gather and discuss the ESAC results on antimicrobial consumption as well as the results obtained from the subprojects on ambulatory care (AC), hospital care (HC), nursing homes (NH), and socio‐economics (EC). The third ESAC annual meeting was held in Stockholm, Sweden on May 27‐28, 2010. The ESAC project will be transferred to ECDC on July 1, 2011. The ESAC final meeting will be held in Riga, Latvia on May 19‐20, 2011.

GRACE Meetings/workshops GRACE (Genomics to combat Resistance against Antibiotics in Community‐acquired LRTI in Europe; www.grace‐lrti.org) is a Network of Excellence focusing on the complex and controversial field of community‐acquired lower respiratory tract infections (CA‐LRTI), which is one of the leading reasons for seeking medical care. The promiscuous use of antibiotics to treatment of CA‐LRTI accounts for a major part of the community burden of antibiotic use and contributes dramatically to the rising prevalence of resistance among major human pathogens. The overall objective of GRACE is to combat antimicrobial resistance through integrating centres of research excellence and exploiting genomics in the investigation of CA‐LRTI. Microbial and human genomics are integrated with health sciences research consisting of clinical observational and intervention studies, health economics and health education to specifically change practice in managing CA‐LRTI. GRACE is exceptional as it brings together 28 academic groups with a wide spectrum of expertise, spread widely across 13 EU Member States, and 4 SMEs. GRACE organises professional education, through two leading European scientific societies (European Society of Clinical Microbiology and Infectious Diseases and European Respiratory Society). Structure and modus operanding: The structure of GRACE includes the GRACE management team, the Governing Council (GC), Executive Council (EC), the Scientific Advisory Board (SAB), the Patient Advisory Board (PAB), and the Ethics Management Unit (EMU). A multi‐disciplinary management team was installed at the Laboratory of Medical Microbiology, Vaccine & Infectious Disease Institute, University of Antwerp. This management team ensures day‐to‐day management and monitoring of the project activities. The GC consists of all partners and the project‐manager. The partners have responsibilities for the objectives set up for the workpackages to which they contribute. The EC consists of the GRACE Network co‐ordinator, the WP leaders, and the project manager. The WP leaders have management responsibilities for their contribution to the project, are responsible for the content of their WP and the partners involved as described in the proposal. The EMU will take into account the multidisciplinary nature of ethical issues (e.g. data protection, animal testing, placebo in clinical trials) arising in the conduct of the project. The SAB and PAB provide scientific input on the progress of the project. GRACE meetings, workshops and postgraduate courses: Both the European Respiratory Society and the European Society of Clinical Microbiology and Infectious Diseases are providing an educational programme to spread knowledge to those working


29

in this field and to the wider public in Europe. Content from previous courses and educational documents can be found through an open access portal: http://www.grace‐edut.org/pages.

• 9th GRACE Postgraduate Course, ERS Educational Workshop, Barcelona, Spain, 18 September 2010: Antimicrobial treatment of LRTI ‐ important new aspects for clinical practice

• 8th GRACE Postgraduate Course, ECCMID Educational Workshop, Vienna, Austria, 1 April 2010: Viruses and the respiratory tract – current and future issues

• 5th GRACE Workshop, ECCMID Educational Workshop, Budapest, Hungary, 4‐5 November 2010: Hot topics in Lower Respiratory Tract Infection

• GRACE 4th annual meeting (Warsaw, February 4‐5, 2010) The GRACE project will end on August 31, 2011. The GRACE final meeting will be held on June 16‐18, 2011 in Antwerp, Belgium.

VHPB Meetings The objective of VHPB (Viral Hepatitis Prevention Board; www.vhpb.org) is to contribute to the control and prevention of viral hepatitis, by drawing the attention to this important public health problem, by encouraging actions to improve control and prevention. VHPB focus audiences are, in the first instance, health care professionals, policymakers, and opinion leaders in Europe. VHPB has, in support of its main objective, a wide range of functions, including the following:

• To monitor and evaluate the currently implemented immunisation programmes. • To bring together, during VHPB meetings, an international forum of specialists to examine,

discuss, and judge on specific topics, closely related with the control and prevention of viral hepatitis.

• To produce and distribute a number of publications, including Viral Hepatitis, a newsletter on viral hepatitis and reports of VHPB meetings.

• To disseminate viral hepatitis control and prevention guidelines for the health care workers and policymakers.

• To closely collaborate with international agencies dealing with control and prevention of viral hepatitis (World Health Organization, Centres of Disease Control and Prevention, European Centre of Disease Prevention and Control, Bill and Melinda Gates Children's Vaccine Program, European Commission, and Non Governmental Organisations) in order to maximise the impact of the efforts.

• To participate and organise international meetings in the field of viral hepatitis control and prevention.

• To promote the implementation of WHO recommendations on viral hepatitis control and prevention.

• To assist implementation of national plans of action for the introduction of vaccines Structure and modus operandi: The structure of the VHPB includes an executive secretariat, advisory members, and honorary members. The executive secretariat is located at the Centre for the Evaluation of Vaccination, Vaccine & Infectious Disease Institute, University of Antwerp. The advisory members, internationally recognised experts in the field of viral hepatitis, come from international organisations, academia, and/or national health authorities. The VHPB executive secretariat sets the strategy, defines the actions, and prepares the meetings of the VHPB, all of this in consultation with the VHPB advisory members. Advisory members are appointed for a period of three years, on a renewable basis. VHPB Meetings: Yearly the VHPB organizes at least two international meetings for this meeting an international


30

forum of specialists are invited to examine, discuss and judge on specific topics related with the control of the viral hepatitis. Back to back to these meetings the VHPB organizes two adviser meetings where the strategy is discussed and approved, meetings prepared and output evaluated:

• Identification and management of persons with chronic viral hepatitis in Europe, 18‐19 March 2010, Budapest, Hungary. As several European organizations have recently begun to promote screening and identification of persons with chronic hepatitis. The VHPB brought together international experts from public health and academic sector to discuss this development. Following an overview of existing screening programmes and new developments in treatment of hepatitis B and C, they evaluated the applicability to chronic hepatitis of the criteria for screening elaborated 40 years ago by Wilson and Jungner. Reports were presented of health technology assessments of such programmes, and participants weighed the benefits of screening against costs and potential harm that may ensue. Further discussions covered the conditions for screening, the strengths and weaknesses of the approach and its public health and social implications, including impact on individuals. The meeting concluded with a review of lessons learnt, challenges, needs and proposed steps forward

• Burden and prevention of viral hepatitis in Portugal, 18‐19 November 2010, Lisbon, Portugal. The main objectives of the meeting were to provide an overview of surveillance systems for infectious diseases, review the epidemiology of viral hepatitis in Portugal and current measures for prevention and control, and discuss progress in prevention 10 years after the introduction of universal vaccination against hepatitis B. Other objectives were to review implementation of new prevention strategies, control measures and monitoring systems, and, the way forward and possible obstacles.

Beside the organization of their own meetings, the VHPB also endorsed and assisted in the organization of the Summit conference Hepatitis B and Hepatitis C (SOTA), Brussels, Belgium, 14‐15 October 2010. This conference brought together a wide range of stakeholders united in their goal to encourage European and national leaders to devise effective policies and implement targeted actions to curb the epidemic of hepatitis B and C in Europe. The Conference presented scientific data and other evidence to an invited audience to urge the formulation of a European‐wide strategy on the communication, prevention and management of Viral Hepatitis as a healthcare priority.

Summer Course in Vaccinology Within the framework of the EU‐VACSATC (2007‐2010), a European collaboration project with 14 countries, a clear need to improve training of healthcare workers on aspects of vaccines and vaccinations, including vaccine safety and communication with health consumers was identified. The organization of both the vaccination services and the education system are far from uniform in the different European Countries. Research showed that healthcare workers, regardless of their professional involvement in immunization, are the major source for information on immunization and vaccine safety. However in pre‐service training the topic is usually spread over several courses leaving most doctors and nurses with too little training to communicate with healthcare consumers regarding the benefits and safety of vaccines. With an exception of healthcare workers who receive post‐graduate or in‐service training on vaccination, there is insufficient objective knowledge on immunization and vaccine safety to achieve and maintain high vaccine uptake. The Vaccine & Infectious Disease Institute (VAXINFECTIO) of the University of Antwerp, as chair of the work package responsible for the improvement of pre‐service immunization training of health professionals, developed a set of criteria for good pre‐service training in immunization and vaccine safety based on the national minimum standards for (in‐service) immunization training developed by the Health Protection Agency in the UK.


31

As an answer to this clearly identified gap, the University of Antwerp organized in July 2009 and July 2010 a 5 day summer school, called “the summer school on Vaccinology”. The proposed training focuses on the many aspects of immunization and vaccine safety. It is a basic course mainly targeted to students but applications of in‐service healthcare workers are considered and approved. Basic knowledge of immunology is required to enroll. The course is endorsed by a panel of high level experts and supported by WHO Euro and ESPID (European Society for Pediatric Infectious Diseases). The content as well as the practical organization are discussed and validated by students through close cooperation with EMSA‐Antwerp vzw, the local branch of the European Medical Students Association. The previous editions were very well evaluated by both teachers and students. A third edition of the summer school is planned for July 2011. These summer schools contributed to the development and evaluation of generic education packages in accordance with the set of minimum criteria for good immunization and vaccine training. Ideally universities and other higher education institutes across Europe will incorporate them in their curricula which however will be a long and slow process. Training objectives:

- To be able to describe the history of vaccination in the world and in Europe. - To know the basic concepts of immunology and vaccine immunology and epidemiological

and ecologic principles underlying infection spread. - To know and understand the types, composition and development of vaccines. - To be able to describe and recognize the main features of vaccine preventable diseases and

the nature and frequency of their acute and long term complications. - To be able to use immunization techniques, to follow correct procedures for storage and

handling of vaccines, to reconstitute and administer vaccines correctly and to manage anaphylaxis and other adverse events correctly.

- To be able to explain the aims of immunization, describe national policy and schedules and to deal with variations to the schedule.

- To understand the health economic basis of an evaluation of a vaccination program. - Increased awareness and capacity to respond to current issues and controversies regarding

immunization. - To be able to find and assess the reliability of information sources. - To be able to communicate effectively with patients and parents about vaccination. - To have knowledge of the future perspectives on vaccine development.

Training methodology: During the training a mix of teaching methods are used including different interactive teaching methods, lectures of experts, individual ‐ and group works as well as practical training. Next to a baseline knowledge and skills test, the students are evaluated on an ongoing basis as well as in the end. Also the set‐up and the effectiveness of the course program and used methodology are evaluated. ECTS accreditation for the course has been obtained (3 ECTS credits).

AUHA Research Days The third Research Day entitled ‘Onderzoek Doen! “Be good and tell it”’ was organised by AUHA (Associatie Universiteit & Hogescholen Antwerpen) and held on March 4, 2010. During this research day attention was drawn to Arts, Conservation – Restauration and Applied Linguistics, topics which did not receive attention during the second AUHA Research Day in 2008. New this year was the interactive feedback for researchers during which researchers had to present their research in lay terms. An award was given to the best presenter. The main focus groups are all involved or interested in education within AUHA, but also outside of AUHA. The research days aim to


32

attract companies in particular. Vaxinfectio presented their fields of research of interest to companies and members of AUHA in order to seek opportunities for future collaborations. Three posters were presented: 1) Product innovation in the medical sector showing two prototypes ‘Septicare’ and ‘Vaccinase’ which were developed by the Department Product Development of Artesis College in collaboration with Vaxinfectio; 2) A mindmap showing the research expertises of Vaxinfectio and collaborations not only within AUHA, but also with industry, hospitals, and research institutes; 3) Vaxinfectio: an overview of the three core research groups and their ongoing research. The Vaxinfectio Research & Innovation Manager presented the three Vaxinfectio posters and was in charge of the PR of the Institute.

4.4 Intellectual property rights Already within Vaxinfectio and later within the Methusalem Consortium, the need for a manager became apparent. Vaxinfectio applied for a managerial position in 2008 and in 2009, such a position was offered at the University of Antwerp to recruit a research and innovation manager (funded by the Industrial Research Fund) for Vaxinfectio. As of Nov 1, 2009, Dr. Vanessa Vankerckhoven started as research and innovation manager at Vaxinfectio. With regard to technology transfer and intellectual property rights (IPR) efforts are made by the research and innovation manager to raise awareness among the researchers of the Consortium concerning the valorisation of research results and the possibilities concerning commercial exploitation thereof. She participates in the information sessions that are organised by the interface services of the Universities of Antwerp and Hasselt and closely collaborates with their staff on valorisation of results, licensing deals, spin‐offs possibilities and other technology transfer opportunities. She also attends courses on technology transfer organized by international organisations, such as ASTP (Assocation of Technology Transfer Professionals). Moreover, active networking during international conferences and at partnering events is important to increase visibility of the Methusalem consortium and to set‐up collaborations with academia and industry. The research and innovation manager gives, in line with the UA and the UH rules and regulations, special attention to a policy of technology transfer. All inventions or research results with commercial potential are discussed with the research and innovation manager who reports to the interface services of UA and UH and discusses the valorisation potential and determines the best strategy to market any invention (patenting, licencing, spin‐off,...). Eventual profits (1/3 that goes to the Consortium according to University regulations) will be reinvested in the research capacity of the Consortium to further support the planned research strategy to be persued. The Board of Advisors of the Consortium advises on the names of the inventors. In 2010, LEH owned 2 patents: cytokine analogues granted in 2001 and mRNA electroporation technology for dendritic cell vaccines granted in June 2009. For both patents licensing strategies were set‐up as well as a further valorisation strategy. In Nov 2009 a new patent application was filed on stabilized interferon for treatment of acute myloid leukemia. After the priority year the patent application was ended as there was not enough interest from industry in licensing deals or uptake in their R&D pipeline. In May 2010, again a new patent application was filed on Bioimaging beads – arising from the IWT‐SIMID project. Unfortunately, the application was no longer pursued after receiving the examination report from the patent examiner due to a lack of FTO (freedom to operate). Also for LEH and LMM opportunities for valorisation have come during 2010 and are now actively being persued. In addition to the recent appointment of a research and innovation manager, an IOF project entitled ‘Creation of a translational platform for integrated vaccine research’ was approved by RIOFI (Board for Industrial Research Funding) at UA and will be funded for a period of 4 years. The project entails a


33

close collaboration with GlaxoSmithKline Biologicals (Rixensart, Belgium) as industrial partner. Next to several scientific outcomes, the project also offers a large technology transfer potential, e.g. patents and spin‐offs. The research and innovation manager closely monitors the project in terms of technology transfer opportunities in collaboration with the interface service at UA. Next to the IOF project, also the IWT‐SIMID and IWT‐BRAINSTIM are closely monitored in terms of valorisation potential arising from these projects. Finally, for the EU‐funded projects consortium agreements are analyzed and improvements are set forth to ensure an optimal IP policy for the Methusalem Consortium.


34


35

5 Communication

5.1 Press releases The leading researchers already had a proven track record in terms of communication with the press and the wider general public. This track record was further substantiated in 2010. An overview is given below.

National press releases

2010

Vaccin ontmoet populatie: welke interacties? (de Huisarts, 23/12/ 2010) Pierre Van Damme

e_SDLq Het belangrijkste is dat mijn tekening toont wat MS inhoudt. (Gazet

van Antwerpen, 14/12/2010)

Nathalie Cools

Cinq stratégies pour combattre le VIH (Metro, 13/12/2010) Zwi Berneman

Des chercheurs belges présentent cinq stratégies pour combattre le VIH

(Belga, 10/12/ 2010)

Zwi Berneman

Belgische onderzoekers presenteren 5 strategieën om HIV aan te pakken

(Belga, 10/12/2010)

Zwi Berneman

Vaxinfectio wordt WGO‐partner in strijd tegen infectieziekten (de Huisarts,

2/12/2010)

Pierre Van Damme

Kankervaccins: de keuze van het antigeen. ( de Specialisten, 30/11/2010) Viggo Van Tendeloo

Welk adjuvans bij een vaccin tegen kanker? (de Specialisten, 30/11/2010) Viggo Van Tendeloo

L’Anversois Vaxinfectio, partenaire privilégié de l'OMS (Metro, 26/11/2010) Pierre Van Damme

Antwerps centrum bestrijdt ziektes in heel Europa (Het Laatste Nieuws,

26/11/2010)

Pierre Van Damme

Mazelen en polio zijn terug (De Standaard, 26/11/2010) Pierre van Damme

Weerstand tegen resistentie (de Huisarts, 25/11/2010) Herman Goossens

Antwerpen bestrijdt mazelen en hepatitis in Europa (HBvL.be, 25/11/2010) Pierre Van Damme

We volgen infectieziekten van Lissabon tot Vladivostok (Gazet van

Antwerpen, 25/11/2010)

Pierre Van Damme

Un institut anversois spécialisé choisi pour lutter contre la résurgence de

maladies infectieuses en Europe (Flanders Today (version française),

25/11/2010)

Pierre Van Damme

Antwerp infectious diseases institute fights comeback of infectious diseases in

Europe (Flanders Today (english version), 25/11/2010)

Pierre Van Damme

BELGA CORRECTION: L'Anversois Vaxinfectio, partenaire privilégié de l'OMS

(Belga, 25/11/2010)

Pierre Van Damme

L’anversois Vaxinfectio, partenaire privilégié de l'OMS (Belga, 25/11/2010) Pierre Van Damme

Antwerpse Vaxinfectio wordt bevoorrecht partner van WHO (Belga, Pierre Van Damme

- Communication -

36

25/11/2010)

Medische experts waarschuwen voor een nieuwe opstoot van infectieziekten

(AuxiPress National Radio, 25/11/2010)

Herman Goossens

Tijdbom antibiotica tikt in rusthuizen (Het Belang van Limburg, 17/11/2010) Herman Goossens

Helft ziekenhuispatiënten slikt onnodige antibiotica (Het Belang van Limburg,

17/11/2010)

Herman Goossens

Bijna helft patiënten in ziekenhuizen slikt nog onnodig antibiotica (Gazet van

Antwerpen, 17/11/2010)

Herman Goossens

Alarmerend misbruik antibiotica in rusthuizen (Gazet van Antwerpen,

17/11/2010)

Herman Goossens

De huisarts en de vergrijzing (de Huisarts, 28/10/2010) Pierre Van Damme

Wat er deze winter rond griepvaccinatie moet gebeuren (de Huisarts,

28/10/2010)

Pierre Van Damme

Een grotere behoefte aan griepvaccins? (de Huisarts, 28/10/2010) Pierre Van Damme

Gratis griepprik in alle rusthuizen (Het Belang van Limburg, 30/09/2010) Pierre Van Damme

Rusthuizen starten met gratis griepvaccin (Het Belang van Limburg,

30/09/2010)

Pierre Van Damme

We willen dit jaar meer bejaarden bereiken (Gazet van Antwerpen,

30/10/2010)

Pierre Van Damme

1 Belg op de 10 (Het Laatste Nieuws, 27/09/2010) Herman Goossens

Vaccin tegen kinkhoest ook nuttig voor ouders (Het Belang van Limburg,

15/09/2010)

Pierre Van Damme

Snellere grieptest wapen tegen pandemie (Het Belang van Limburg,

10/09/2010)

Pierre Van Damme

Snellere grieptest op komst (Gazet van Antwerpen, 10/09/2010) Pierre Van Damme

HPV‐vaccinatie tegen sociale ongelijkheid (de Huisarts, 9/09/2010) Pierre Van Damme

Overheid moet bijspringen om antibiotica te ontwikkelen (De Standaard,

9/09/2010)

Herman Goossens

Persoonlijk Vaccin (Knack, woensdag 8 september 2010) Zwi Berneman

Sociaal zwakkeren minder ingeënt tegen baarmoederhalskanker (De Morgen,

1/9/2010)

Pierre Van Damme

Zogezegd (de Huisarts, 19/8/2010) Herman Goossens

Niet meer naïef hopen op wondermiddelen (Het Nieuwsblad, 14/8/2010) Herman Goossens

Paniek rond superbacterie echt niet nodig (Het Nieuwsblad, 14/8/2010) Herman Goossens

Twee Belgische patiënten besmet (Het Belang van Limburg, 14/8/2010) Herman Goossens

Er zullen zeker nog nieuwe gevallen opduiken (Gazet van Antwerpen,

14/8/2010)

Herman Goossens

Niet zo snel als griep (De Standaard Online, 14/8/2010) Herman Goossens


37

Nieuwe superbacterie maakt tweede slachtoffer in België (De Morgen,

14/8/2010)

Herman Goossens

Eerste Belgische dode door superbacterie (Het Nieuwsblad, 13/8/2010) Herman Goossens

Superbacterie eist leven in UZ Brussel (De Morgen, vrijdag 13/8/2010) Herman Goossens

Superbacterie: geen extra maatregelen in Ziekenhuizen (Belga Web, 13 /8/

2010)

Herman Goossens

Bactérie NDM‐1: pas de mesures supplémentaires dans les hôpitaux (Belga

Web, 13 /8/ 2010)

Herman Goossens

Artsen slaan alarm om superbacterie (Het Laatste Nieuws, 12 /8/ 2010) Herman Goossens

Nieuwe superbacterie op komst (De Morgen, 12 /8/ 2010) Herman Goossens

UA ontwikkelt vaccin (Het Laatste Nieuws, 3 /8/ 2010) Zwi Berneman

Onderzoekers UA ontwikkelen vaccin tegen acute leukemie (De Morgen, 3 /8/

2010)

Zwi Berneman

Doorbraak in strijd tegen acute leukemie (Het Belang van Limburg, 2 /8/

2010)

Zwi Berneman

Vaccin tegen leukemie (HBvL.be, 2 /8/ 2010) Zwi Berneman

Doorbraak in de strijd tegen acute leukemie (Gazet van Antwerpen, 2 /8/

2010)

Zwi Berneman

De artsen geven me nog 6 maanden (Gazet van Antwerpen, 2 /8/ 2010) Viggo Van Tendeloo

Pijnloze griepprik (Het Laatste Nieuws, 26 /7/ 2010) Pierre Van Damme

Geen pijn meer bij griepprik dankzij ultra korte naald (De Standaard, 26 /7/

2010)

Pierre Van Damme

Primeur: geen pijn bij griepprik (Het Nieuwsblad op Zondag, 25 /7/ 2010) Pierre Van Damme

Pijnloze alternatieven injectie (Het Belang van Limburg, 24 /7/ 2010) Pierre Van Damme

Griepprik met pijnloze naald (Het Belang van Limburg, 24 /7/ 2010) Pierre Van Damme

Spuitjes steeds pijnlozer (Gazet van Antwerpen, 24 /7/ 2010) Pierre Van Damme

Vaccinatie tegen wintergriep dit jaar pijnloos ( De Morgen Telex, 24 /7/

2010)

Pierre Van Damme

La vaccination contre la grippe quasi indolore cette année (Belga Web, 24

/7/ 2010)

Pierre Van Damme

Les indésirable de l’hôpital (Equilibre, 23/6/2010) Herman Goossens

La bactérie E colli transmissible à l’homme (le Pharmacien, 24 /5/ 2010) Herman Goossens

Resistentie kippenbacterie overdraagbaar (de Apotheker, 24 /5/ 2010) Herman Goossens

Superbacterie aan het spit (Knack, 12 /5/ 2010) Herman Goossens

L’ ABC de l’hépatite E reste énigmatique (le Pharmacien, 10 /5/ 2010) Pierre Van Damme

Het ABC van hepatitis E blijft raadselachtig (de Apotheker, 10 /5/ 2010) Pierre Van Damme

Taskforce of label? (de Huisarts, 22 /4/ 2010) Herman Goossens

Werkt de wegwasoperatie? (Bodytalk, 21 /4/ 2010) Herman Goossens

- Communication -

38

4 op de 10 kippenbroederijen gebruiken verboden antibiotica (Het Laatste

Nieuws, 20 /4/ 2010)

Herman Goossens

Een tikkende tijdbom (De Standaard, 17 /4/ 2010) Herman Goossens

Volksgezondheid richt taskforce voor superbacterie op (Metro, 16 /4/ 2010) Herman Goossens

De esbl‐bacterie is in opmars (Het Belang van Limburg, 15 /4/ 2010) Herman Goossens

Taskforce voor superbacterie op komst (De Morgen, 15 /4/ 2010) Herman Goossens

De vleesetende bacterie zit op onze huid en vooral in onze keel. Bij de meeste

mensen doet ze geen kwaad. Maar bij sommige mensen kan ze heel gevaarlijk

worden. (Wablieft, 14 /4/ 2010)

Herman Goossens

Des bactéries ultraresistantes (Metro, 13 /4/ 2010) Herman Goossens

Superbacterie is aan opmars bezig (Metro, 13 /4/ 2010) Herman Goossens

Al 1 Belg op de 10 drager van superbacterie (Het Nieuwsblad, 13 /4/ 2010) Herman Goossens

Grijp nu in tegen superbacterie (Gazet van Antwerpen, 13 /4/ 2010) Herman Goossens

Ongerustheid over verspreiding superbacterie (De Standaard, 13 /4/ 2010) Herman Goossens

Derde van alle levende braadkippen in België positief op superbacterie (De

Morgen, 13 /4/ 2010)

Herman Goossens

5.2 Website To enhance the visibility and to improve dissemination activities within the Consortium, a website was created. The website can be accessed through: www.vaxinfectio.be, www.vaxinfectio.org, www.vaxinfectio.eu and www.vaxinfectio.com. Next to information on the Centre of Excellence, Vaxinfectio, also information on Methusalem Funding is available (see parts below). The website is hosted by the University of Antwerp. The website was recently reorganised and improved. It is available in English and contains the following parts:

• Organisation o Laboratory of Medical Microbiology o Laboratory of Experimental Hematology o Centre for the Evaluation of Vaccination o Governing council o Staff

• Research o EU‐funded projects o Non EU‐funded projects o Chair in Vaccinology o Dissemination

Papers Newsletters Books & Book chapters Posters

o Innovation • Methusalem Funding

o Methusalem Consortium o Board of Directors o Board of Advisors


o Research Objectives o Annual Joint Research Days o Contact

• Partnerships o Expertise o Patents o Available Equipment

• News o Events o Press releases Dutch o Press releases English o Newsletters

• Jobs • Contact

An electronic library will be added to the dissemination part of the website. This library will contain all publications of the consortium. The e‐library will have an easy‐to‐use search engine, enabling searches by author, publication date, keywords and/or journal. Figure 5.1: Screenshot homepage Vaxinfectio website

5.3 Newsletters GRACE News GRACE issues a 3‐monthly newsletter which reports on the progress of GRACE activities since the official launch March 17, 2006 in Brussels. More information and issues of the newsletter are available at: https://www.grace‐lrti.org/portal/en‐GB ESAC Newsletter The ESAC newsletter is made available 3 times per year. In each of the newsletters 4 of the National

- Communication -

40

Networks present themselves and news on the core data and/or the subprojects is presented. Upcoming events are announced and previous events such as congresses are discussed. A PDF version of the ESAC Newsletters can be downloaded from the ESAC website: http://www.esac.ua.ac.be. The Viral Hepatitis Newsletter VHPB provides a forum for experts to exchange ideas and to develop consensus guidelines and recommendations on issues related to viral hepatitis prevention and control. Most of its findings, actions and meeting reports are published in the VHPB newsletter 'Viral Hepatitis', which is distributed to a list of more than 4000 members. The VHPB newsletters can be found on the website: www.vhpb.org.


41

6 International and National Collaborations

6.1 Strategic collaborations with other research groups & industry

National Collaborations At the start of the Methusalem funding relationships with a number of other research groups in and outside the University as well as with industry had already been established. Since 2007, the Consortium has fostered these existing relationships, but has also developed new relationships with new groups.

• AHUA o IOF project ‘Creation of a translational platform for integrated vaccine research’ with

the department of Product Development at Artesis (Dr. Stijn Verwulgen) • Institute of Public Health

o EU project entitled ‘European Surveillance of Antimicrobial Consumption (ESAC)’ in collaboration with Boudewijn Catry and Béatrice Jans (funded by DG Sanco from 2001 to 2007 and as from 2007 by ECDC)

o IWT‐SBO project entitled ‘Simulation models of infectious disease transmission and control processes – SIMID’ (Herman Van Oyen)

• Institute of Tropical Medicine (ITG) o GOA project entitled ‘Induction of immunity and tolerance by dendritic cells in

cancer and AIDS’ in collaboration with Guido Vanham o IUAP project entitled "Inhibition of HIV replication" HIV‐STOP (# P6/41); in

collaboration with Guido Vanham o IWT‐TBM project entitled ‘A phase I/II study of therapeutic vaccination with

autologous dendritic cells of HIV infected individuals under stable HAART’ in collaboration with Guido Vanham

o FWO project entitled ‘Mechanisms of secondary control of HIV infection after an episode of anti‐retroviral treatment’ in collaboration with Guido Vanham

• Industry o Algonomics within the framework of technology exchange o GSK: IOF project ‘Creation of a translational platform for integrated vaccine research’ o Coris BioConcept within the framework of the EU‐FP6 project Grace o Wyeth: Scientific chair on Evidence Based Vaccinology

• University of Antwerp o Collaboration with LMPH (Prof. Dr. L. Maes and Prof. Dr. P. Cos) o Collaboration with AMBIOR (Prof. Dr. JP Bogers) o GOA project entitled ‘Infectious disease models: wildlife ecology, ecological

disturbance and transmission to humans’ (Prof. Dr. Herwig Leirs) • Other Belgian Universities (joint projects funded by FWO, IUAP, IWT, and EU)

o Ghent University (UGent) IUAP project entitled "Inhibition of HIV replication" HIV‐STOP (# P6/41);

Promotor: UA (Berneman/Van Tendeloo), co‐promotors: Institute of Tropical Medicine (ITG; G. Vanham), UGent (B. Verhasselt), KUL (A. Van Damme), ULg (M. Moutschen) and VU Amsterdam (B. Berkhout)

EU‐FP7 project Intopsens (A highly integrated optical sensor for point of care

- International and National Collaborations -

42

label free identification of pathogenic bacteria strains and their antibiotic resistance): Ghent University (P. Bienstman)

BELSPO project DRUSEB (Drug use among female sex workers in Belgium): Ghent University (T. Decorte)

IWT‐SBO project entitled ‘Non‐invasive imaging of migration and survival of stem cells in the brain – BRAINSTIM’; promotor: Prof. Catherine Verfaillie (KuLeuven – SCIL); co‐promotors: Prof. Zwi Berneman & Prof. Annemie Van der Linden (UA); Prof. Veerle Baekelandt & Prof. Koen van Laere (KuLeuven), Prof. Stefaan De Smedt (Ghent University).

o University of Liege (ULg) Foundation against cancer project entitled ‘Dendritic cell vaccination against

human cytomegalovirus in leukemia patients following allogeneic hematopoietic stem cell transplantation: A phase I/II study’, collaboration with University of Liège (Y. Beguin)

IUAP project entitled "Inhibition of HIV replication" HIV‐STOP (# P6/41); Promotor: UA (Berneman/Van Tendeloo), co‐promotors: Institute of Tropical Medicine (ITG; G. Vanham), UGent (B. Verhasselt), KULeuven (A. Van Damme), ULg (M. Moutschen) and VU Amsterdam (B. Berkhout)

o KULeuven IUAP project entitled "Inhibition of HIV replication" HIV‐STOP (# P6/41);

Promotor: UA (Berneman/Van Tendeloo), co‐promotors: Institute of Tropical Medicine (ITG; G. Vanham), UGent (B. Verhasselt), KULeuven (A. Van Damme), ULg (M. Moutschen) and VU Amsterdam (B. Berkhout)

IWT‐SBO project entitled ‘Simulation models of infectious disease transmission and control processes – SIMID’; promotor: Prof. Dr. Philippe Beutels (UA), co‐promotors Marc Van Ranst (KuLeuven), Marc Aerts (UHasselt), Herman Van Oyen (IPH)

IWT‐SBO project entitled ‘Non‐invasive imaging of migration and survival of stem cells in the brain – BRAINSTIM’; promotor: Prof. Catherine Verfaillie (KuLeuven – SCIL); co‐promotors: Prof. Zwi Berneman & Prof. Annemie Van der Linden (UA); Prof. Veerle Baekelandt & Prof. Koen van Laere (KuLeuven), Prof. Stefaan De Smedt (Ghent University).

o University of Hasselt FWO project entitled ‘Clinical and preclinical research of the effect of cellular

mediators on the modulation of pathogenic responses in multiple sclerosis’ in collaboration with UHasselt (P. Stinissen)

IWT‐SBO project entitled ‘Simulation models of infectious disease transmission and control processes – SIMID’; promotor: Prof. Dr. Philippe Beutels (UA), co‐promotors Marc Van Ranst (KuLeuven), Marc Aerts (UHasselt), Herman Van Oyen (IPH)

EU project entitled ‘European Surveillance of Antimicrobial Consumption (ESAC)’ (funded by DG Sanco from 2001 to 2007 and as from 2007 by ECDC) in collaboration with Marc Aerts, Christel Faes and Niel Hens

o Vrije Universiteit Brussel (VUB) IWT‐TBM project entitled ‘A phase I/II study of therapeutic vaccination with

autologous dendritic cells of HIV infected individuals under stable HAART’; Promotor VUB (K. Tielemans); co‐promotor: UA (Z. Berneman)

FWO project with VUB/VIB ‘Identification of novel surface‐expressed factors mediating virulence and biofilm formation in methicillin‐resistant Staphylococcus aureus’ Promoter: UA (Herman Goossens); copromoters UA (Surbhi Malhotra), VUB/VIB (Henri De Greve), VUB (Jean‐Pierre Hernalsteens)


43

• University Hospital Antwerp (UZA) o Use of the Clinical Research Unit o Collaboration with several units (gynecology, paediatrics, …)


International Collaborations The Methusalem Consortium has built‐up an international network and currently collaborates with 158 scientific and industrial partners worldwide (38 countries). Country Name Institute / Organisation Contact Person Type of Institute /

Organisation Type of project involved

Austria Elisabethinen Hospital Linz Helmut Mittermayer academic EU Other

Bulgaria National Center of Infectious and Parasitic diseases Mira Kojouharova public organisation EU Other

Bulgaria Transport Medical Institute Miteva Boyka industrial partner EU Other

Bulgaria University Multipurpose Hospital for Active Treatment "Aleksandrovska" Boyka Markova academic EU Other

Croatia University Hospital for Infectious Diseases Croatia Arjana Tambic Andrasevic academic EU Other

Cyprus Ministry of Health of Cyprus Antonis Kontemeniotis public organisation EU Other

Czech Republic Univerzita Karlova Vlcek Jiri academic EU Other

Denmark Aarhus Universitet Martin Kristensen academic EU FP 7

Denmark Righospitalet Peter Garred public organisation EU FP 6

Denmark Statens Serum Institut Niels Frimodt‐Møller academic EU Other

Denmark WHO Regional Office Europe Nedret Emiroglu public organisation Research collaboration

Estonia State Agency of Medecines Ly Rootslane public organisation EU Other

Estonia University of Tartu Irja Lutsar academic EU Other

Finland Mobidiag Ltd Jaakko Pellosniemi SME EU FP 7

Finland National Institute of Health and Welfare Jaana Vuopio academic EU Other

France AbAg Camille Cyncynatus industrial EU FP 6

France Agence Française de sécurité sanitaire des produits de santé Philippe Cavalié public organisation EU Other

France ARTTIC Andrea Kuperberg SME EU FP 7

France Centre Hospitalier Universitaire de Nice Pia Touboul academic EU Other

France Commissariat à l’ Energie Atomique (CEA), Paris Roger Legrand research institute Agence National de Recherche sur le SIDA

France Fondation Hôpital Saint Joseph Laurent Gutman academic EU FP 7


Country Name Institute / Organisation Contact Person Type of Institute / Organisation

Type of project involved

France French National Institute for Research in Computer Science and Control Eric Fleury research Institute EU FP 6

France INSERM (French National Institute of Health and Medical Research) Christian Brun‐Buisson research Institute EU FP 6

France Institut Cochin Paris Anne Hosmalin research institute Agence National de Recherche sur le SIDA

France Pasteur Institute Didier Guillemot academic EU Other & EU FP 6

France Université Paris 5 Françoise Roudot‐Thoraval academic Research collaboration

France Université Paris‐Val de Marne Isabelle Durand‐Zaleski academic EU FP 6

Germany AmpTec GmbH, Hamburg Guido Krupp industrial EU FP 6

Germany Array‐On Gmbh, Gatersleben Dirk Fischer industrial EU FP 6

Germany BAG Health Care GmbH, Lich Nicolas Sachsenberg industrial EU FP 6

Germany Diakoniekrankenhaus Rotenberg Gmbh, Rotenburg Tom Schaberg industrial EU FP 6

Germany Institut fur Mikrotechnik Mainz Gmbh Klaus Stefan Drese SME EU FP 7

Germany The European Society for Paediatric Infectious Diseases, Muenchen Maria Tsolia European organisation EU Other

Germany Universität Kaiserlautern, Kaiserlautern Regine Hakenbeck academic EU FP 6

Germany Universitât Würzburg Ulrich Dobrindt academic EU FP 7

Germany University Bielefeld Markus Sauer academic EU FP 7

Germany University Dresden Petra Schwille academic EU FP 7

Germany University Hospital Center for Infectious Diseases and Travel Medecine Freiburg Winfred V.Kern academic EU Other

Germany University Medical Center Freiburg Philipp Henneke academic EU Other

Germany University of Rostock Michael Schmitt academic EU FP7‐SCALA (pending)

Germany Universitätsklinikum Charité Johannes Hallauer academic Research collaboration

Germany University of Regensburg Wolfgang Jilg academic Research collaboration

Greece National and Kapodistrian University of Athens Maria Tsolia academic EU Other

Greece National School of Public Health J.Kourea‐Kremastinou academic EU Other

Greece University General Hospital ATTIKON Helen Giamarellou academic EU Other

Greece National School of Public Health Georges Papaevangelou academic Research collaboration




Hungary University of Pecs Gabor Ternak academic EU Other

Iceland Landspitali University Hospital Haraldur Briem academic EU Other

Ireland Sta National Disease Surveillance Centre Robert Cunney academic EU Other

Israel Infectious Diseases Unit Raul Raz academic EU Other

Israel Tel‐Aviv Sourasky Medical Centre (Fund‐Tasmc) Yehuda Carmeli academic EU FP 6 & EU FP7

Israel Ben‐Gurion University of the Negev Dagan Ron academic Research collaboration

Israel Nanopass Yotam Almagor industrial Clinical trials

Italy Agenzia Italiana del Farmaco Pietro Folino Gallo public organisation EU 90 ‐ 10

Italy Consorzio per Valutazioni Biologiche e Farmacologiche Adriana Ceci public organisation EU Other

Italy Fondazione Penta Carlo Giaquinto public organisation EU Other

Italy INSERM‐Transfert Jerome Weinbach industrial EU FP 6

Italy Ridgeback sa Paolo Barattini SME EU FP7

Italy Società Servizi Telematici srl Luigi Catarutti private non profit organisation EU Other

Italy Università Cattolica Sacro Cuore Evelina Tacconelli academic EU FP7

Italy Universita degli Studi di Milano Fransesco Blasi academic EU FP 6

Italy Universita degli Studi di Milano Nicola Principe academic EU Other

Italy Università degli Studi Verona G.Cornaglia academic EU Other

Italy Università degli studi di Firenze Paolo Bonanni academic Research collaboration

Japan Yakult Jia Zhao industrial partner Research collaboration

Latvia P. Stradins University Uga Dumpis academic EU Other

Lithuania Institute of Hygiene Rolanda Valinteliene public organisation EU Other

Lithuania Vilnius University Children Hospital Vytautas Usonis academic EU Other

Luxembourg Direction de la Santé Marcel Bruch public organisation EU Other

Malta Mater Dei Hospital Michael Borg academic EU Other

Norway Norwegian Institute Of Public Health Hege Salvesen Blix public organisation EU Other

Norway University of Oslo Morten Lindbaek academic NIH

Poland Medical University of Lodz Maciek Godyck‐Cwirko academic partner EU FP 6 & EU FP 7 & EU Other




Poland National Institute of Public Health Magdzik Wieslaw public organisation Research collaboration

Poland National Institute of Public Health P. Grezesiowski public organisation EU FP6

Poland National Medecines Institute (NMI) Waleria Hryniewicz public organisation EU FP6 & EU Other

Portugal Associação de Saúde Infantil de Coimbra Fernando Rodrgues public organisation EU Other

Portugal Instituto de Tecnologia Quimica e Biologica Herminia de Lencastre academic EU FP 6

Portugal Instituto Nacional de Farmacia e do Medicamento Mafalda Ribeirinho public organisation EU Other

Portugal Tekever‐Technolgias de Informacao sa Lara Próspero SME EU FP7

Romania Institut for Infectious Diseases "Matei Bals" Liliana Preotescu public organisation EU FP 7

Romania National Institute of Research Development for Microbiology and Immunology Băicuş Anda public organisation EU Other

Russia Dept of Clinical Pharmacology Svetlana Ratchina public organisation EU Other

Russia St Petersburg Pasteur Institute Serge Mukumolow research Institute EU other

Serbia Clinical Centre of Serbia Biljana Jovanovic academic EU FP 7

Slovak Republic Clinical Research Associates and Consultants (CLINRAC) Zuzana Bielicka SME EU FP 6 & EU FP 7

Slovak Republic Comenius University Viliam Foltan academic EU Other

Slovenia University Medical Centre Ljubljana Milan Cižman academic EU Other

South Africa University of Limpopo Maphosane Nchabeleng academic VLIR

Spain Biokit sa Pau Bruguera SME EU FP 7

Spain Fundacio Clinic per a la Recerca Biomedica Antoni Torres academic EU FP 6

Spain Fundacio Privado Salut del Consorci Sanitari del Maresme Jordi Almirall academic EU FP 6

Spain Fundación para la Investigación Biomédica del Hospital Gregorio Jesus Saavedra academic EU Other

Spain Hospital Clinic i Provincial de Barcelona Antoni Torres academic EU FP 7

Spain Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS) Jordi Vila academic EU FP 6 & EU FP 7

Spain Instituto de Salud Carlos III, Centro Nacional de Microbiologia José Campos academic EU FP 6 & EU Other

Spain Instituto de Salud Carlos III, Centro Nacional de Microbiologia Maria Mellado academic EU Other

Spain NTE sa Jordi Carrera SME EU FP 7

Spain Universidad Politécnica de Valencia Daniel Hill academic EU FP 7

Spain Universitat de Barcelona Prof Josep Samitier academic EU FP 7




Spain University Miguel Hernandez Jesus Rodriguez Marin academic EU FP 6

Spain University of Barcelona Angela Dominguez academic EU other

Sweden Karolinska Institutet Staffan Normark academic EU FP 6

Sweden KTH ‐ The Royal Instiute of Technology Wouter van der Wijngaart academic EU FP 7

Sweden Linköpings Universitet Sigvard Mölstad academic EU FP 6 & EU FP7

Sweden Smittskyddinstitutet Birgitta H.Normark academic EU FP 6

Sweden Strama Gunilla Skoog academic EU Other

Switzerland European Respiratory Society Séverin Tania European organisation EU FP 6

Switzerland Hôpitaux Universitaires de Genève Stephan Harbarth academic EU FP 6 & EU FP7

Switzerland Lausanne University Hospital Giorgio Zanetti academic EU Other

Swizerland University Hospital Basel Heiner C. Bucher academic NIH

Switzerland University of Zurich Steffen Zeisberger academic EU FP6

Switzerland WHO Headquarters Steve Wiersma public organisation Research collaboration

The Netherlands Academical medical Center of the University of Amsterdam Lia van der Hoek academic EU FP 6

The Netherlands AMC, VU Amsterdam Ben Berkhout academic IUAP

The Netherlands Canisius Wilhelmina Hospital Joan W.Mouton public organisation EU FP 7

The Netherlands DCPrime Ada Kruisbeek industrial Consultancy

The Netherlands DIAC Leiden Cees Clemens public organisation Research collaboration

The Netherlands Erasmus Universitair Medisch Centrum Rotterdam Miriam Sturkenboom academic EU Other

The Netherlands MRC ‐ Holland Jan Schouten industrial EU FP 6

The Netherlands Nijmegen Center for Molecular Life Sciences Jolanda De Vries academic Clinical trials (UZA funding)

The Netherlands NIVEL François Schellevis public organisation EU FP7

The Netherlands Pathofinder Guus Simons industrial EU FP 6

The Netherlands Radboud University, Nijmegen Medical Center Stephanie Natsch academic EU Other

The Netherlands Universiteit Maastricht Ad Masclee academic Research collaboration

The Netherlands Universiteit Maastricht Ellen Stobberingh academic EU FP7

The Netherlands University Medical Center Leiden Alexander Gorbalenya academic EU FP 6




The Netherlands University Medical Centre Utrecht Theo Verheij academic EU FP 6, NIH

The Netherlands University Medical Centre Utrecht Marc Bonten academic EU FP 6 & EU FP 7

The Netherlands University of Maastricht Gerard Bos academic Research collaboration

The Netherlands University Twente Albert van den Berg academic EU FP 7

Turkey ESCMID Murat Akova international public organisation EU FP 6

Turkey Haceteppe University Serhat Unal academic partner EU Other

Turkey National ref lab influenza Selim Badur academic Research collaboration

UK Acolyte Biomedica Ltd Steve O'Hara industrial EU FP 6

UK Cardiff University David Price academic Research collaboration

UK Cardiff University Christopher C.Butler academic EU FP 6, NIH

UK City University London, Health Protecting Agency Peter Borriello academic EU Other

UK Ely Bridge Research Ltd Peter Edwards industrial EU FP 6

UK Farfield Group Ltd Gerry Ronan SME EU FP 7

UK Health Protection Agency Ben Cooper public organisation EU FP 6

UK Imperial College London David Holden academic EU FP 6

UK London School of Enconomics Marieke Huysentruyt academic Research collaboration

UK London School of Hygiene and Tropical Medicine Richard Smith academic EU FP 6

UK Mr Trevor Lewis Trevor Lewis SME EU FP 7

UK St George's University of London Michael Sharland academic EU Other

UK University Cambridge David Klenerman academic EU FP 7

UK University College London Hans Stauss academic Research collaboration

UK University of Birmingham Joanna Coast academic EU FP 6

UK University of Dundee Peter Davey academic EU Other

UK University of Nottingham Roger Finch academic EU FP 6

UK University of Nottingham Mike Pringle academic EU FP 7

UK University of Oxford Adrian V.S.Hill academic EU FP 6

UK University of Southampton Paul Little academic EU FP 6




USA Medstar Research Institute Nawar Shara public organisation NIH

USA Georgetown University, Washington Daniel Merenstein academic NIH

USA Washington University, St.Louis Jane Garbutt academic NIH

USA University of Wisconsin, Madison David Rabago academic NIH


51

These strategic collaborations ensure access to other equipment and scientific resources not readily available at the Consortium. In addition, they create possibilities for the mobility of researchers. The newly appointed research and innovation manager will play an important role not only in fostering existing collaborating, but also in setting‐up new ones. In case new collaborations are set‐up, the research and innovation manager will closely collaborate with the Interface Services at UA and UH to ensure contracts that safeguard the scientific work and provide sufficient remuneration. Also, possibilities in terms of technology transfer will be closely monitored. A detailed overview of projects is available in Tables 7.1‐7.4.

6.2 Ad hoc collaboration with industry Collaborating with industry has many advantages for the Consortium, such as clinical trial contract research, grants for research and access to specialised services. In the present research environment, collaboration with industry is unavoidable, and in some cases also a must, although we do bear in mind that this collaboration should not jeopardize the academic value and perception of the scientific work performed by the researchers. The long experience of the research groups with contracts and sponsoring from industry has led to the development of a policy to safeguard scientific independence with carefully negotiated contracts and with an emphasis on unrestricted grants and disclosure of conflicts of interest, if required. Currently ongoing industrial collaborations:

• AML‐RIATOL • Baxter (through CRO PPD and CRO Harrison) • Genticel (formerly: BT Pharma) • Crucell • GSK Biologicals • Innogenetics • Merck • Nanopass • Nobilon‐Schering Plough • Novartis • Novartis Vaccines Institute for Global Health • Pfizer • SP • SP‐MSD • Wyeth • Yakult

A detailed overview of projects is available in Tables 7.1‐7.4. Also future collaborations will have to be clearly structured, with the required guarantees for independent scientific work. The research and innovation manager will closely collaborate with the Interface Services at UA and UH to ensure contracts that safeguard the scientific work and provide sufficient remuneration. Also, possibilities in terms of technology transfer will be closely monitored. Importantly, these ad hoc collaborations could lead to long‐term strategic collaborations with industrial partners.


52

6.3 Flanders Vaccine Beginning of 2010 collaboration was set‐up with the Life Sciences project manager, Ir. Hilde Van Raemdonck from FlandersBio. Within the framework of an IWT‐TETRA application Flemish SMEs active in the field of vaccine related research were sought to participate in the project committee. It become soon clear that the position of Flanders in the field of vaccines is currently fairly weak in terms of vaccine related research as well device development. In contrast to the SME market in Wallonia and France, few Flemish SMEs were found. This led to the set‐up of the ‘Flemish Vaccinatie Platform’ by Vaxinfectio (Pierre Van Damme and Vanessa Vankerckhoven). The Platform aims to bring to together expertise in the field of vaccine related research, to identify hurdles in the vaccination sector and to stimulate networking. A coordination team was set‐up, composed of Vaxinfectio, Biomaric (Hugo Van Heuverswyn), Provaxs (Sven Arnouts, IOF manager) and Flandersbio. Relevant industrial and acadmic partners were contacted concerning the initiative and a first meeting was held on 10/09/2010 (list of participants: see Table below) with an impressive participation rate from industry as well as academia active in this field. Participants First Meeting September 2010:

Name First name Affiliation

Aernouts Sven UGent ‐ PROVAXS

Beyers Koen Voxdale

De Backer Jan Fluidda

De La Porte Christiaan Jansen Cilag

Dierick William Terumo

Hendriks Jerome UHasselt

Jahraus Andrea Apitope

Redig Pascale UA ‐ Interface

Smits Elke UZA

Thielemans Kris VUB

Van Broekhoven Annie Innogenetics Biologicals

Van Damme Pierre UA ‐ VAXINFECTIO

Van Raemdonck Hilde FlandersBio

Van Tendeloo Viggo UA ‐ VAXINFECTIO

Vanheuverswyn Hugo BioMaric/AIP

Vankerckhoven Vanessa UA ‐ VAXINFECTIO

Vicaire Albert Biotech Tools During this first meeting it was decided to prepare an inventory of available expertise in vaccine related research and device development in Flanders. This inventory will allow setting‐up a database. The coordination team meets on a regular basis to take the initiative a step further. A second big meeting is planned early 2011.


Please note that the information presented in Figures 7.2‐7.9 and Tables 7.1‐7.3 was provided by ADOC (Dept of Research at UA), Vaxinfectio cannot be held responsible for possible errors.

53

7 External Research Funding

7.1 Overview of submitted projects 2010 Over 60 new project proposals were submitted by the Consortium in 2010. BOF GOA (2nd round application 2010)

• Prof. Dr. Zwi Berneman / Prof. Dr. Luc De Clerck / Prof. Dr. Viggo Van Tendeloo / Dr. Nathalie Cools (Dendritic cells and basophils as key players in immunotolerance: Focus on IgE receptors) – not granted

• Prof. Dr. Herman Goossens and Dr. Surbhi Malhotra in collaboration with LMPH (Prof. Drs Louis Maes and Paul Cos) and Laboratory of Protein Chemistry (Prof. Dr. Sylvia DeWilde) (Elucidation of the role of mono‐ and polymicrobial biofilms as a major cause of therapeutic failure in intensive care units (ICU): an in vitro and in vivo study of ‘biofilm’ virulence factors) – granted

BOF ID • Sarah Bals (UA‐EMAT) / Peter Ponsaerts / Annemie Van der Linden ("Molecular Imaging"

meets "Imaging Molecules") – granted BOF Kleine projecten

• Dr. Nathalie Cools (Characterization of circulating dendritic cells in multiple sclerosis: evaluation of subtypes and functionality) – granted

• Dr. Katherine Loens / Elke Leuridan (Maternele immuniteit in het puerperium) – granted • Dr. Evelien Smits (In vivo niet‐invasieve beeldvorming van acute myeloide leukemie

immunotherapie) – granted BOF LP UA

• Blaumeiser Bettina (CMG ‐ UA) / Cools Nathalie / Bervoets An (Dermato ‐ UZA) (Role of dendritic cells in the development and treatment of alopecia areata: interaction with Toll‐like receptors) – not granted

• Conraads Viviane / Van Tendeloo Viggo (Bone marrow dysfunction and reversibility in patients with ischemic cardiomyopathy) – not granted

• Cools Nathalie / Op 't Eijnde Bert (REVAL ‐ Uhasselt) / Van Craenenbroeck Emeline (Cardio ‐ UZA) (The impact of physical training on quality of life and immunological status of patients with multiple sclerosis: dendritic cells as key modulators) – not granted

BOF NOI (Letter of Intent submitted: 2010) • Prof. Dr. Viggo Van Tendeloo / Dr. Nathalie Cools (Dendritic cells in multiple sclerosis: Study

of possible deficiencies and of the effect of cellular intervention on the modulation of pathogenic responses) – not granted

• Prof. Dr. Viggo Van Tendeloo / Dr. Nathalie Cools (Induction of immune tolerance by tolerogenic DC: Towards a "negative" cellular vaccine for multiple sclerosis) – not granted

BOF UHasselt • Prof. Dr. Niel Hens / Prof. Dr. Geert Molenberghs / Prof.Dr. Philippe Beutels (Modelling

epidemics using new statistical methodology based on network data and incomplete data methodology) – granted

• Prof. Dr. Niel Hens (Short visit James Wood) – granted • Prof. Dr. Niel Hens / Prof. Dr. Chirstel Faes (mathematical epidemiology) – not granted

Charcot Research Fund • Prof. Dr. Zwi Berneman & Prof. Dr. Viggo Van Tendeloo (The immune‐modulating role of

vitamin D3‐treated dendritic cells in multiple sclerosis) – granted

- External Research Funding -

54

Duitslandinitiatief Dep. Universiteit & Samenleving • Van Damme Pierre / Van Tendeloo Viggo / Van Herck Koen (Wetenschappelijke workshop (1

dag) en lab training (3 dagen): Lange termijn opvolging van hepatitis B‐specifieke cellulaire immuniteit bij gevaccineerde vrijwilligers) – granted

EU‐DG Sanco • HEPSCREEN – Screening for Hepatitis B and C among migrants in the European Union

(Coordinator: Erasmus University MC Rotterdam ; partner UA: Prof. P. Van Damme) EU‐ECDC

• ESAC IV – European Surveillance of Antimicrobial Consumption (Coordinator: Herman Goossens)

• EU‐HAI AB – European HAI‐AB point prevalence survey pilot "Support to the pilot point prevalence survey of healthcare‐associated infections and antimicrobial use in European acute care hospitals (Coordinator: Herman Goossens)

EU‐ERC Starting Grant (call 2010) • SMILER – Simulation Models of Infections Linked with Economic Research (Philippe Beutels)

– not granted EU‐Eurostars (call 2010)

• DC Lung – Development of Novel DC‐based Vaccine for Lung Cancer (Coordinator: Ada Kruisbeek, DC Prime, The Netherlands; partner UA – Viggo Van Tendeloo)

EU‐FP7 (HEALTH call 2010) • SANDRINE – Sample Preparation and Detection of antibioticResistance and Infections at

Emergency (Coordinator: Till T. Bachmann, University of Edinburgh; partner UA – Herman Goossens): collaborative project – Stage 1 awarded

• ARMED – Antibiotic resistance : Mechanisms of evolution and dissemination (Coordinator: Frank Møller Aarestrup (Denmark); partner UA – Herman Goossens): collaborative research project – Stage 1 awarded

• RGNOSIS – Resistance in Gram‐Negative Organisms: Studying Intervention Strategies – (Coordinator: Marc Bonten (The Netherlands); Partner UA – Herman Goossens): collaborative project – awarded

• BEhAVE – Behaviour and Communication on Vaccination Uptake in Europe (Coordinator: Richard Amlôt, Health Protection Agency, UK; Partner UA – Herman Goossens): Collaborative project – Stage 1 awarded

• TRANSFORM – Transforming outbreak communication in a changing world (Coordinator: Heidi Larsson, London School for Tropical Medicine and Hygiene, UK; partner UA – Pierre Van Damme): Collaborative project – Stage 1 awarded

EU‐IMI (call 2010) • RAPP‐ID – Development of Rapid Point‐of‐Care test Platforms for Infectious Diseases

(Coordinator: Jorge Villacian, Tibotec; Academic coordinator: Herman Goossens) – awarded FWO Krediet aan Navorsers

• Dr. Cools Nathalie (Dendritic cells in multiple sclerosis: key players in the immunopathogenesis, key players for new cellular immunotherapies) – not granted

• Dr. Loens Katherine (Bordetella) – not granted FWO Postdoctoral Fellowship

• Characterisation and modulation of innate immune responses in the central nervous system: functional studies in a combined in vitro & in vivo mouse model of glioblastoma – Promotor: Prof. Dr. Z. Berneman; Fellow: B. Tambuyzer – not granted

• Impact of antibiotic therapy on the human gastro‐intestinal microbiome – Promotor: Prof. Dr. H. Goossens; Fellow: S. Malhotra‐Kumar

FWO Onderzoeksprojecten • Zwi Berneman / Ponsaerts Peter, Jorens Philippe, Ysebaert Dirk, Van der Linden Annemie,

Gugliano Michele, Chatterjee Shyama, Pauwels Patrick (Neural Stem Cells: molecular and



55

physiological control of in vivo migration and differentiation) – granted • Zwi Berneman / Ponsaerts Peter, Ysebaert Dirk, Van der Linden Annemie, Chatterjee Shyama,

Pauwels Patrick (Characterisation of innate immune responses in the central nervous system: modulation towards immunological acceptance of allogeneic cellular grafts.) – granted

• Zwi Berneman / Ponsaerts Peter, Ysebaert Dirk, Chatterjee Shyama, Pauwels Patrick (Control of glioblastoma by modulation of the brain's innate immune responses) – granted

• Philippe Beutels / Antoon Van de Velde, Van Damme Pierre (Ethics of Vaccination) – granted • Philippe Beutels / Niel Hens, Viggo Van Tendeloo, Marc Aerts (Immunological modeling of

VZV boosting) – granted • Conraads Viviane / Van Tendeloo Viggo, Colls Nathalie (Bone marrow dysfunction and

reversibility in patients with ischemic cardiomyopathy) – not granted • De Clerck Luc / Berneman Zwi, Van Tendeloo Viggo, Cools Nathalie (Dendritic cells and

basophils as key players in immunotolerance: Focus on IgE receptors) – not granted • Goossens Herman / Malhotra‐Kumar Surbhi (Characterizing the naso‐oro‐pharyngeal

microbiome and resistome in the European population) – granted • Goossens Herman / Malhotra‐Kumar Surbhi (Elucidation of host‐pathogen interactions in

patients with assisted ventilation developing pneumonia) – not granted • Hendrickx Sven (U Hasselt) / Ponsaerts Peter (Immunomodulatory therapy for spinal cord

injury via IL‐4 en IL‐13 secreting stem cells) – granted • Hens Niel / Molenberghs Geert Beutels Philippe (Modelling epidemics using new statistical

methodology based on network data and incomplete data methodology) – not granted • Van Tendeloo Viggo / Berneman Zwi, Cools Nathalie, Chantal Mathieu (KUL) (Dendritic cell

manipulation by vitamin D3: exploitation of molecular mechanisms for DC‐based immunotherapy in multiple sclerosis – not granted

FWO Reiskrediet • Bergwerf Irene (Towards understanding brain innate immune responses: “Do placental‐

derived cells harbour the key to immune tolerance) • Fabienne Paasch (Kort studieverblijf Medunsa (Zuid Afrika))

IWT‐TETRA • Prof. Dr. Pierre Van Damme / Dr. Vanessa Vankerckhoven ism Dr. Stijn Verwulgen (Artesis)

(In kaart brengen van alternatieven voor intramusculaire toediening) – not granted KCE

• Prof. Dr. Niel Hens / Prof. Dr. Philippe Beutels (Effectiveness and cost‐effectiveness of influenza vaccination in children, adults, elderly, health care workers and pregnant women) – granted

• Prof. Dr. Philippe Beutels (Prioritisering van de doelgroepen m.b.t. De vaccinatie voor seizoensgriep ‐ deel 2) – granted

Legaat Deceunynck • Conraads Viviane (UZA) / Cools Nathalie (Bone marrow dysfunction and reversibility in

patients with ischemic cardiomyopathy) – not granted • Malhotra‐Kumar Surbhi (Elucidation of host‐pathogen interactions in patients with assisted

ventilation developing pneumonia) – not granted • Ponsaerts Peter (Validation of in vivo “Sleeping Beauty Transposon” gene transfer for

treatment of spinal cord injury) – not granted NIH Grant

• NOSES – Nasal irrigation, Oral steroids, antbiotics and Subgroup targeting for Effective management of Sinusitus (Coordinator: Tina Tan, US; partner UA: Prof. Dr. H. Goossens)

PWO Academiseringsmiddelen • Prof. Dr. Pierre Van Damme / Dr. Vanessa Vankerckhoven ism Dr. Stijn Verwulgen (Artesis)

(In kaart brengen van alternatieven voor intramusculaire toediening) – not granted


56

Stichting tegen kanker • Prof. Dr. Zwi Berneman / Prof. Dr. Viggo Van Tendeloo (Feasibility and safety of a WT1‐

targeted cancer vaccine in patients with malignant mesothelioma and locally advanced breast cancer: an open‐label phase I trial) – granted

• Prof. Dr. Zwi Berneman / Dr. Peter Ponsaerts / Dr. Patrick Pauwels (In vivo functional characterisation of glioblastoma interaction with endogenous and ex vivo engineered therapeutic microglia) – not granted

• Prof. Dr. Viggo Van Tendeloo / Dr. Evelien Smits (Boosting the cross‐talk between human dendritic cells and natural killer cells by Toll‐like receptor ligand‐loaded leukemia cells for optimal anti‐leukemia T cell responses) – granted

TOP BOF • Prof. Dr. Niel Hens / Prof. Dr. Philippe Beutels (Developing methods to account for

demographic evolution, maternal antibody decay and heterogeneity in social contacts and health care costs as part of simulation models of the spread of infectious diseases and economic evaluation of vaccination programmes) – pending

VLIR • Prof. Dr. Greet Ieven & Dr. Katherine Loens (Molecular detection of Mycoplasma

pneumoniae and Chlamydophila pneumoniae in Cuban HIV infected subjects) – not granted VLIR‐UOS Fellowship

• Antibiotic resistant pathogenic bacteria present in the environment and human commensal flora: is there a link with disease? – Promotors: Herman Goossens / Surbhi Malhotra‐Kumar, Fellow: Fabienne Paasch – granted

WIV • Prof. Dr. Greet Ieven & Dr. Katherine Loens (NRC: Respiratoire pathogenen: adenovirus,

coronavirus including SARS, human parainfluenzavirus, Mycoplasma pneumoniae, Chlamydia pneumoniae, respiratory syncytial virus (RSV), human metapneumovirus (HMPV)) – pending

7.2 Overview of granted projects 20072010 According to audit report from the Consultancy Company McKinsey Vaxinfectio was identified as a company spearhead, to use their terminology. According to them Vaxinfectio has potential to set‐up additional industrial collaborations thereby improving the 4th flow of money. Furthermore, Vaxinfectio was shown to obtain the highest budget in 2009 in terms of industrial funding at the University of Antwerp, thereby ranking the Faculty of Medicine first not only at UA, but also when compared to the Faculty of Medicine at UGent and KuLeuven.



Figure 7.1 External funding (M€) obtained by Vaxinfectio (Source: McKinsey Company)

Figure 7.2 Overall Number of projects Vaxinfectio 2007‐2010 split by type of funding

0

10

20

30

40

50

60

70

80

90

100

2007

2008

2009

2010


Figure 7.3 Overall obtained budget (M€) Vaxinfectio 2007‐2010 split by type of funding

In contrast to the report by the McKinsey Company in which the amount of external funding obtained by Vaxinfectio in 2008 was mentioned to be €6.8M, the total external funding according to our data amounted to almost M€20 in 2008. Figure 7.4 Number of projects LEH 2007‐2010 split by type of funding

0

5

10

15

20

25

2007

2008

2009

2010

0

5

10

15

20

25

30

35

2007

2008

2009

2010



Figure 7.5 Obtained budget (M€) LEH 2007‐2010 split by type of funding

Figure 7.6 Number of projects LMM 2007‐2010 split by type of funding

0.00

1.00

2.00

3.00

4.00

5.00

6.00

2007

2008

2009

2010

0

5

10

15

20

Total EU FP EU Other FWO/IWT BOF Private Other

2007

2008

2009

2010


Figure 7.7 Obtained budget (M€) LMM 2007‐2010 split by type of funding

Figure 7.8 Number of projects CEV 2007‐2010 split by type of funding

0.00

1.00

2.00

3.00

4.00

5.00

6.00

7.00

Total EU FP EU Other FWO/IWT BOF Private Other

2007

2008

2009

2010

0

5

10

15

20

25

30

35

40

2007

2008

2009

2010



Figure 7.9 Obtained budget (M€) CEV 2007‐2010 split by type of funding

Figure 7.10 Number of projects CenStat 2007‐2010 split by type of funding

0.00

2.00

4.00

6.00

8.00

10.00

12.00

2007

2008

2009

2010

0

10

20

30

40

50

60

70

2007

2008

2009

2010


Figure 7.11 Obtained budget (M€) CenStat 2007‐2010 split by type of funding

0.00

0.50

1.00

1.50

2.00

2.50

3.00

3.50

4.00

4.50

5.00

2007

2008

2009

2010



Table 7.1 Projects LEH

Project Title Acronym Promotor Start date End date

Dendritic cells: biology and immunomodulation with dendritic cells Zwi Berneman 1/01/1999 31/12/2008

Gene therapy: from gene transfer to clinical applications Zwi Berneman 1/01/2002 31/12/2011

Feasibility of dendritic cell immunotherapy for cancer using the Wilms' tumor WT1 protein as a candidate universal tumor antigen Zwi Berneman 23/01/2004 22/01/2007

Preclinical design of RNA‐modified dendritic cell vaccines for cancer and HIV Zwi Berneman 1/10/2004 30/09/2007 Wilms' tumor gene mRNA‐transfected autologous dendritic cell vaccination for patients with acute myeloid leukemia in remission ‐ a pilot dose escalation study Zwi Berneman 24/12/2004 24/12/2007

Induction of immunity by dendritic cells in cancer and aids Zwi Berneman 1/01/2005 31/12/2008

Modulation of immune responses directed against allogeneic cell transplants in mouse Peter Ponsaerts 1/07/2006 31/12/2010 Characterisation of the in vitro activation conditions of anti‐leukemic T‐cells from leukemia patients using different types of antigen‐presenting cells Zwi Berneman 1/10/2006 30/09/2008

Transplantation of embryonic stem cell‐derived neural cells after spinal cord and traumatic brain injury Zwi Berneman 1/10/2006 30/09/2009

Transplantation of embryonic stem cell‐derived neural cells after spinal cord and traumatic brain injury Zwi Berneman 1/01/2007 31/12/2010

Inhibition of human immunodeficiency virus replication Zwi Berneman 1/01/2007 31/12/2011 Activation of dendritic cells and natural killer cells by leukemia cells loaded with Toll‐like receptor ligand: development of a new generation of leukemia vaccines Zwi Berneman 1/01/2007 31/12/2008 Dendritic cell vaccination against human cytomegalovirus in leukemia patients following allogeneic hematopoietic stem cell transplantation: A phase I/II study Zwi Berneman 1/01/2007 31/12/2010

A phase I/II study of therapeutic vaccination with autologous dendritic cells of HIV infected individuals under stable HAART Zwi Berneman 1/01/2007 31/12/2009

CRYo‐banking of stem cells for human therapeutic application CRYSTAL Peter Ponsaerts 1/02/2007 31/01/2010

Culture and characterization of neural stem cells Zwi Berneman 1/05/2007 1/07/2009

Cellular immunology in cancer and HIV, and multidisciplinary cell therapy and clinical studies Vigor Van Tendeloo 1/10/2007 30/09/2012

Effect of innate signals on leukemia cells for the stimulation of natural killer cells and T helper type 1‐polarizing dendritic cells Zwi Berneman 1/01/2008 31/12/2011

Mechanisms of secundary control of HIV infection after an episode of anti‐retroviral treatment Zwi Berneman 1/01/2008 31/12/2011

Functional characterisation of regulatory cell populations: in vitro induction of tolerance using dendritic cells Nathalie Cools 1/01/2008 31/12/2009

Non‐invasive imaging of migration and survival of stem cells in the brain BRAINSTIM Zwi Berneman 1/01/2008 31/12/2011

Effects of TLR ligand‐loaded leukemic cells and type I IFN on dendritic cell‐induced tumor specific T‐cell immunity Zwi Berneman 1/10/2008 30/09/2010 Stimulation of innate immune responses targeted against acute myeloid leukemia cells after exposure to Toll‐like receptor ligands, in view of the development of a leukemia vaccin Vigor Van Tendeloo 13/10/2008 12/10/2009

Becton Dickinson FACSAria II: highspeed, fixed alignment benchtop cell sorter platform Zwi Berneman 19/12/2008 18/12/2013

Clinical and preclinical research on the effect of cellular mediators on the modulation of pathogenic responses in multiple sclerosis Vigor Van Tendeloo 1/01/2009 31/12/2012


Project Title Acronym Promotor Start date End date

Characterization of immune responses against allogeneic stem cell implants in the central nervous system Peter Ponsaerts 1/01/2009 31/12/2011

Belgian multidisciplinary HIV research Zwi Berneman 1/01/2009 31/12/2013 Activation of dendritic cells and natural killer cells by leukemia cells loaded with Toll‐like receptor ligand: development of a new generation of leukemia vaccines Zwi Berneman 1/01/2009 31/12/2010 Feasibility and potency of a IL‐12‐secreting multi‐antigen dendritic cell vaccine in patients with leukemia and myeloma: a two‐center trial Zwi Berneman 1/01/2009 31/12/2010 Induction of multiple sclerosis specific immune toleration using tolerogene dendritic cells and regulatory T cells. Preclinical evaluation of the therapeutic potential of cellular immune therapy in MS Vigor Van Tendeloo 1/01/2009 31/12/2010 Characterization and modulation of microglial responses following transplantation of allogeneic bone marrow‐derived stromal cells in the central nervous system of immune competent mice Bart Tambuyzer 1/02/2009 31/12/2010

Induction of multiple sclerosis specific immune tolerance using tolerogenic dendritic cells and regulatory T cells Vigor Van Tendeloo 1/02/2009 31/07/2013

The effect of cellular mediators on the modulation of pathogenic responses in multiple sclerosis patients Zwi Berneman 1/10/2009 30/09/2012 Role of the Wilms tumor gene as biomarker for predicting leukemia relapse and for assessing efficacy of DC vaccination using WT1 mRNA‐transfected autologous dendritic cells of patients with acute myeloid leukemia Zwi Berneman 1/09/2009 31/08/2012

Neural stem cells: molecular and physiological control of in vivo differentiation migration and immunogenicity Zwi Berneman 1/10/2009 30/09/2012

Support maintenance scientific equipment Zwi Berneman 1/01/2005 31/12/2010

Multiple Sclerosis, a multidisciplinary approach Zwi Berneman 1/01/2010 31/12/2014 RHAMM as an attractive immunotherapeutic target antigen for dendritic cell‐based induction of T‐cell immunity to leukemia and myeloma Zwi Berneman 1/10/2010 30/12/2011

Increasing the immunotherapeutic capacity of human dendritic cells using innate immune signals Zwi Berneman 1/10/2010 30/09/2013 Development of novel strategies to improve the immunostimulatory potential of dendritic cell‐based immunotherapy of acute myeloid leukemia Zwi Berneman 1/10/2010 30/09/2012

CSL Behring Chair in von Willebrand disease Zwi Berneman 1/10/2010 30/09/2013

Characterization of circulating dendritic cells (DC) in multiple sclerosis: evaluation of subtypes and functionality Nathalie Cools 1/01/2010 31/12/2011

In vivo non‐invasive imaging of acute myeloid leukimia (AML) immunotherapy in mice Evelien Smits 1/01/2010 31/12/2011

In vivo non‐invasive imaging of acute myeloid leukimia (AML) immunotherapy in mice Evelien Smits 1/02/2010 31/12/2012 Tolerance and Immunogenicity of ProCervix and adjuvanted therapeutic vaccine composed of 2 recombinant adenylate cyclases, in HPV 16 and/or 18 infected woman with normal cytology Vigor Van Tendeloo 1/06/2010 31/03/2011

Table 7.2 Projects LMM

Project Title Acronym Promotor Start Date End Date

European Surveillance of Antimicrobial Consumption II ESAC II Herman Goossens 1/02/2004 30/04/2007

Genomics to Combat Resistance against Antibiotics in Community‐acquired LRTI in Europe CT2005‐518226 GRACE CT2005‐ Herman Goossens 1/03/2006 28/02/2011



Project Title Acronym Promotor Start Date End Date 518226

A randomised, placebo controlled double blind study to assess the efficacy of the probiotic dairy product Yakult on symptoms in Irritable Bowel Syndrome

Yakult IBS Pre‐test Herman Gooossens 26/09/2006 30/06/2007

A randomised, placebo controlled double blind study to assess the efficacy of the probiotic dairy product Yakult on symptoms in Irritable Bowel Syndrome Yakult IBS Herman Goossens 5/03/2007 31/12/2009

Development and dissemination of a school antibiotic and hygiene education pack and website across Europe E‐Bug Pack 2005211 Herman Goossens 15/06/2006 14/09/2009

European Surveillance of Antimicrobial Consumption ESAC ECD.556 Herman Goossens 18/05/2007 17/08/2007

Changing behavior of Health care professionals and the general public towards a More Prudent use of anti‐microbial agents CHAMP Herman Goossens 1/04/2007 31/03/2011

Changing behavior of Health care professionals and the general public towards a More Prudent use of anti‐microbial agents CHAMP Samuel Coenen 19/01/2009 31/05/2009

European Surveillance of Antimicrobial Consumption ESAC III ECD.609 Herman Goossens 3/09/2007 2/09/2008

Evidence‐based management in primary care: the case for respiratory tract infections Herman Goossens 1/10/2006 30/09/2009


Mechanisms of antibiotic resistance and tolerance and the associated fitness costs in streptococci causing respiratory tract infections Herman Goossens 1/10/2007 30/09/2010

Mechanisms of antibiotic resistance and tolerance and the associated fitness costs in streptococci causing respiratory tract infections Herman Goossens 1/10/2007 30/09/2010 Improving the management of lower respiratory tract infections in general practice by means of etiological, prognostic and interventional studies. Herman Goossens 1/01/2008 31/12/2011

Mastering hOspital Antimicrobial Resistance and its spread into the community MOSAR Herman Goossens 1/02/2007 31/01/2012

Integrated vaccine and infectious disease research Methusalem

Herman Goossens/Pierre Van Damme/ Zwi Berneman 1/01/2008 31/12/2014

Evidence for a Novel Efflux Pump Mediating Telithromycin Resistance in Macrolide‐Resistant Streptococcus pyogenes Surbhi Malhotra 1/01/2008 31/12/2009

An integrated platform enabling Theranostic applications at the Point of Primary Care TheraEDGE Herman Goossens 1/03/2008 29/02/2012


A highly integrated optical sensor for point of care label free identification of pathogenic bacteria strains and their antibiotic resistance Intopsens Herman Goossens 1/09/2008 31/08/2011 Elucidating Antibiotic Resistance Mechanisms Mediating High‐level Resistance to Ketolides and Fluoroquinolones in Streptococcus pyogenes Surbhi Malhotra 1/01/2009 31/12/2011


European Surveillance of Antimicrobial Consumtion III ECD.1702 ESAC III ECD.1702 Herman Goossens 3/09/2009 2/09/2010

The appropriateness of prescribing antibiotics in primary health care in Europe with respect to antibiotic resistance APRES Herman Goossens 1/10/2009 30/09/2013

Antibiotic Resistance and Prescribing in European Children ARPEC Herman Goossens 1/01/2010 31/08/2013



Impact of Specific Antibiotic Therapies on the prevalence of human host Resistant bacteria SATURN Herman Goossens 1/01/2010 31/12/2014


Identification of novel surface‐expressed factors mediating virulence and biofilm formation in methicillin‐resistant Staphylococcus aureus Herman Goossens 1/01/2010 31/12/2012

Collecting national data on the resistance profile of Streptococcus pyogenes Herman Goossens 1/01/2010 31/12/2010

Support to the pilot point prevelance survey of healthcare‐associated infections and antimicrobial use in Europe acute care hospitals Herman Goossens 1/06/2010 31/03/2011

Antibiotic Resistant pathogenic bacteria present in the environment and human commensal flora: is there a link with disease? Herman Goossens 1/10/2010 30/09/2012

Maternal immunity around delivery Katherine Loens 1/01/2010 31/12/2011

Table 7.3 Projects CEV


Support to the activities of the Viral Hepatitis Prevention Board (VHPB) Pierre Van Damme 1/01/2000 31/12/2011

Preventative health of prostitutes in Antwerp Pierre Van Damme 1/01/2002 31/12/2008 Statistical properties of the force of infection, the contact matrix and the reproduction rate estimation, interrelation and impact on mathematical models for the dynamic transmission of infectious diseases. Pierre Van Damme 1/01/2004 31/12/2009 A double blind, randomized, controlled study to evaluate the immunogenicity and safety of GlaxoSmithKline Biologicals ‐ herpes simplex candidate vaccine (gD2 ASO4) in healthy HSV seronegative and seropositive female subjects aged 10‐17y. Pierre Van Damme 23/04/2004 30/06/2009 Improving Public Health Policy in Europe through Modelling and economic evaluation of Interventions for the Control of Infectious Diseases. POLYMOD Pierre Van Damme 1/09/2004 31/08/2008

Effective and acceptable strategies for the control of SARS and new emerging infections in China and Europe, SARSControl Pierre Van Damme 1/01/2005 31/03/2008

Transmission of material antibodies in a low endemic country Pierre Van Damme 1/12/2005 31/12/2008 Prevalence of maternal antibodies against vaccine preventable infections: sero‐epidemiological survey of antobody concentrations in woman in third trimester of pregnancy; comparison between vaccinated and mothers with natural immunity. Pierre Van Damme 1/03/2006 31/12/2007 A Open‐label, Randomized, Multicenter Study of the Safety, Tolerability, and Immunogenicity of Gardasil TM Given Concomitantly with Repevax TM in Healthy Adolescents 11‐17 Years of Age. Pierre Van Damme 4/05/2006 31/05/2007

Safety and Immunogenicity of an intramuscular, inactivated, Split‐Virion, Pandemic Influenza A/H5N1 Vaccine in Adults and the Elderly. Pierre Van Damme 1/07/2006 30/06/2008 A long‐term, open follow‐up of the immunogenicity and safety of GSK HPV‐16/18/31/45 L1/AS04 vaccine in healthy female subjects vaccinated in the HPV‐TETRA‐051 study. Pierre Van Damme 31/08/2006 31/08/2009

Vaccine Safety ‐ Attitudes, Training and Communication. VACSATC Pierre Van Damme 1/09/2006 31/10/2009 Duration of vaccine‐induced protection against hepatitis B: detailed mathematical modelling of long‐term data vaccinated persons, evaluating the influencing factors and the correlation between humoral and cellular immune responses. Pierre Van Damme 1/10/2006 30/09/2009

NanoVax. Pierre Van Damme 1/03/2007 31/12/2009

Has the time to control Hepatitis A globally? Pierre Van Damme 1/06/2007 31/05/2008



A phase I, open‐label, vaccination study to evaluate the safety and immunogenecity of the GSK Biologicals recombinant CMV gB sub‐unit GSK1492903A in CMV‐seronegative healthy adult subjects. Pierre Van Damme 1/07/2007 30/06/2008 A phase I/II, observer‐blind, randomized multicentre study to assess the safety and immunogenicity of an HPV‐16/18/33/58 L1 vaccine formulated with different adjuvant systems when administered intramuscularly in healthy adult females. Pierre Van Damme 1/08/2007 31/07/2008 A Study of the Immunogenicity and Safety of an inactivated Split‐Virion Influenza Vaccine administered by Intradermal Route versus an Inactivated adjuvanted Influenza Vaccine administered by Intramuscular Route in subjects of 65 years of age or older. Pierre Van Damme 1/10/2007 31/10/2007

Creation of a translational platform for integrated vaccine research. Pierre Van Damme 1/12/2007 26/11/2012

Health Economics Research and Mathematical Modelling of Infectious Diseaeses. Pierre Van Damme 1/12/2007 30/11/2010

Study of vaccination coverage in children and adolescents in Flanders in 2008. Pierre Van Damme 1/12/2007 31/12/2008

Economic evaluation of rotavirus immunisation of infants in Belgium. Philippe Beutels 1/12/2006 31/05/2007

A phase III clinical trial to evaluate the efficacy, immunogenicity, safety and tolerability of ZOSTAVAX in subjects 50 to 59 years of age Pierre Van Damme 1/01/2008 31/05/2010 A phase IV, open, multicentre, multicountry study to evaluate the immune response to a challenge dose of GSK Biologicals Twinrix vaccine, approximately 48 months after primary vaccination Pierre Van Damme 1/01/2008 30/09/2008 Case‐control study to evaluate the vaccine effectiveness of live attenuated rotavirus vaccines against community‐acquired rotavirus severe gastroenteritis among hospitalized children born after 1 October 2006 in Belgium. Pierre Van Damme 1/02/2008 31/05/2010 A phase IV, open, multicentric study to evaluate the immune response to hepatitis B challenge dose in healthy subjects, 72 to 78 months after they received a primary vaccination course of GSK Biologicals' Engerix‐B vaccine, in the primary study HBV‐280. Pierre Van Damme 1/02/2008 1/03/2009

Clinical Study "Maternal Antibodies against Pertussis in Neonates: Natab 2 Study". Pierre Van Damme 30/04/2008 30/06/2008 An Open‐Label Phase III Study to Assess the Safety and Immunogenicity of a Vero Cell‐Derived Whole Virus H5N1 Influenza Vaccine in an Adult and Elderly Population as well as in Specified Risk Group. Pierre Van Damme 1/06/2008 30/09/2009 Immunogenicity of the Investigational, Inactivated, Split‐Virion Influenza vaccine administered by the Intradermal route in comparison with the intramuscular reference vaccine Vaxigrip (c) in the elderly. Pierre Van Damme 6/06/2008 31/10/2009 A blinded phase I/II dose escalation study to assess safety and immunogenicity and investigate the optimal dose level of a formalin‐treated, uv‐inactivated, vero cell‐derived ross river virus (RRV) vaccine in healthy volunteers aged 18 to 40 years Pierre Van Damme 9/06/2008 31/03/2009 A phase 1, multicenter, randomized, placebo‐controlled study ... plasmid competition and payload on the immunogenicity of a DNA influenza vaccine administered by particle mediated epidermal delivery to healthy adults. Pierre Van Damme 21/08/2008 20/08/2009

Drug use among female sex workers in Belgium. DRUSEB Pierre Van Damme 1/10/2008 28/02/2011 A double blind, randomized study to evaluate the immunogenicity and reactogenicity of two different lots of inactivated hepatitis A vaccine containing 1440EI.U of antigen per ml and injected according to a 0‐12 months schedule. Pierre Van Damme 28/10/2008 31/01/2013 A double blind, randomized study to evaluate the immunogenicity and reactogenicity of two different lots of inactivated hepatitis A vaccine containing 1440EI.U of antigen per ml and injected according to a 0‐6 months schedule. Pierre Van Damme 28/10/2008 31/03/2013

What explains socio‐economic differences in health behaviour? Vaccination of Children. Cornelius Van den Bosch 1/10/2008 30/09/2010 A phase II, randomized, multicentre, observer‐blind study to ... with the Hepatitis B surface antigen (HBsAg), according to a 0,1 month schedule with a booster at month 12,in healthy, Hepatitis B virus (HBV) naïve, adults. (112115) Pierre Van Damme 1/01/2009 20/08/2010 A Rising Single Dose, Double‐Blind, Randomized, Placebo‐ Controlled Study to Evaluate Safety, Tolerability and Immunogenicity of SCH 900795 in Healthy Adults P05653‐01. Pierre Van Damme 1/02/2009 31/01/2011 A phase III, open, multi‐centre, non‐randomized, trial to evaluate the immunogenicity and safety of a two‐dose schedule of the A/California/7/2009 (H1N1)v‐like candidate vaccine manufactured in Dresden adjuvanted with ASO3A, in adults of 18 years & above Pierre Van Damme 1/08/2009 31/10/2010 A randomized, single‐blind, dose‐ranging...of adjuvanted and non adjuvanted egg‐derived inactivated novel swine rigin A/H1N1 monovalent subunit influenza virus vaccine in healthy subjects 18 or more years of age Pierre Van Damme 5/08/2009 31/08/2011


Vaccination coverage and timing of vaccination in children and adolescents in Belgium (retrospective study carried out via an internet‐based questionnaire). Pierre Van Damme 26/08/2009 25/08/2010

Surveillance of hepatitis B en C. Pierre Van Damme 6/09/2009 30/03/2010 An open, single centre study to evaluate the long‐term antibody persistence and immune memory between 16 and 20 years after the primary study HAB‐028 (208127/021) in which healthy adults were vaccinated with Twinrix Adult following a three‐dose schedule Pierre Van Damme 1/10/2009 31/10/2015

Multidisciplinary research on vaccination and infectious diseases. Pierre Van Damme 1/11/2009 31/10/2011

Scientific Chair "Evidence Based Vaccinology". Philippe Beutels 1/01/2009 31/12/2011

Infectious diseases models: wildlife ecology, ecological disturbance and transmission to humans. Herwig Leirs 1/01/2009 31/12/2012

Scientific Chair "Advanced research and development in addiction medicine & psychiatry". Bernard Sabbe 1/01/2009 31/12/2011 Contacts between children with chickenpox and varicella zoster immune adults: an analysis of the post‐exposure impact on cellular immunity. Philippe Beutels 1/01/2007 31/12/2008

Simulation models of infectious diseases transmission and control processes. SIMID Philippe Beutels 1/03/2007 28/02/2011

Standardization of Economic Evaluations. Philippe Beutels 1/03/2007 31/08/2007

Program Evaluation of universal and targeted options for use of hepatitis A vaccines in Belgium. Philippe Beutels 1/07/2007 1/09/2008

Evaluation of Crisis and Case Management. ECCAM Guido Van Hal 1/10/2008 30/04/2010

Health Economics. Philippe Beutels 1/01/2009 31/12/2013

Research project in the context of the study no.2009‐10‐HTA VZV vaccination in children and adults aged over 50 years. Philippe Beutels 1/06/2009 31/05/2010

Innovative research of pertussis specific anti‐pertactine IgG as a proxi for incident infections. Koen Van Herck 1/01/2007 31/12/2008

A study of the HBsAg specific T‐cell and B‐cell‐mediated immunity in adults, many years after hepatitis B vaccination. Koen Van Herck 1/01/2008 31/12/2010

Surveillance of invasive pneumococcal disease (IPD) in adults in Belgium: scientific advice and validation of the results. Koen Van Herck 2/11/2008 1/01/2009

Kosteneffectiviteit van 7, 10 en 13‐valente pneumokokken conjugaat vaccin 2009‐52_HTA Philippe Beutels 10/12/2009 15/04/2011

Determination of target groups that should receive priority for seaonal influenza vaccination Philippe Beutels 1/01/2010 14/09/2010

Maternal Antibodies against Mumps in a Cohort of children up to the age of 1 year Elke Leuridan 31/01/2010 30/11/2010 A phase III clinical trial to study the immunogenicity, tolerability, and manufacturing consistency of V503 in preadolescents and adolescents with a comparison to young women Pierre Van Damme 11/12/2009 30/04/2013 A Phase III Open‐Label Clinical Trial to study the Immunogenicity and tolerability of V503, a Multivalent Human Papillomavirus (HPV) L1 Virus‐Like Particle (VLP) Vaccine, Given Concomitantly With REPEVAX in Preadolescents and adolescents Pierre Van Damme 22/01/2010 21/01/2011

Need, target pompulation and product profile of the development of a hepattitis E vaccine Pierre Van Damme 3/02/2010 2/02/2010 Immunogenicity and safety of the influenza vaccine (Split Virion, Inactivated), Northern Hemisphere 2010‐2011 Formulation (Intradermal Route) Pierre Van Damme 1/03/2010 30/06/2010 A Phase I, randomized, single blind, controlled, single center study to evaluate the safety and immunogenicity of the NVGH Glycoconjugate Vaccine against S.Typhi in Adult Subjects 18 to 40 years of age. Pierre Van Damme 2/03/2010 1/03/2011 A phase IV, open, non‐randomized, multicentre study to assess the reactogenicity and immunogenicity of a booster dose of GSK … in study 263855/029 Pierre Van Damme 1/05/2010 31/03/2012



Tolerance and Immunogenicity of ProCervix , an adjuvanted therapeutic vaccine composed of 2 recombinant adenylate cyclases, in HPV 16 and/or 18 infected women with normal cytology Pierre Van Damme 25/05/2010 24/05/2011 Consultancy for the project "Tolerance and Immunogenicity of ProCervix , an adjuvanted therapeutic vaccine composed of 2 recombinant adenylate cyclases, in HPV 16 and/or 18 infected women with normal cytology" Pierre Van Damme 26/07/2010 25/07/2011 A phase 2, randomized, observer‐blind, controlled, single center study to evaluate the safety and immunogenicity of three formulations of the NVGH Glycoconjugate Vaccine against S.Typhi in Adult Subjects 18 to 40 years of age Pierre Van Damme 1/09/2010 28/02/2011

A population‐based nationwide surveillance of invasive pneumococcal disease (IPD) among adults > 50 years old in Belgium Koen Van Herck 20/11/2009 19/11/2010

Analyses supporting the validation of the estimated duration of protection provided by Havrix Koen Van Herck 1/12/2010 31/10/2011

Table 7.4 Projects CenStat

Project Title Promotor Start Date End Date Analysis of the EU‐wide baseline surveys on Campylobacter spp. in broiler flocks and on Campylobacter spp. and Salmonella spp. in broiler carcasses Lot No. 2 Marc Aerts 1/12/2008 1/08/2010 Beleidsgegevens over psychiatrische diensten en instellingen: permanente registratie van klinische en sociale variabelen. Overeenkomst inzake de ondersteuning van registratiesysteem: "Minimale Psychiatrische Gegevens" Marc Aerts 1/01/2009 31/12/2009

Berekening van de sample size voor de klinische studie voor AMT Herbert Thijs 22/06/2009 23/09/2009

Berekening voor de FDA meeting voor AMT Herbert Thijs 22/06/2009 23/09/2009

Biostatistical consulting for UCB Geert Molenberghs 1/01/2005 31/12/2009

Committee member agreement with Sanofi‐Aventis Geert Molenberghs 1/07/2008 31/12/2011

Consultancy Master Agreement with Mars Marc Aerts 1/08/2008 31/07/2009

Consultancy overeenkomst Geert Molenberghs 4/08/2008 4/08/2009

Consulting agreement with Schwarz Biosciences Marc Aerts 1/11/2008 31/10/2009

Consulting Agreement with Eli Lilly Geert Molenberghs 1/05/2009 30/04/2010

Consulting Agreement with Tibotec Pharmaceutical Ltd. ‐ consulting January 2009 Geert Molenberghs 1/01/2009 31/01/2009

Consulting Agreement with MARS Petcare UK Ltd Marc Aerts 7/07/2009 6/07/2010

Contract wetenschappelijke dienstverlening Marc Aerts 8/07/2008 7/01/2009

Coördinatie van wetenschappelijke dienstverlening en contractonderzoek Marc Aerts 1/01/2009 31/12/2013

Creatie MPG‐eenheidsbestanden voor SPIL Geert Molenberghs 1/01/2007 31/12/2009

Datasafety Monitoring Board with Sanofi‐Aventis Herbert Thijs 1/07/2008 31/07/2011 De analyse van gegevens verzameld binnen het PWO 'Goed Onderwijs' van de XIOS Hogeschool door STATCOM UHasselt onder de supervisie van A. Laenen Herbert Thijs 16/03/2009 15/04/2009

De bio‐informatica‐aspecten van mathematische en statistische modellen voor infectieziekten Ziv Shkedy 1/01/2007 31/12/2010 Development of a SAS macro to import, analyse and visualize data from the DG‐SANCO Rapid Alert System for Foood and Feed Savety as a tool for “early warning” Geert Molenberghs 2/12/2008 1/07/2009


Een flexibele methode voor het modelleren van niet‐normale hierarchische gegevensstructuren Geert Molenberghs 1/01/2009 31/12/2012

Een krachtig modelleringskader voor het efficiënt opzetten en analyseren van levenswetenschappelijke studies Geert Molenberghs 1/01/2009 31/12/2012

Gezamelijke vormgeving van HCV en HIV van de longitudinale (tijd‐reeks) gegevens van Italië Ziv Shkedy 11/02/2009 31/12/2009

Input voor het vervolg protocol waar de nadruk pancreatitis is Herbert Thijs 22/06/2009 23/09/2009

Internationale cursus "Master of Science in Biostatistics" Paul Janssen 1/09/2008 30/06/2009

Milieu en Gezondheid Geert Molenberghs 1/01/2007 31/12/2011 Opmaak en uitvoeren van een draaiboek voor het uitvoeren van een moedermelkcampagne voor de gevalsstudie: ' Gechloreerde verbindingen in landelijke gebieden' in het kader van een geïntegreerd faseplan. Marc Aerts 1/02/2009 31/01/2010 Overeenkomst voor de implementatie van een samenwerkingsproject in kader van het Noord‐Zuid‐samenwerkingsprogramma (NSSCP) van de institutionele universitaire samenwerking tussen Universiteit Hasselt, Jimma University (JU), Ethiopia and University Eduardo Mondlane (UEM), Mozambique ‐ R 1942 Marc Aerts 1/04/2009 31/03/2011

Personeelsdatabank Marc Aerts 19/01/2009 31/12/2009

Project Title: " Solving the interpretation versus misspecification dilemma in psychological, social and behavioral measurements" Geert Molenberghs 31/08/2008 31/08/2009

Project Title: " Solving the interpretation versus misspecification dilemma in psychological, social and behavioral measurements" Geert Molenberghs 31/08/2009 31/08/2010

Samenwerking in het kader van de voorbereiding van een Vlaams Supercomputer Centrum voor publiek en privaat gefinacierd onderzoek Paul Janssen 23/05/2008 23/05/2009 Schatting van het onderwerp heterogeniteit, co‐infectie en de gezamenlijke ontwikkeling van modellen van HCV, HBV en HIC uit Cross‐sectionele serologische gegevens Ziv Shkedy 11/02/2009 31/12/2009

Schatting van infectieziekte‐parameters gebaseerd op mixture modellen Ziv Shkedy 1/10/2008 30/09/2010

Semi‐parametrische Cox’s regressie modellen voor multivariate, links‐gecensureerde overlevingsdata met extra nullen Roel Braekers 1/10/2009 30/09/2011 Simulatiemodellen voor overdracht van besmettelijke ziekten en controleprocessen, met toepassing op de vijf grote gezondheidstopics vanuit het Vlaamse beleid Marc Aerts 1/03/2007 31/12/2011

Statistische analyse voor Pronota Geert Molenberghs 27/01/2007 26/01/2009

Statistische analyse van associatie en afhankelijkheid in complexe data Noel Veraverbeke 1/01/2007 31/12/2011

Statistische analyse van isotoop‐gemerkte MALDI‐TOF massa spectra Tomasz Burzykowski 1/01/2009 31/12/2012

Statistische analyses "'Jongeren met een rugzak ... 't werkt" Geert Molenberghs 10/06/2006 30/09/2009 Statistische eigenschappen en impact van onvolledige gegevens op de analyse van spatio‐temporele modellen voor de ruimtelijke en temporele dynamica van infectieziekten Noel Veraverbeke 1/10/2007 30/09/2010 Statistische eigenschappen van de infectiedruk, de contractmatrix en de reproductiesnelheid: kwantificering, onderlinge wisselwerking en impact in mathematische modellen voor de dynamische transmissie van infectieziekten Marc Aerts 1/01/2004 31/12/2009

Statistische verwerking en ondersteuning in het kader van het onderzoek naar het huidige blootstellingsniveau aan zware metalen in de Noorderkempen Geert Molenberghs 1/11/2006 31/12/2009

Wetenschappelijke dienstverlening in kader van experiment 1051: Taminco Marc Aerts 1/07/2009 31/07/2009

Wiskundige en statistische methode voor bacteriologische risico vaststelling en besmettelijk ziektemodel Marc Aerts 4/05/2008 31/03/2009

Work Order in functie van het IWT (n° 80536) project "Cell Line based compound prioritization and response prediction" Marc Aerts 1/12/2008 30/11/2010



Analyse uitvoeren en draft papers schrijven Ziv Shkedy 1/07/2007 30/09/2007

Analyseren van veiligheidsdata: EPO‐ANE‐4008 Bestuurs Commissie Vergaderingen Oktober 2008 Herziening van documenten Geert Molenberghs 1/10/2008 31/10/2008

Bewezen diensten aan DSMB in functie van het TMC114‐C229 onderzoek: December 2008 Herziening van het rapport Geert Molenberghs 1/12/2008 31/12/2008

Bijstand bij de statistische analyse van baseline enquetes rond het voorkomen en de risicofactoren van Salmonella in slachtvarkens en kalkoenen Marc Aerts 20/12/2007 31/10/2008

Consultancy Agreement Geert Molenberghs 27/04/2006 27/07/2007

Consultancy Agreement Herbert Thijs 27/04/2006 27/04/2007

Consultancy service Geert Molenberghs 15/09/2006 14/09/2007

Consulting juli 2008 Consulting Overeenkomst dd. 27/04/2005 Geert Molenberghs 1/07/2008 31/07/2008

Consulting november 2008 Consulting Overeenkomst dd. 27/04/2005 Geert Molenberghs 1/11/2008 30/11/2008

Consulting oktober 2008 Consulting Overeenkomst dd. 27/04/2005 Geert Molenberghs 1/10/2008 31/10/2008

Consulting september 2008 Consulting Overeenkomst dd. 27/04/2008 Geert Molenberghs 1/09/2008 30/09/2008

Convention Marc Aerts 1/07/2008 31/12/2008

Flexibele wiskundige en statistische modellen voor microbiologische risicobeoordeling Geert Molenberghs 1/01/2005 31/12/2008

Geavanceerde statistische modellen voor de risico‐analyse van toxicologische studie in de farmaceutische industrie (type 3) Marc Aerts 1/04/2005 31/03/2007

Improving public health policy in Europe through Modelling and Economic Evaluation Marc Aerts 1/07/2004 30/06/2008

Internationale cursus "Master of Science in Biostatistics" Paul Janssen 1/09/2007 30/06/2008

Intra‐ en inter‐individuele variaties bij key biomarkers binnen een algemene populatie Geert Molenberghs 15/03/2006 31/03/2008 Onderaannemingscontract ‐ Beleidsgegevens over psychiatrische diensten en instellingen: permanente registratie van klinische en sociale variabelen. Onderzoeksovereenkomst inzake de ontwikkeling van registratiesystemen. Marc Aerts 1/01/2008 31/12/2008

Ondersteuning van het registratiesysteem 'Minimale Psychiatrische Gegevens (0.5 VTE) Annouschka Laenen 1/01/2008 31/12/2008

Ontwikkeling van een methodologie voor de kwantitatieve beoordeling van zoönotische risico's in België toegepast op het model Salmonella bij varkens Marc Aerts 1/12/2004 30/11/2007

Project title: " Solving the interpretation versus misspecification dilemma in psychological, social and behavioral measurements" Geert Molenberghs 1/09/2007 31/08/2008

Statistische analyses Geert Molenberghs 15/03/2006 14/03/2008








Statistische dienstverlening Geert Molenberghs 14/06/2006 19/08/2008

Statistische ondersteuning en verwerking van de resultaten van het onderzoek naar het huidig blootstellingsniveau aan zware metalen rond Hoboken Marc Aerts 1/01/2008 31/12/2008

T‐bedden in psychiatrie: Studie over langdurige psychiatrische opnames Geert Molenberghs 15/10/2006 30/11/2007

VLIR‐UOS Beurzentoekenningsprogramma Uhasselt Paul Janssen 1/01/2008 31/12/2008

Wetenschappelijke dienstverlening Geert Molenberghs 5/11/2007 31/12/2008

Acute cardiologie ‐ Evaluatie van het Impella 2.5 LVA toestel (R‐2332) Herbert Thijs 24/02/2010 23/03/2010 Beleidsgegevens over psychiatrische diensten en instellingen: permanente registratie van klinische en sociale variabelen. Overeenkomst inzake de ondersteuning van registratiesysteem: "Minimale Psychiatrische Gegevens" (R‐2493) Geert Molenberghs 1/01/2010 31/12/2010 Consortium Agreement in het kader van het ECDC‐project :"VACCINE PREVENTABLE DISEASES MODELLING IN THE EUROPEAN UNION AND EEA/EFTA COUNTRIES: FORECASTING THE EFFECT OF INTRODUCING A NEW VACCINE IN A NATIONAL/REGIONAL PROGRAM" (R‐2345) Ziv Shkedy 1/07/2009 30/06/2011

Continuation of Consultancy services under the terms of our agreement Dated 7the July, 2008. (R‐2584) Marc Aerts 7/07/2010 6/07/2011 Contract van wetenschappelijke samenwerking tussen de Universiteit Hasselt en het Federaal Agentschap voor Geneesmiddelen en Gezondheidsproducten. (R‐2781) Niel Hens 1/11/2010 15/12/2010

Controle van de juistheid van de gegevens van de bestanden van de leerlingentelling op 12 mei 2010 (R‐2726) Geert Molenberghs 8/11/2010 7/12/2010 Coronaire hartziekten in de spoedgeneeskunde: de juistheid van de gezondheidsgeschiedenis en de fysieke bevindingen. Een systematische review met individuele patiëntgegevens. (R‐2679) Marc Aerts 15/05/2010 31/10/2011

Cursus over 'Longitudinal data analysis' (R‐2466) Yovanna Castro Sanchez 9/06/2010 8/07/2010

De schatting van de infectiekracht voor HCV, onder injecterende drugsgebruikers gebruik makend van interval gecensureerde data (R‐2599) Ziv Shkedy 24/08/2010 31/08/2010 Dienstverleningsopdracht voor een statistische analyse : "Re‐analysis and further exploration of the datasets of two phase 3 clinical trials comparing TMC278 with Sustiva for the treatment of Naïve HIV patients" (R‐2724) Herbert Thijs

20/10/2010 ‐31/12/2010

In House consulting ‐ April 2010 (R‐2629) Geert Molenberghs 1/04/2010 30/04/2010

In House consulting ‐ Februari 2010 (R‐2630) Geert Molenberghs 1/02/2010 28/02/2010

In House consulting ‐ Juni 2010 (R‐2631) Geert Molenberghs 1/06/2010 30/06/2010

In House consulting ‐ Mei 2010 (R‐2632) Geert Molenberghs 1/05/2010 31/05/2010

In house consulting ‐ November 2010 (R‐2727) Geert Molenberghs 1/11/2010 30/11/2010

In house consulting december 2010 (R‐3017) Geert Molenberghs 1/12/2010 31/12/2010

Informatie‐gestuurde modellering van de impact van vervroegde, grootschalige HIV behandeling op de HIV incidentie in Zuidelijk Afrika (R‐2085) Marc Aerts 1/01/2010 31/12/2013

Kostenbaten analyse ‐ Malaria (R‐2464) Niel Hens 7/06/2010 6/07/2010

Longitudinale methoden voor de complexe interacties bij populaties van ouderen. (R‐2373) Geert Molenberghs 1/09/2009 31/08/2011

Milieugezondheidsenquête Noord‐Limburg Deel 1 (R‐2637) Liesbeth Bruckers 19/07/2010 18/08/2010

Milieugezondheidsenquête Noord‐Limburg Deel 2 (R‐2636) Liesbeth Bruckers 19/07/2010 18/08/2010



Milieugezondheidsenquête West‐Limburg deel 1 (R‐2347) Liesbeth Bruckers 9/03/2010 8/04/2010

Milieugezondheidsenquête West‐Limburg deel 2 (R‐2348) Liesbeth Bruckers 9/03/2010 8/04/2010

nalezing / verbetering thesistekst door A.Laenen (R‐2640) Annouschka Laenen 22/06/2010 21/07/2010 Onderaanneming in het kader van het WHO‐project: " Influenza illness and vaccination in Asia: Data collection of Social Contacts and Mixing Patterns" (R‐2371) Niel Hens 1/02/2010 31/08/2010

Onderzoek naar de blootstelling van kleuters aan lood in Beerse en Rijkevorsel. (R‐2309) Liesbeth Bruckers 10/02/2010 9/03/2010

Onderzoek naar klantengegevens (R‐2333) Christel Faes 15/02/2010 14/03/2010

Ontbrekende gegevens in een kosten‐effectiviteit studie (R‐2331) Lien Beunckens 8/02/2010 7/03/2010

Personeelsdatabank 2010 (R‐2910) Marc Aerts 19/01/2010 31/12/2010

Proposal: Kaak hoeken (R‐2588) Herbert Thijs 29/07/2010 ‐ 28/08/2010

Radio Therapie: Risicofactoren voor bestralingswonden (R‐2595) Herbert Thijs 19/07/2010 ‐ 18/08/2010

Res.Project: Consumenten data (R‐2473) Christel Faes 14/06/2010 ‐ 14/07/2010 Samenwerkingsovereenkomst in het kader van het doctoraat : "Nieuwe informatica algoritmen voor de analyse van post‐translationele modificaties in massaspectrometrie gegevens" (R‐2722) Tomasz Burzykowski 5/11/2010 4/11/2014

Spatio‐temporeel modelleren van infectieziekten. (R‐2088) Christel Faes 1/01/2010 31/12/2013

Statistisch advies ‐ HiBMenCY‐TT‐009/‐010 (R‐2541) Geert Molenberghs 28/06/2010 28/07/2010

Statistische verwerking van de gegevens van de "Humerusblock" studie (R‐2725) Liesbeth Bruckers 10/08/2010 9/09/2010

Statistische verwerking voor dienst Nefrologie (R‐2474) Liesbeth Bruckers 14/06/2010 ‐ 14/07/2010

Studietijd: een kernvariabele in actief en zelfstandig studeren (R‐1257) Chris Masui 1/10/2006 31/12/2011

Themadag "The challenge of data analysis in the Life sciences" ‐ Small data sets (R‐2465) Liesbeth Bruckers 7/06/2010 6/07/2010

Voorbereiding + vergadering met G. Molenberghs 01/07/2010 UHasselt (R‐2593) Geert Molenberghs 17/08/2010 16/09/2010


74

7.3 Project proposals in the pipeline 2011 BiR&D (Deadline for submission: May 31, 2011)

VAXINTRADERMAL: Pierre Van Damme, Vanessa Vankerckhoven, Stijn Verwulgen (Artesis), Monique Elseviers (UA‐GEN), Annouck Lievens (UA‐TEW)

E‐RARE PROJECT Evaluation of transcript replacement therapy using mRNA constructs for Cystic Fibrosis. (Joseph Rosenecker (Germany, Coordinator), Zwi Berneman (Belgium), Jean‐Francois Lutz (France), Olga Zegarra‐Moran (Italy), Carsten Rudolph (Germany))

FWO Aspirant • RHAMM as an attractive immunotherapeutic target antigen for dendritic cell‐based induction

of T cell immunity to leukemia and myeloma: groundwork for the development and optimization of a clinical grade multi‐antigenic therapeutic vaccine (Yannick Willemen)

• In vivo identification and validation of immune‐suppressive signalling proteins and/or receptors involved in glioblastoma‐mediated suppression of microglia. (Chloé Hoornaert, Promotors Berneman en Ponsaerts)

FWO Onderzoeksprojecten (Deadline for submission at UA: March 14, 2011) • Incidence, microbial aetiology, diagnosis and prognosis of lower respiratory tract infections

(LRTI) in nursing home (NH) residents and association between antimicrobial resistance and antibiotic consumption (Herman Goossens / Greet Ieven / Samuel Coenen / Katherine Loens)

• The role of CMV‐infection in age‐related hypo‐responsiveness to influenza vaccination. (Pierre Van Damme / Viggo Van Tendeloo / Heidi Theeten)

• Quantification of varicella‐zoster virus boosting mechanisms with their public health implications for vaccination. (Philippe Beutels/ Niel Hens/ Evelien Smits/ Pierre Van Damme)

• T cell immunogenicity of RHAMM and BMI‐1 in leukemia and myeloma patients: towards a multi‐antigen dendritic cell vaccine for hematological malignancies (Zwi Berneman / Viggo Van Tendeloo / Evelien Smits)

• Characterizing host‐pathogen interactions and biofilm formation in patients developing pneumonia on assisted ventilation (Herman Goossens / Surbhi Malhotra‐Kumar / Samir Kumar‐Singh)

• Role of dendritic cells in the development and treatment of alopecia areata: interaction with Toll‐like receptors. (Nathalie Cools / Julien Lambert / An Bervoets)

• The extent of bone marrow dysfunction and the potential to reverse underlying mechanisms in patients with ischemic cardiomyopathy. (Nathalie Cools / Viviane Conraads / Emeline Van Craenenbroeck)

• MSC/MAPC‐based modulation of immune/inflammatory mechanisms underlying hypoplastic MDS (Catherine Verfaillie (KULeuven, Coordinator) / Michel Delforge (KULeuven) / Zwi Berneman (UA))

FWO Coordinatieprojecten (Deadline for submission: April 30, 2011) Continuation GRACE NoE (Herman Goossens / Samuel Coenen / Greet Ieven / Katherine Loens)

FWO Collaboration with Vietnam (joint research projects in the framework of the bilateral agreement Senacyt‐FWO; deadline for submission: April 1, 2011)

Reducing the burden of Pertussis disease in very young infants in different epidemiological settings through Pertussis vaccination in pregnancy. (Promotor Pierre Van Damme (Vlaanderen), co‐promotor Kris Huygen (WIV), promotor: Ang Duc Dang (Vietnam))

FWO Krediet aan Navorsers • Immunomodulatory effects of pregnancy‐related serum factors on autoimmune reactions in

multiple sclerosis (Nathalie Cools)



75

• Methicillin‐resistant Staphylococcus aureus: Exploring the 'biofilmome' for markers of infection (Surbhi Malhotra‐Kumar)

• In vivo non invasive imaging of immunotherapy for acute myeloid in mice (Evelien Smits) FWO Postdoc mandaten

• Control of glioblastoma by modulation of innate immune responses in the central nervous system. (Bart Tambuyzer, Promotors Berneman en Ponsaerts).

• Characterization of innate immune responses in the central nervous system: modulation towards immunological acceptance of allogeneic cellular grafts. (Irene Bergwerf, Promotors Berneman en Ponsaerts).

FWO‐WOG (Deadline for submission: not yet known) Pierre Van Damme & Vanessa Vankerckhoven: negotiations ongoing within the framework of Flanders Vaccine with Marc Van Ranst (KULeuven), Sven Arnouts (UGent), Kris Tielemans (VUB), Niels Hellings (UHasselt), Geert Leroux‐Roels (UGent), ea

IWT‐SBO Interaction‐Transcriptome‐Based Identification of Small Molecules/Proteins That Affect Endogenous Neural Stem Cells, Angiogenesis And Immunomodulation In Diseased Brain (INTERBRAIN). Catherine Verfaillie (KULeuven, Coordinator), Annemie Van der Linden (UA), Veerle Baekelandt (KULeuven), Zwi Berneman (UA), Uwe Himmelreich (KULeuven), Adrian Liston (VIB), Lieven Clement (KULeuven), Geert Verbeke (KULeuven)

IWT‐VIS/TIS (Deadline for submission: not yet known) Pierre Van Damme & Vanessa Vankerckhoven: negotiations ongoing within the framework of Flanders Vaccine

7.4 Difficulties encountered with obtaining additional funding The leading researchers of the Consortium at UA have encountered problems with applying for internal BOF funding, including GOA, NOI, and BOF kleine projecten, as these projects, according to internal UA regulation, do not allow submission by a promotor who already has been granted Methusalem Funding or is promotor of a Center of Excellence. This policy is however only pursued by the University of Antwerp, whereas this is not the case for other Universities, including the partner University within this Methusalem Consortium, Hasselt University. This UA policy contradicts Article 14 undies of the Flemish Government Directive which states that ‘Methusalem Funding does not exclude researchers from applying for additional funding, in particular funding from sources mentioned under Article 1bis’. It should be noted that Article 1bis refers to BOF resources (see Annex IV). Next to BOF funding, the Consortium forsees problems with future FP7, DG Sanco and other EU grant applications. Too few permanent staff is currently employed within the consortium thereby jeopardizing future grant applications for FP7, which require an input of permanent staff next to staff employed by the project. The University of Antwerp decided to limit the percentages of permanent staff to be employed for FP7 projects to 20% for ZAP (in case of coordination otherwise 10%), 5% for AAP and ATP. Next to FP7, DG Sanco and other EU grants require the input of co‐funding of 10% up to 60% which is to be financed through the input of once again permanent staff. The University decided to limit the percentages of permanent staff to be employed for these projects to 20% for ZAP (in case of coordination otherwise 10%), and to merely 5% for AAP and ATP. These rules combined with the shortage of permanent employed within the consortium makes future applications virtually impossible based on the current track record of EU projects submitted or in the pipeline as well as ongoing (see 7.1 and 7.2).


76


8 Human Resources

8.1 Overview of Methusalem Personnel The scientific expertise and excellence of the Consortium, grouping more than 140 staff members, is entrenched in four core research units (Laboratory of Medical Microbiology, Centre for the Evaluation of Vaccination, Laboratory of Experimental Hematology, Center for Statistics) and their leading researchers, Prof. Dr. Herman Goossens (Laboratory of Medical Microbiology, LMM), Prof Dr. Pierre Van Damme (Centre for the Evaluation of Vaccination, CEV), Prof. Dr. Philippe Beutels (Centre for health economics and Modelling & Infectious Disease Modelling), Prof. Dr. Zwi Berman (Laboratory of Experimental Hematology, LEH), Prof. Dr. Viggo Van Tendeloo (Centre for Cell Therapy en Regenerative Medicine, CCRM), Prof. Dr. Geert Molenberghs, Prof. Dr. Marc Aerts, and Prof. Dr. Ziv Shkedy, Prof. Dr. Niel Hens (Center for Statistics, CenStat). The number of staff employed within the Methusalem consortium has increased with 51 staff members from 2007 to date. Currently, 141 staff members are employed in the consortium of which 100 at UA and 42 at UH (Niel Hens has a double affiliation). Within Vaxinfectio, 31 staff members belong to LMM, 39 to CEV and 30 to LEH. The distribution by personnel category from 2007‐2010 of the Methusalem Consortium is presented in Figure 8.1. Figure 8.1 Personnel by category 2007 (n=90) – 2010 (n=141)

Annex VI provides a list of staff members currently employed within the Methusalem Consortium.

11

34

14

9

22

13

40

25

9

28

3 3

13

54

27

11

29

2

5

0

10

20

30

40

50

60

2007

2009

2010

- Human Resources -

78

The Consortium applies, to the maximum extent possible, the university’s policy for equal opportunities; hence gender equality principles are being applied in the personnel policy of the Consortium. In 2007, almost 60% (53 out of 90) of the staff was female of which almost 75% (39 out of 53) belonged to the academic personnel (1 ZAP, 5 postdocs and 33 predocs). The number of women employed within the Consortium slightly decreased in 2009 to 55% (67 out of 121) of which 67% (45 out of 67) belonged to the academic personnel, but there were more women in higher positions (2 ZAP, 11 postdocs and 32 predocs). In 2010, the number slightly increased again to 57% (80 out of 141) of which 71% belonged to the academic personnel (57 out of 80). Again, more women were noted in higher positions (2 ZAP, 14 postdocs, 36 predoc and 5 scientific personnel).

8.2 Opportunities for Postdoctoral Researchers Due to its relative size, the Consortium tries to offer career opportunities and perspectives for young researchers, as well as a career perspective to more established researchers. The Methusalem Consortium was in, terms of gender equality, able to offer career perspectives for women. From 2007 to now, one postdoc was promoted to ZAP and 6 employees were offered a postdoc position. Also, since 2009 Vaxinfectio has a young female postdoc appointed as IOF (Industrial Research Fund) manager (now called research & innovation manager) for Vaxinfectio. This position is being paid by the Industrial Research Fund (IOF) of the University of Antwerp. The Consortium is investing in proper and suitable training and guidance for their young predoctoral researchers under the spupervision of its postdoctoral researchers. Also, Vaxinfectio has adopted the policy that specific training and education needs will be identified and incorporated as much as possible for each individual staff member. Nevertheless, additional funding and career perspectives by the University of Antwerp are needed to enable sufficient long‐term perspectives for postdoctoral staff. This includes establishing middle management opportunities for postdoc researchers at UA.

8.3 PhD students & PhDs obtained In 2007, a total of 43 PhD students were employed within the Consortium. This number further increased to 58 in 2009 and to 65 in 2010. Figure 8.2 gives an overview of the PhD students in 2007 to 2010. Figure 8.3 clearly shows that the vast majority of all newly recruited PhD students are being paid through external funding. Moreover, more than 80% of the PhD students are being paid by external funded projects (national and international funding). To date, 2 PhDs (Evelien Smits and Vanessa Vankerckhoven) have been succesfully obtained within the Consortium; both postdoc researchers have been able to continue their career within Vaxinfectio (FWO postdoctoral fellowship, IOF Research and Innovation Manager). Brice Amadeo defended his PhD end 2010 at the University of Bordeaux. Although part of his PhD consisted of work performed at LMM, we were unable to obtain a double PhD diploma in collaboration with the University of Bordeaux. However, this policy will be persued for future PhDs in which a substantial collaboration with other universities, e.g. UHasselt, leads to the work described in the PhD thesis. We expect that 21 PhDs will be obtained during the next 2 years (2011‐2012) of which 5 at CEV (H. Theeten, E. Leuridan, B. De Vos, J. Bilcke, G. Hanquet), 4 at LMM (C. Vael, P. Zarb, N. Adriaenssens, L. Van Heirstraeten), 5 at LEH (A. Van Driessche, E. Lion, A. Van de Velde, I. Bergwerf, K. Reekmans), and 7 at UH (A. Gaddah, A. Kasim, P. Haldermans, Q.A. Zhu, A. Creemers, N. Goeyvaerts, S. Pramana).


Figure 8.2 PhD Students 2007‐2010

Figure 8.3 External vs UA funding of PhD students

9 911

34

40

54

2

7

0

10

20

30

40

50

60

2007 2009 2010

AAP

BAP

Consultant

Other

0%

10%

20%

30%

40%

50%

60%

70%

80%

90%

100%

2007 2009 2010

Predoc UA/UH Funding

Predoc External Funding

- Human Resources -

80


81

9 Budget & Investments

9.1 Overall budget 20082014 3.453.079 EUR (incl.10% overhead) for the University of Antwerp part, and 1.726.540 EUR (incl. 10% overhead) for the Hasselt University part. Thus, for the period 2008‐2014, the total Methusalem budget amounts to 5.179.619 EUR.

9.2 Budget Vaxinfectio The resources of the Methusalem programme are considered as a continuous basic investment fund in support of ongoing and future research. Next to Methusalem Funding, the Consortium has also applied for additional external and internal funding (see heading 5: External Research Funding) and will continue to apply for resources in terms of projects and scholarships from traditional research funding agencies such as BOF, FWO, IWT, EU and others, to complement or increase the Methusalem funding. A central operational budget has been set aside to strengthen the collaboration among the participating research teams, and to develop new common collaborations with other teams in and outside the consortium and the 2 universities. The remaining budget at UA has been divided equally among the three leading research groups, as to provide them with a minimum of means to implement their research activities.

Investments in expert personnel 2010 CEV has continued the funding of expert personnel for vaccine study coordination and improvement of internal quality of vaccine studies (e.g. drafting SOPs) as well as for translational research in collaboration with the industry. This investment has led to a diversification of the number of companies that have initiated vaccine trials at the clinical trials centre. Meanwhile, the investment in this expert personnel has led to an increased capacity for research project and protocol development. LMM has recruited 1 additional technician to conduct the experimental work for the newly granted and ongoing EU and non‐EU projects. One additional PhD student was recruited to work on the newly granted VLIR project in collaboration with the University of Limpopo. Within the ESAC project a new data manager was recruited who has started a PhD as well as a clinical scientist for the Hospital Care subproject who has also started a PhD. All PhD students are working on a PhD thesis of which the topics are in line with the newly granted EU and non‐EU projects. Moreover, several new EU‐funded and non‐EU funded projects will start as from 2011 for which additional personnel (PhD students as well as postdoc researchers) will be recruited. LEH continues the funding of expert personnel for the analysis of cellular immunity in longitudinal vaccine trials performed by CEV as well as for the preparation of therapeutic DC vaccines in cancer patients. LEH has recruited 1 additional lab technician involved in the preparation of therapeutic DC vaccines in cancer patients. Also, they recruited 2 new PhD students active on the topic of cellular immunotherapy of cancer and on correlates of cellular immunity following prophylactic HPV vaccination.

Investments in stateoftheart technologies, methodologies and equipment 2010 It is obvious that an investment in the latest available technologies and equipment is a must, if the Consortium wishes to remain in the forefront of academic research. The investments in specific equipment have been determined by the ongoing and future research topics. The Methusalem funding made investment in specific equipment possible:

- Budget & Investments -

82

EQUIPMENT at LEH 1. Microscopy facility Part of Methusalem funding was used to co‐finance the establishment and maintenance of an internal microscopy facility. The current set‐up includes: (i) a new Olympus BX51 fluorescence microscope (+ Z‐axis controller) equipped with an Olympus DP71 digital camera, and (ii) a refurbished Leica inverted fluorescence microscope with an Olympus UC30 digital camera. Additionally, Olympus deconvolution and Tissuequest fluorescence analysis software is available for respectively image enhancement and quantitative data analysis (i.e. digital image conversion to FACS‐like images for co‐localisation studies). 2. Transgenic mouse collection Part of Methusalem funding was used to co‐finance the establishment and housing of an internal transgenic mouse collection for in vivo cell transplantation and immunogenicity research. This collection includes the following transgenic mice: FVB‐Luc, FVB‐eGFP/Luc, albino C57BL/6, C57BL/6‐eGFP and C57BL6‐CX3CR1/eGFP. All equipment is available for use by all members of the Consortium.

Future Investments in stateoftheart technologies, methodologies and

equipment For the planned shift of LMM and the labs of LEH to the 6th floor of Building S end of 2011, the Methusalem funding will be used to invest in laboratory equipment, which will lead to not only optimatisation of the labs and an improvement of their competitive position, but will also enable accreditation of the laboratory of Medical Microbiology. As it is planned now by the UA infrastructure department, the move of the CEV clinical trial team to the second floor of Building S will take place in 2013. From experience with previous moves, CEV plans to make some financial provisions for extra costs that will not be covered by the central infrastructure budget. CCRG is gearing up to obtain a manufacturing authorization (MA) of investigational medicinal products (IMP’s) from the Belgian authorities (FOD‐Public Health) and will likely undergo an early‐phase GMP inspection in 2011. Eventually, this will allow the production of IMP for multicenter clinical trials between different EU member states in the field of cancer vaccination.

9.3 Budget CenStat CenStat considers the Methusalem funding a continuous reseach fund. The CenStat budget is used to fund predoctoral positions focusing on statistical methodology within the collaboration with all research partners at UA. In addition, a part time postdoctoral position, overseeing the collaboration between CenStat and Vaxinfectio is funded. Next to the Methusalem funding, CenStat continuously applies for additional external and internal funding and will continue to apply for resources in terms of projects and scholarships from traditional research funding agencies such as BOF, FWO, IWT, EU, and others, to complement or increase the Methusalem funding. Furthermore, Methusalem funding has been used to buy laptops and powerful desktops as well as to fund participation at scientific conferences of its Methusalem‐funded researchers.

Investments in expert personnel 20082009 Next to the two predoctoral researchers already working on the Methusalem grant, CenStat has attracted a third predoctoral researcher focusing on modelling epidemic data in collaboration with the research partners at UA. A new postdoctoral fellow is now partly funded by the Methusalem project. Her role is to intensify the collaboration in the field of bioinformatics. Moreover, she


83

together with Prof. Dr. Niel Hens who holds a shared UHasselt‐UA appointment supervises the collaboration between CenStat and Vaxinfectio.

Future Investments The new postdoctoral fellow will be fully funded by the Methusalem project from mid 2011. Given the available funding, CenStat will continuously recruit new pre‐ and postdoctoral researchers to maximize the implementation of the Methusalem research plan. It will also further expand its computing facilities and active participation at international conferences by presentations and short courses presenting up‐to‐date statistical methodology as used in the research activities of the consortium.

- Budget & Investments -

84


85

10 Annexes

Annex I: Administrative information Annex II: Minutes of the Board of Directors Annex III: List of papers, book and book chapters Annex IV: Programmes of the workshops/conferences Annex V: Extract from the Flemish Government Directive Annex VI: Personnel list

- Annex I -

86


87

10.1 ANNEX I: Administrative Information Team leader at the University of Antwerp: Prof. Dr. Herman Goossens Responsibile for the scientific and technical coordination of the project at the University of Antwerp. Address: Medical Microbiology, Campus Drie Eiken, Universiteitsplein 1, BE 2610 Antwerpen Telephone: +32‐3‐821.37.87 Fax number: +32‐3‐825.42.81 Email: [email protected] Leading researchers: These are leading the core and collaborating research units, which constitute the Centre of Excellence, Vaxinfectio. 1. Prof. Dr. Pierre Van Damme Address: CEV, Campus Drie Eiken, Universiteitsplein 1, BE 2610 Antwerpen Telephone: +32‐3‐265.25.38 Fax number: +32‐3‐265.26.40 Email: [email protected] 2. Prof. Dr. Zwi Berneman Address: Hematology, UZA, Wilrijkstraat 10, BE 2650 Edegem Telephone: +32‐3‐821.37.80 Fax number: +32‐3‐821.42.86 Email: [email protected] 3. Prof. Dr. Samuel Coenen Address: Huisartsgeneeskunde, Campus Drie Eiken, Universiteitsplein 1, BE 2610 Antwerpen Telephone: +32‐3‐265.25.25 Fax number: +32‐3‐265.25.26 Email: [email protected] 3. Prof. Dr. Philippe Beutels Address: CHERMID, Campus Drie Eiken, Universiteitsplein 1, BE 2610 Antwerpen Telephone: +32‐3‐265.25.38 Fax number: +32‐3‐265.27.52 Email: [email protected] 4. Prof. Dr. Viggo Van Tendeloo Address: CCRG, UZA, Wilrijkstraat 10, BE 2650 Edegem Telephone: +32 3 821 36 61 Fax number: +32 3 821 44 56 Email: [email protected] or [email protected] Team leader at Hasselt University: Prof. Dr. Geert Molenberghs Responsibile for the scientific and technical coordination of the project at Hasselt University. Address: Center for Statistics, Hasselt University, Campus Diepenbeek, Agoralaan 1, BE 3590, Diepenbeek. Telephone: +32‐11‐26.82.38 or +32‐11‐26.82.02 Fax number: +32‐11‐26.82.99 Email: [email protected] Leading researchers: 1. Prof. Dr. Marc Aerts

- Annex I -

88

Address: Center for Statistics, Hasselt University, Campus Diepenbeek, Agoralaan 1, BE 3590, Diepenbeek. Telephone: +32‐11‐26.82.47 or +32‐11‐26.82.02 Fax number: +32‐11‐26.82.99 Email: [email protected] 2. Prof. Dr. Ziv Shkedy Address: Center for Statistics, Hasselt University, Campus Diepenbeek, Agoralaan 1, BE 3590, Diepenbeek. Telephone: +32‐11‐26.82.40 or +32‐11‐26.82.02 Faxumber: +32‐11‐26.82.99 Email: [email protected] 3. Prof. Dr. Niel Hens Address: Center for Statistics, Hasselt University, Campus Diepenbeek, Agoralaan 1, BE 3590, Diepenbeek. Telephone: +32‐11‐26.82.32 or +32‐11‐26.82.02 Faxumber: +32‐11‐26.82.99 Email: [email protected] Research and Innovation Manager (IOF): Responsible for overall management and technology transfer of the Vaxinfectio & Methusalem consortium. Dr. Vanessa Vankerckhoven Address: Medical Microbiology, Campus Drie Eiken, Universiteitsplein 1, BE 2610 Antwerpen Telephone: +32‐3‐265.21.57 Fax number: +32‐3‐265.27.52 E‐mail: [email protected] Administrative coordinator: Responsibile for the administrative and financial coordination of the Vaxinfectio & Methusalem consortium. Gino Verwimp Address: Department of Epidemiology and Social Medicine, Campus Drie Eiken, Universiteitsplein 1, BE 2610 Antwerpen Telephone: +32‐3‐265.25.21 Fax number: +32‐3‐265.26.40 Email: [email protected] Recipient institution 1: University of Antwerp Legal address: Contact address: Stadscampus Campus Drie Eiken Prinsstraat 13 Universiteitsplein 1 BE 2000 Antwerpen BE 2610 Antwerpen Recipient institution 2: Hasselt University Legal and contact address: Campus Diepenbeek Agoralaan 1 BE 3590 Diepenbeek Participating institution: Universitair Ziekenhuis Antwerpen (UZA) Legal and contact address: Wilrijkstraat 10 2650 Edegem


89

10.2 ANNEX II: Minutes of the meeting of the Board of Directors

UA‐UH METHUSALEM CONSORTIUM VAXINFECTIO‐CENSTAT

Minutes of the Board of Directors Meeting

Wednesday 13 October 2010

12.00 to 13.00 hrs

Meeting room

University of Hasselt, Campus Diepenbeek

Participants

The Board of Directors of the UA‐UH Methusalem Consortium Vaxinfectio‐CenStat is composed of

the heads of the 4 participating core research groups, the (part‐time) ZAP members (9), all

postdocoral researchers (13), the Vaxinfectio Research & Innovation ('IOF') Manager, the designated

administrative coordinator, the administrative officers of the Department of Research of UA and UH,

and the respective chairmen of the Research Councils UA and UH:

(Present number (as per 01/09/2010): 31)

Goossens Herman , Chair and Head LMM (UA)

Molenberghs Geert, Vice‐chair and Head CenStat (UH)

Van Damme Pierre, Head CEV (UA)

Berneman Zwi , Head LEH (UA)

Vankerckhoven Vanessa , Research & Innovation Manager (IOF) – (UA)

Verwimp Gino, Administrative coordinator (UA)

Spruyt Eric , Head Department of Research, ADOC (UA)

Peters Ann , Head Research Coordination (UH)

Timmermans Jean‐Pierre , Chairman Research Council (UA)

Janssen Paul , Chairman Research Council (UH)

Aerts Marc (100% ZAP) (UH)

Beutels Philippe (100% ZAPBOF) (UA)

Faes Christel (100% ZAP) (UH)

- Annex II -

90

Hens Niel (100% ZAP) (UA/UH)

Shkedy Ziv (100% ZAP) (UH)

Van Tendeloo Viggo (100% ZAPBOF) (UA)

Ieven Greet (10% ZAP) (UA)

Schroyens Wilfried (10% ZAP) (UA)

Van Herck Koen (10% ZAP) (UA)

Andraud Mathieu (100% postdoc BAP) (UA)

Anthierens Sibyl (80% postdoc BAP) (UA)

Coenen Samuel (100% BAP) (UA)

Cools Nathalie (100% postdoc BAP) (UA)

Lejeune Olivier (100% postdoc BAP) (UA)

Loens Katherine (80% postdoc BAP) (UA)

Malhotra Surbhi (100% postdoc BAP) (UA)

Muller Arno (100% postdoc BAP) (UA)

Ponsaerts Peter (100% postdoc BAP) (UA)

Smits Evelien (100% postdoc BAP) (UA)

Tambuyzer Bart (100% postdoc BAP) (UA)

Vermeulen Katrien (100% postdoc BAP) (UA)

Present at the meeting (16):

Aerts Marc

Andraud Mathieu

Berneman Zwi

Beutels Philippe

Coenen Samuel

Cools Nathalie

Hens Niel

Malhotra Surbhi

Ponsaerts Peter

Sage Caroline (on behalf of the Research Departments)

Smits Evelien

Goossens Herman, Chairman

Van Damme Pierre

Van Herck Koen

Van Tendeloo Viggo

Verwimp Gino (Minutes)


91

Agenda

• Introduction of participants • Administrative issues • Overview of activities in the current year ‐ annual report • Research plan

Meeting report

Introduction of participants

Prof. Goossens, Chair of the meeting, welcomes the members present at the meeting. Prof.

Molenberghs, vice‐chair, is excused because of other urgent commitments. As introduction, the

members are requested to briefly present their background and present assignment, as well as their

role in the Methusalem consortium.

Administrative issues

Recently, preparatory discussions were held at the level of the University administration regarding

the management and follow‐up of the activities of the UA‐UH Methusalem consortia, also in terms of

evaluation of the scientific output. The set of rules that have been developed based on the legislation

providing the Methusalem funding is under review.

The Board of Directors is responsible for the management of the consortium, and more specifically

for setting the guidelines of the scientific strategy to be developed over the coming years.

Overview of activities in the current year ‐ annual report

The members are informed that, in line with the Methusalem rules, an Advisory Board has been

established, composed of 3 internationally renowned scientists: Prof. Chris Butler, Cardiff University,

Prof. Ron Dagan, Ben‐Gurion University, and Prof. Haruo Sugiyama, Osaka University. The mandate

of this Board is to provide support and advice on the long‐term research policy and on the priorities

of the research agenda of the consortium. In the present set‐up, an annual report is composed and

submitted for advice to the advisory Board. The first report covered both the years 2008 and 2009,

and has been positively evaluated by the Advisory Board members. The next report will be published

in the first quarter of 2011. The preliminary version will be presented to the UA Rector during an

audition at the end of January ‐ beginning of February 2011. It is expected that this evaluation

process should be completed by the end of March 2011.

According to the terms of the collaboration agreement between UA en UH on the Methusalem

funding dd. 01/01/2008, there should be an initiative for a joint evaluation at the end of the second

and 4th year. The evaluation at the end of the second year has not taken place. We might expect an

- Annex II -

92

evaluation at the end of the 4th year (beginning 1012). It is perceived that our consortium has the

closest and most intense research collaboration compared to the 3 other consortia. Therefore, it is

assumed that more stringent deadlines will not be applied.

Research Plan

The research activities and research opportunities will be extensively covered during the afternoon

session of the Third Methusalem Research Day, taking place this afternoon. A relevant selection of

the presentations can be found on the website activated as part of the information exchange. The

meeting will again present an opportunity to find linkages between the different research topics and

research projects, ongoing as well as planned, between the various research units within the

consortium. A number of opportunities of a more structural nature are forthcoming:

1. Project on Biobanking ‐ Clinical Research Centre Anwerp

The recent establishment of the Center for Medical Innovation (CMI) with funding from the Flemish

government might open some interesting opportunities for research innovation and development.

Some members of Vaxinfectio are directly involved in this new setting, i.e. Greet Ieven and Viggo Van

Tendeloo, the latter being formally proposed as a member of the steering committee of the Clinical

Research Centre (CRC).

2. Flemish Vaccination Platform

The establishment of a vaccination platform, with the support from BioFlanders, has been initiated

by Vaxinfectio, i.e. Pierre Van Damme and Vanessa Vankerckhoven. The main purpose of this

initiative is to initiate a wider network to establish collaboration links with the various SMEs active in

the Biotechnology sector in order to be prepared when specific calls for proposals from various

funding agencies are launched such as EU, IWT. The platform is hence a network of academics and

industry, i.e. biotechnology companies active in the field of diagnostics and vaccine development.

3. Forthcoming calls for research proposals

Information is exchanged on the various projects that have been submitted to the FWO, during the

last call, and for which the evaluation procedure is still ongoing. In addition, information is presented

on the ongoing evaluation of a major GOA project (LMM), and on the forthcoming calls from the

respective UA and UH Special Research Fund (BOF), such as interdisciplinary PhD projects and NOI.

Plans for new submissions for mandates and projects in response to the forthcoming FWO call are

briefly mentioned. Reference is also made to the new IMI Call 2010 with deadline on 18/01/2011.

The meeting is closed at 13.00hrs. The members proceed to attend the Third Joint Scientific Meeting


93

10.3 ANNEX III: List of Papers, Books and Book chapters 2010 Joint publications UA‐UH (also listed under Vaxinfectio and CenStat separately)

• Bilcke, J.; van Hoek, A.; Hens, N.; Aerts, M.; Edmunds, W. & Beutels, P. Cost‐effectiveness of varicella and zoster vaccination in England &Wales: importance measures for correlated parameters Procedia. In: Social and Behavioral Sciences, 2010, 2, 7611 ‐ 7612

• Goeyvaerts N., Hens N., Ogunjimi B., Aerts M., Shkedy Z., Van Damme P., Beutels P. Estimating transmission parameters and the basic reproduction number using social contact data and serological data on varicella zoster virus in Belgium." JRSS‐C, In press.

• Goeyvaerts N., Hens N., Ogunjimi B., Aerts M., Shkedy Z., Van Damme P., Beutels P. Estimating infectious disease parameters from data on social contacts and serological status. In: JRSS‐C, Appl. Statist. (2010) , 59, Part 2.pp255‐277.

• Hens N., Van Ranst M., Aerts M., Robesynd E., VanDamme P., Beutels P. Estimating the effective reproduction number for pandemic influenza from notification data made publicly available in realtime: Amulti‐country analysis for influenzaA/H1N1v2009. In: Vaccine (article in press).

• Hens, N., Aerts, M., Faes, C., Shkedy, Z., Lejeune, O., Van Damme, P. and Beutels, P. Seventy‐ five years of estimating the force of infection. In: Epidemiology and Infection, 138(6), pp. 802‐812.

• Hens, N., Kvitkovicova, A., Aerts, M., Hlubinka, D., Beutels, P. Modelling Distortions in Seroprevalence Data Using Change‐point Fractional Polynomials. In: Statistical Modelling, 10, 159‐175

• Lenders K., Ogunjimi B., Beutels P., Hens N., Van Damme P., Berneman ZN., Van Tendeloo VF., Smits E. The effect of apoptotic cells on virus‐specific immune responses detected using IFN‐gamma ELISPOT. In: J Immunol Methods. 2010 May 31;357(1‐2):51‐4. Epub 2010 Mar 6.PMID: 20214906 [PubMed ‐ indexed for MEDLINE].

• Leuridan E, Hens N, Hutse V, Aerts M, Van Damme P. Kinetics of maternal antibodies against rubella and varicella in infants. Vaccine. 2010 Jun 14.

• Leuridan, E., Hens, N., Hutse, V., Ieven, M., Aerts, M., Van Damme, P. Early Waning of Maternal Measles Antibodies in the Era of Global Measles Vaccination. In: The British Medical Journal. 340:c1626.

• Leuridan, E., Hens, N., Hutse, V., Ieven, M., Aerts, M., Van Damme, P. Early Waning of Varicella and Rubella Antibodies. In: Vaccine. 2010 Jun 14.

• Mebis J., Jansens H., Minalu G., Molenberghs G., Schroyens WA, Gadisseur A., van de Velde A., Vrelust I., Goossens H., and Berneman Z.N. Long‐term epidemiology of bacterial susceptibility profiles in adults suffering from frebile neutropenia withhematologic malignancy after antibiotic change. In: Infection and Drug resistance 3:53‐61

• Theeten H., Hutse V., Hens N., Yavuz Y., Hoppenbrouwers K., Beutels P., Vranckx R, Van Damme P. Are we hitting immunity targets? The 2006 age‐specific seroprevalence of measles, mumps, rubella, diphtheria and tetanus in Belgium. In: Epidemiol. Infect., Page 1 of 11. f Cambridge University Press 2010 Vaxinfectio

• Adriaenssens N., Coenen S.,Muller A., Vankerckhoven V., Goossens H. and on behalf of the ESAC Project Group. European Surveillance of Antimicrobial Consumption (ESAC): outpatient systemic antimycotic and antifungal use in Europe. In: Journal of Antimicrobial Chemotherapy. 8/2/2010, 10.1093/jac/dkq023.

• Adriaenssens N., De Corte S., Coenen S., Grieten E., Goossens H. E‐Bug: implementation of e‐BUG in Belgium. In: J Antimicrob Chemother (in press).

• Aldeyab M., Kearney M., McElnay J., Magee F., Conlon G., Gill D., Davey P., Muller A., Goossens H., Scott M. A point prevalence survey of antibiotic prescriptions: benchmaking and patterns of use. In: British Journal of Clinical Pharmacology. 17/10/2010

• Amadeo B., Zarb P., Muller A., Drapier N.,Vankerckhoven V., Rogues A., Davey P., Goossens H. ESAC Point Prevalence Survey 2008: Paediatric Antimicrobial Prescribing in 32 Hospitals of 21 European Countries.‐ In: Journal of Antimicrobial Chemotherapy, Manuscript ID: JAC‐2010‐0520.R1

• Amadeo B., Dumartin C., Parneix P., Fourrier‐Réglat A., and Rogues AM. Relationship between antibiotic consumption and antibiotic policy: an adjusted analysis in the French healthcare system. In:JAC Advance Access published on December 9, 2010 , J. Antimicrob. Chemother. 2011 66: 434‐442;

- Annex III -

94

• Anguille S., Smits E., Cools N., Goossens H., Berneman Z.,Van Tendeloo V. Short‐term cultured, interleukin‐15 differentiated dendritic cells have potent immunostimulatory properties. In: Journal of Translational Medicine 2009, 7:109.

• Ansari F., Molana H., Goossens H., Davey P., ESAC II Hospital Care study group. Development of standardized methods for analysis of changes in antibacterial use in hospitals from 18 European countries: the European Surveillance of Antimicrobial Consumption (ESAC) longitudinal survey, 2000‐06. In: J Antimicrob Chemother 2010 Dec;65(12):2685‐91.

• Arbyn M., Simoens C., van Damme P., Scharpantgen C., Meijer C., Beutels P. Introduction of human papillomavirus vaccination in Belgium, Luxembourg and the Netherlands In: Gynecologic and obstetric investigation ‐ ISSN 0378‐7346 ‐ 70:4(2010), p. 224‐232

• Bankole A., Saegerman A., Berkvens D., Fretin D., Geerts S.,Ieven M., Walravens K. ‐ Phenotypic and genotypic characterization of Brucella strains isolated from cattle in the Gambia In: Veterinary Record 2010; 166: 753‐756

• Berneman Z., Anguille S., Van Marck V., Schroyens W., Van Tendeloo V. Induction of complete remission of acute myeloid leukaemia by pegylated interferon‐alpha‐2a in a patient with transformed primary myelofibrosis. In: Br J Haematol Apr;149(1):152‐5.

• Beutels P., Jit M. A brief history of economic evaluation for human papillomavirus vaccination policy In: Sexual health ‐ ISSN 1448‐5028 ‐ 7:3(2010), p. 352‐358

• Butler C., Hood K., Goossens H., Kelly M., Verheij T. et al. Treatment of acute cough/LRTI by antibiotic class and associated outcomes: A 13 European country observational study in primary care. In: J Antimicrob Chemother. 65:2472‐8

• Coosemans A., Wölfl M., Berneman ZN., Van Tendeloo V., Vergote I., Amant F., Van Gool SW. Immunological response after therapeutic vaccination with WT1 mRNA‐loaded dendritic cells in end‐stage endometrial carcinoma. In: Anticancer Res. Sep;30(9):3709‐14.

• David M‐P., Van Herck K., Hardt K., Tibaldi F., Dubin G., Descamps D., Van Damme P. Long‐term persistence of anti‐HPV‐16 and ‐18 antibodies induced by vaccination with the AS04‐adjuvanted cervical cancer vaccine: Modeling of sustained antibodyresponses. In: Gynecologic Oncology 115 (2009) S1–S6.

• De Schryver A.,Verstrepen K.,Vandersmissen L.,Vandermeeren N.,Vernaillen I.,Vranckx R.,Van Damme P.,van Sprundel M. Comparative immunogenicity of two vaccination schedules of a combined hepatitis A and B vaccine in healthy volunteers. In: Journal of Viral Hepatitis, 2010.

• FitzSimons D., Hendrickx G., Vorsters A., Van Damme P. Hepatitis A and E: Update on prevention and epidemiology. In: Vaccine, 2010; 28: 583‐588.

• Giaquinto C., Van Damme P., REVEAL Study Group. Age distribution of paediatric rotavirus gastroenteritis cases in Europe: The REVEAL Study. In: Scand J Infect Dis, 2010; 42(2): 142‐147.

• Goeyvaerts N., Hens N., Ogunjimi B., Aerts M., Shkedy Z., Van Damme P.,Beutels P.Estimating infectious disease parameters from data on social contacts and serological status.In:Journal of the Royal Statistical Journal.Appl. Statist. (2010)59, Part 2.

• Hens N.,Van Ranst M., Aerts M., Robesynd E., VanDamme P., Beutels P. Estimating the effective reproduction number for pandemic influenza from notification data made publicly available in realtime: Amulti‐country analysis for influenzaA/H1N1v2009. In: Vaccine (article in press).

• Ho E., Coveliers J., Amsel B.J, Stockman B., Walpot J., Ieven M., Rodrigus I. A Case of Endocarditis due to Aerococcus urinae. In: J of Heart Valve Disease 2010;19( 2): 264‐266

• Hunter PA., Dawson S., French GL., Goossens H., et al. Antimicrobial‐resistant pathogens in animals and man: prescribing, practices andpolicies. ‐In: J Antimicrob Chemother. 2010;65 Suppl 1:i3‐17.

• Huttner B., Goossens H., Verheij T. and Harbarth S. Characteristics and outcomes of public health campaigns with the aim to improve outpatient antibiotic use in high income countries. In: Lancet Infectious Disases 10:17‐31.2010.

• Itzler R., Koch G., Matson D., Gothefors L., Van Damme P., DiNubile M., Heaton P. Robustness of the healthcare utilization results from the Rotavirus Efficacy and Safety Trial (REST) evaluating the human‐bovine (WC3) reassortant pentavalent rotavirus vaccine (RV5). In: BMC Pediatrics, 2010.

• Ieven M., Loens K. Pathogens in lower respiratory tract infections. In: Molecular diagnostics of infectious diseases / Kessler, Harald H. [edit.] ‐ CISB 978‐3‐11‐021485‐7 ‐ Berlin, De Gruyter, p. 115‐134


95

• Keogh‐Brown M., Wren‐Lewis S., Edmunds J., Beutels P., Smith R. The possible macroeconomic impact on the UK of an influenza pandemic In: Health economics ‐ ISSN 1057‐9230 ‐ 19:11(2010), p. 1345‐1360

• Keogh‐Brown M., Smith R., Edmunds J., Beutels P. The macroeconomic impact of pandemic influenza: estimates from models of the UK, France, Belgium and The Netherlands. In: European Journal of Health Economics 2010;11(6):543‐54.

• Kleinberger G., Wils H., Ponsaerts P., Joris G., Timmermans JP., Van Broeckhoven C., Kumar‐Singh S. Increased caspase activation and decreased TDP‐43 solubility in progranulinknock‐out cortical cultures In: Journal of Neurochemistry 2010; 115:3,

• Lambrechts N., Vanheel H., Nelissen I., Witters H., Van Den Heuvel R., Van Tendeloo V., Schoeters G., Hooyberghs J. Assessment of chemical skin sensitizing potency by an in vitro assay based on human dendritic cells. Toxicol Sci 2010 Apr 7.

• Lambrechts N., Vanheel H., Hooyberghs J., De Boever P., Witters H., Van Den Heuvel R., Van Tendeloo V., Nelissen I., Schoeters G. Gene markers in dendritic cells unravel pieces of the skin sensitization puzzle. In: Toxicol Lett 196(2):95‐103.

• Lenders K., Ogunjimi B., Beutels P., Hens N., Van Damme P., Berneman ZN., Van Tendeloo VF., Smits E. The effect of apoptotic cells on virus‐specific immune responses detected using IFN‐gamma ELISPOT. In: J Immunol Methods. 2010 May 31;357(1‐2):51‐4. Epub 2010 Mar 6.PMID: 20214906 [PubMed ‐ indexed for MEDLINE].

• Leuridan E., Hens N., Hutse V., Aerts M., Van Damme P. Kinetics of maternal antibodies against rubella and varicella in infants. In: Vaccine. 2010 Jun 14. [Epub ahead of print]

• Leuridan E., Hens N., Hutse V., Ieven M., Aerts, M., Van Damme, P. Early waning of maternal measles antibodies in era of measles elimination: longitudinal study. In: BMJ, 2010; 340: 1626

• Leuridan, E., Hens, N., Hutse, V., Ieven, M., Aerts, M., Van Damme, P. Early Waning of Varicella and Rubella Antibodies. In: Vaccine. 2010 Jun 14.

• Loens K., Mackay WG., Scott C., Goossens H., Wallace P., Ieven M. A multicenter pilot external quality assessment programme to assess the quality of molecular detection of Chlamydophila pneumoniae and Mycoplasma pneumoniae. Journal Microbiol Methods. 2010 May 18.

• Loens K., Goossens H., and Ieven M. Update on the detection and characterization of bacterial pathogens by nucleic acid amplification. In: David Persing, Editor in Chief. 2010.

• Loens K., Goossens H., Ieven M. Acute respiratory infection due to Mycoplasma pneumoniae: current status of diagnostic methods. In: Eur J Clin Microbiol Infect Dis. 2010 Jun 6. [Epub ahead of print]PMID: 20526788

• Mahieu L., van Gasse N., Wildemeersch D., Jansens H., Ieven M. Number of sites of perinatal Candida colonization and neutropenia are associated with nosocomial candidemia in the neonatal intensive care unit patient. In: Pediatric Critical Care Medicine. 11:240‐245

• Malhotra‐Kumar S., Abrahantes JC., Sabiiti W., Lammens C., Vercauteren G., Ieven M., Molenberghs G., Aerts M., Goossens H; MOSAR WP2 Study Team. Evaluation of chromogenic media for detection of methicillin‐resistant Staphylococcus aureus. In: J Clin Microbiol. 48:1040‐6.2010.

• Malhotra‐Kumar S., Van Heirstraeten L., Lee A., Abrahantes JC., Lammens C., Vanhommerig E., Molenberghs G., Aerts M., Harbarth S., Goossens H; MOSAR WP2 Study Team. Evaluation of molecular assays for rapid detection of methicillin‐resistant Staphylococcus aureus. In: J Clin Microbiol. 48:4598‐601.

• Martinet W., De Meyer I., Cools N., Timmerman V., Bosmans J, De Meyer G. Cell death‐mediated cleavage of the attraction signal p43 in human atherosclerosis: Implications for plaque destabilization. In: Arteriosclerosis, Thrombosis, and Vascular Biology, 30: 1415‐22.

• Masiero G., Filippini M., Ferech M., Goossens H. Socioeconomic determinants of outpatient antibiotic use in Europe. In: Int.Journal of Public Health. July 2010.

• Mebis J., Goossens H.,Berneman Z. Cefepime and mortality: a real issue? In: Scandinavian Journal of Infectious Diseases : 1‐4.

• Mebis J., Jansens H., Minalu G., Molenberghs G., Schroyens WA, Gadisseur A., van de Velde A., Vrelust I., Goossens H., and Berneman Z.N. Long‐term epidemiology of bacterial susceptibility profiles in adults suffering from frebile neutropenia withhematologic malignancy after antibiotic change. In: Infection and Drug resistance 3:53‐61

• Mebis J., Goossens H., Berneman Z. Antibiotic Management of Febrile Neutropenia: Current Developments and Future Directions. In: Journal of Chemotherapy. 22:5‐12

- Annex III -

96

• Merregaert J., van Langen J., Hansen U., Ponsaerts P., El Ghalbzouri A., Steenackers E., Van Ostade X., Sercu S. Phospholipid scramblase 1 is secreted by an unconventional mechanism and interacts with the extracellular matrix protein 1 in thedermal epidermal junction zone of human skin . In: Journal of Biological Chemistry 2010; 285:48

• Michiels B., Thomas I., Van Royen P., Coenen S. Clinical prediction rules combining signs, symptoms and epidemiological context to distinguish influenza from influenza‐like illnesses in primary care: a cross sectional study. In: BMC Family Practice 2011, 12:4

• Naesens R., Jansens H., Goossens H., Ieven M., Vlieghe E. Potential of doripenem for the treatment of infections with multidrug‐resistant Pseudomonas. In: spp. Int J Antimicrob Agents. 35:514‐5. 2010.

• Nguyen Muriel, Leuridan Elke, Zhang Tong, De Wit Dominique, Willems Fabienne, Van Damme Pierre, Goldman Michel, Goriely Stanislas. Acquisition of adult like TLR responses during the first year of life. PlosOne 2010 Apr 28;5(4):e10407

• Paccalin M.,Weinberger B.,Nicolas J‐F,Van Damme P, Me´gard : The intradermal vaccination route – an attractive opportunity for influenza vaccination in the elderly, In: European Geriatric Medicine 1 (2010) 82–87

• Parolini O., Alviano F., Bergwerf I., Boraschi D., De Bari C., De Waele P., Dominici M., Evangelista M., Falk W., Hennerbichler S., Hess DA., Lanzoni G., Liu B., Marongiu F., McGuckin C., Mohr S., Nolli ML., Ofir R., Ponsaerts P., Romagnoli L., Solomon A., Soncini M., Strom S., Surbek D., Venkatachalam S., Wolbank S., Zeisberger S., Zeitlin A., Zisch A., Borlongan CV. Toward cell therapy using placenta‐derived cells: Disease mechanisms, cell biology, preclinical studies, and regulatory aspects at the round table. In: Stem Cells and Development. In press.

• Peremans L., Rethans JJ., Verhoeven V., Coenen S., Debaene L., Meulemans H., Denekens J., Van Royen P. Empowering patients or general practitioners? A randomised clinical trial to improve quality in reproductive health care in Belgium. In: Eur J Contracep Repr 2010;15:280‐9.

• Poland G., Langley J., Michel JP., Van Damme P., Wicker S. A global prescription for adult immunization: time is catching up with us. In: Vaccine 2010; 28: 7137‐7139.

• Reekmans K., Praet J., De Vocht N., Tambuyzer B., Bergwerf I., Daans J., Baekelandt V., Vanhoutte G., Goossens H., Jorens P., Ysebaert D., Chatterjee S., Pauwels P., Van Marck E., Berneman Z., Van der Linden A., Ponsaerts P. Clinical potential ofintravenous neural stem cell delivery for treatment of neuro‐inflammatory disease in mice? In: Cell Transplant. (in press, DOI: 10.3727/096368910X543411) 2010.

• Roman F., Vaman T., Kafeja F., Hanon E, Van Damme P. AS03A‐Adjuvanted Influenza A (H1N1) 2009 Vaccine for Adults up to 85 Years of Age . In: CID 2010:51 (15 September).

• Romano L., Paladini S., Van Damme P., Zanetti A. The worldwide impact of vaccination in the control and protection of viral hepatitis B. In: Digestive and Liver Disease Supplements 4 (2010) 56–61

• Sanidas I., Kotoula V., Ritou E., Daans J., Lenz C., Mairhofer M., Daniilidou M., Kolbus A., Kruft V., Ponsaerts P., Nikolakaki E. The ratio of SRPK1/SRPK1a regulates erythroid differentiation in K562 leukaemic cells. In: Biochimica et Biophysica Acta – Molecular Cell Research (BBA‐MCR) 1803:12

• Smits E., Cools N., Lion E., Van Camp K., Ponsaerts P., Berneman Z., Van Tendeloo V.. The Toll‐like receptor 7/8 agonist resiquimod greatly increases the immunostimulatory capacity of human acute myeloid leukemia cells. In:Cancer Immunol Immunother 2010;59(1):35‐46. Epub 2009 May 16

• Smits E., Berneman Z. Viral infections following allogeneic stem cell transplantation: how to cure the cure? In: Leuk Lymphoma. 2010 Jun;51(6):965‐6.

• Stanton N., Hood K., Kelly M.J., Nuttall J., Gillespie D., Verheij T., Little P., Godycki‐Cwirko M., Goossens H., Butler CC. Are Smokers with cough in primary care prescribed antibiotics more often; to what benefit? In: European Respiratory Journal. 35:761‐767. 2010.

• Theeten H., Hutse V., Hens N., Yavuz Y., Hoppenbrouwers K., Beutels P., Vranckx R, Van Damme P. Are we hitting immunity targets? The 2006 age‐specific seroprevalence of measles, mumps, rubella, diphtheria and tetanus in Belgium . In: Epidemiol. Infect., Page 1 of 11. f Cambridge University Press 2010

• Van Berendoncks A., Beckers P., Hoymans VY., Possemiers N., Coenen S., Elseviers M., Vrints C., Conraads VM. Beta‐blockers modify the prognostic value of adiponectin in chronic heart failure. In: Int J Cardiol 2010.

• Van Damme P., Arnou R., Kafeja F., Fiquet A., Richard P., Thomas S., Meghlaoui G., Samson S., Ledesma E.and Haugh M. Evaluation of non‐inferiority of intradermal versus adjuvanted seasonal


97

influenza vaccine using two serological techniques: a randomised comparative study In: BMC Infectious Diseases 2010, 10:134doi:10.1186/1471‐2334‐10‐134.

• Van der Wielen M., Giaquinto C., Gothefors L., Huelsse C., Huet F., Littmann M., Maxwell M., MP Talayero J., Todd P.,Vila M.,Cantarutti L.,Van Damme P.: Impact of community‐acquired paediatric rotavirus gastroenteritis on family life: data from the REVEAL study. In: BMC Family Practice 2010, 11:22

• Van Camp K., Cools N., Stein B., Van de Velde A., Goossens H., Berneman ZN., Van Tendeloo V. Efficient mRNA electroporation of peripheral blood mononuclear cells to detect memory T cell responses for immunomonitoring purposes. In: J Immunol Methods. 2010 Mar 31;354(1‐2):1‐10.

• Van Gulck E., Van Tendeloo VF., Berneman ZN., Vanham G. Role of dendritic cells in HIV‐immunotherapy. In: Curr HIV Jun;8(4):310‐22

• Van Ierssel S., Van Craenenbroeck E., Conraads V., Van Tendeloo V., Vrints C., Jorens P., Hoymans V. Flow cytometric detection of endothelial microparticles (EMP): Effects of centrifugation and storage alter with the phenotype studied. In: Thromb Res. Jan 29.

• Vankerckhoven V., Van Damme P. Clinical studies assessing immunogenicity and safety of intradermally administered influenza vaccines. In: Expert Opin Drug Delivery, 2010 Sep;7(9):1109‐25.

• Van Tendeloo V., Van de Velde A., Van Driessche A., Cools N., Anguille S., Ladell C., Gostick E., Vermeulen K., Pieters K., Nijs G., Stein B., Smits E., Schroyens W., Gadisseur A., Vrelust I., Jorens P., Goossens H., de Vries J., Price D., Oji Y., Oka Y., Sugiyama H., and Berneman Z. Induction of complete and molecular remissions in acute myeloid leukemia by Wilms’ tumor 1 antigen‐targeted dendritic cell vaccination ‐ In: PNAS.

• Vesikari T., Itzler R., Karvonen A., Korhonen T., Van Damme P., et al. RotaTeq, a pentavalent rotavirus vaccine: Efficacy and safety among infants in Europe. In: Vaccine; 2010, 28: 345‐351.

• Vesikari T., Van Damme P., Lindblad N., Pfletschinger U., Radley D., Ryan D., et al. An open‐label, randomized, Multicenter study of the safety tolerability, and immunogenicity of quadrivalent human papillomavirus (Types 6/11/16/18) Vaccine given concomitantly with diphtheria, tetanus, pertussis, and poliomyelitis vaccine in healthy adolescents 11 to 17 years of age. In: Ped Infect Dis J, 2009; 29: 314‐318.

• Vorsters A., Tack S., Hendrickx G., Vladimirova N., Bonanni P., Pistol A., Metlicar T., Pasquin MJ., Mayer MA., Aronsson B., Heijbel H., Van Damme P. A summer school on vaccinology: responding to identified gaps in pre‐service immunization training of futurehealth care workers. In: Vaccine, 2010; 25; 28(9): 2053‐9.

• Walker D., Hutubessy R., Beutels P. WHO guide for standardisation of economic evaluations of immunization programmes In: Vaccine / International Society for Vaccines‐ISSN 0264‐410X‐28:11(2010), p. 2356‐2359

• Zakaria N., Koppen C., Van Tendeloo V., Berneman Z., Hopkinson A., Tassignon MJ. Standardized limbal epithelial stem cell graft generation and transplantation. In: Tissue Engineering Part C Methods. Feb 4.

• Zarb P., Amadeo B., Muller A., Drapier N., Vankerckhoven V., Davey P., Goossens H., and on behalf of the ESAC‐3 hospital care subproject group. Identification of targets for quality improvement in antimicrobial prescribing: the web‐based ESAC Point Prevalence Survey 2009. In: JAC Advance Access published on November 17, 2010 , J. Antimicrob. Chemother. 2011 66: 443‐449 CenStat

• Aerts M., Hens N., Simono J.S. Model Selection Based on Presmoothing. In: Journal of Applied Statistics. 37‐9, 1455

• Creemers A., Hens N., Aerts M., Molenbergh, G., Verbeke G. and Kenward M.G. Sensitivity Analysis for Shared‐parameter Models for Incomplete Longitudinal Outcomes. In: The Biometrical Journal. 52, 111‐125.

• Goeyvaerts N., Hens N., Ogunjimi B., Aerts M., Shkedy Z., Van Damme P., Beutels P. Estimating transmission parameters and the basic reproduction number using social contact data and serological data on varicella zoster virus in Belgium." JRSS‐C, In press.

• Goeyvaerts N., Hens N., Ogunjimi B., Aerts M., Shkedy Z., Van Damme P., Beutels P. Estimating infectious disease parameters from data on social contacts and serological status. In: JRSS‐C, Appl. Statist. (2010) , 59, Part 2.pp255‐277.

- Annex III -

98

• Hens N., Van Ranst M., Aerts M., Robesynd E., VanDamme P., Beutels P. Estimating the effective reproduction number for pandemic influenza from notification data made publicly available in realtime: Amulti‐country analysis for influenzaA/H1N1v2009. In: Vaccine (article in press).

• Hens, N., Aerts, M., Faes, C., Shkedy, Z., Lejeune, O., Van Damme, P. and Beutels, P. Seventy‐ five years of estimating the force of infection. In: Epidemiology and Infection, 138(6), pp. 802‐812.

• Hens, N., Kvitkovicova, A., Aerts, M., Hlubinka, D., Beutels, P. Modelling Distortions in Seroprevalence Data Using Change‐point Fractional Polynomials. In: Statistical Modelling, 10, 159‐175 Books & Book Chapters

• Cools N, Ponsaerts P, Van Tendeloo V. “Balancing between immunity and tolerance: Interplay between dendritic cells, effector T cells and regulatory T cells” by Lambert Academic Publishing (2010) ISBN 978‐3‐8383‐3312‐0

• Ieven M.; Loens K., Molecular Diagnostics of Infectious Diseases (Kessler), Chapter10. • Loens K., Goossens H., and Ieven M. Update on the detection and characterization of bacterial

pathogens by nucleic acid amplification. In: David Persing, Editor in Chief. Molecular Microbiology: Diagnostic principles and practice. In press.

• Ieven M. and Loens K. Pathogens in Lower Respiratory Tract Infections. In: H. Kessler. Molecular Diagnostics of Infectious Diseases. In press.

• Walker D., Beutels P., Hutubessy R. Economic evaluation of childhood vaccines.‐ In: Economic evaluation in child health / Ungar, W. [edit.], S.l., , 2009, p. 1‐27.


99

10.4 ANNEX IV: Programme of the Methusalem Research Day n°3 (2010)

Third Joint Scientific Meeting – Methusalem Consortium: Vaccine & Infectious Disease Institute (Vaxinfectio),

University of Antwerp Center for Statistics (CenStat),

University of Hasselt

October 13, 2010

Background: The Methusalem Consortium consists of the Vaccine and Infectious Disease Institute (Vaxinfectio) of the University of Antwerp (UA) and the Center for Statistics (CenStat) of the University of Hasselt (UH). Vaxinfectio consists of the Laboratory of Medical Microbiology (LMM), the Laboratory of Experimental Hematology (LEH), and Centre for Evaluation of Vaccination (CEV). The two research institutes, Vaxinfectio and CenStat, have been awarded Methusalem funding in 2008 and will organise joint annual scientific meetings.

The third meeting will be organised on October 13, 2010, at the University of Hasselt.

Venue: Hasselt University, Campus Diepenbeek, Agoralaan 1, 3590 Diepenbeek Room TBA

Programme:

9.30 ‐ 12.00 Workshop on Linear Mixed Models with hands on session using R

Geert Molenberghs & Niel Hens

12.00 – 13.00 Lunch / Meeting Board of Directors

13.00 – 16.40 Joint research collaborations Vaxinfectio‐CenStat

Chair: Geert Molenberghs & Herman Goossens

13.00 – 13.10 Welcome

Geert Molenberghs, UHasselt

13.10 – 13.20 Objectives of the meeting

Herman Goossens, UA & Geert Molenberghs, UHasselt

13.20 – 13.40 Research at CenStat

Marc Aerts, UHasselt

13.40 – 14.00 Research at CEV

Pierre Van Damme, UA

14.00 – 14.30 Varicella and Zoster vaccination: 1 virus, 2 diseases, and a lot of headaches

Joke Bilcke, UA & Nele Goeyvaerts, UHasselt

14.30 – 14.50 Coffee break

14.50 – 15.10 Research at LMM

Herman Goossens, UA

- Annex IV -

100

15.10 – 15.40 Macrolide resistance in S. pyogenes and link with antibiotic use

Liesbet Van Heirstraeten, UA

15.40 – 16.00 Research at LEH

Zwi Berneman, UA

16.00 – 16.30 Dendritic cells in multiple sclerosis: key players in the immunopathogenesis, key players for

new cellular therapies?

Amber Nuyts, UA

16.30 – 16.45 FlandersBio: Collaboration opportunities academia‐industry

Hilde Van Raemdonck (FlandersBio)

16.45 – 17.00 Concluding remarks

Luc De Schepper, UHasselt

17.00 Reception


101

10.5 ANNEX V: Extracts of the Flemish Government Directive

HOOFDSTUK [Ibis.] - Financieringsbeginselen

B.Vl.R. 24-1-2003

Artikel [1bis.]

§ 1 Elk van de universiteiten, bedoeld in artikel 3 van het decreet van 12 juni 1991 betreffende de universiteiten in de Vlaamse Gemeenschap, brengt de financiële middelen die door de Vlaamse Gemeenschap overeenkomstig artikel 168 van het decreet worden bijgedragen voor wetenschappelijk onderzoek, onder in een intern bestemmingsfonds, genoemd "Bijzonder Onderzoeksfonds".

§ 2 Onder de term "de middelen van het Bijzonder Onderzoeksfonds" wordt in dit Besluit verstaan : de overheidsbijdragen bedoeld in artikel 2 van dit besluit, aangevuld met de eigen bijdrage, bedoeld in § 1 van artikel 6 van dit besluit.

§ 3 Ieder jaar voor 1 oktober deelt de Vlaamse regering aan elke universiteit het bedrag mede van de overheidsbijdragen die zij krachtens artikel 2 van dit besluit kunnen verwachten. De raming van de inkomsten en de uitgaven van het Bijzonder Onderzoeksfonds maakt integraal deel uit van de begroting van de universiteit onder de afdeling IV.

§ 4 De overheidsbijdragen aan het Bijzonder Onderzoeksfonds worden door de Vlaamse Regering definitief vastgesteld van zodra de algemene uitgavenbegroting van de Vlaamse Gemeenschap voor het desbetreffende begrotingsjaar is vastgelegd.

[Hoofdstuk IVbis. - De Methusalem-financiering voor internationaal toonaangevende onderzoekers

Afdeling 1. - Algemeen

Art. 14bis.

Voor het toekennen van langetermijnprogramma-financiering aan een beperkt aantal uitmuntende ZAP-leden, verbonden aan universiteiten in de Vlaamse Gemeenschap, wordt per universiteit een overheidsbijdrage, verder de Methusalem-financiering genoemd, toegekend.

De Methusalem-financiering wordt toegekend en aangewend overeenkomstig de voorwaarden gesteld in dit hoofdstuk.

Afdeling 2. - Kenmerken van de financiering

Art. 14ter.

§ 1. Voor het begrotingsjaar 2006 wordt de Methusalem-financiering vastgesteld op 3.000.000 euro. Dit bedrag geldt als referentiebedrag. Binnen de perken van de

- Annex V -

102

begrotingskredieten wordt de subsidie geleidelijk verhoogd in de periode 2007-2010 om in 2010 haar hoogtepunt te bereiken.

§ 2. De Methusalem-financiering wordt jaarlijks geïndexeerd, conform artikel 2, § 2.

§ 3. De verdeling van de Methusalem-financiering over de Vlaamse universiteiten gebeurt overeenkomstig de in artikel 3 bedoelde verdeelsleutel.

§ 4. De Methusalem-financiering wordt met behoud van bestemming toegevoegd aan het Bijzonder Onderzoeksfonds.

De aan het Bijzonder Onderzoeksfonds toekomende middelen die na afloop van het betrokken kalenderjaar niet zijn toegewezen, kunnen met behoud van bestemming worden overgedragen naar de begroting van de universiteit.

§ 5. Het staat de universiteiten vrij het beschikbare bedrag voor de Methusalem-financiering te verhogen :

1° uit eigen middelen en/of

2° uit het onbestemde deel van het Bijzonder Onderzoeksfonds.

De in het eerste lid, 2°, bedoelde inbreng is vanaf 2010 beperkt tot maximaal 5% van het onbestemde deel van het Bijzonder Onderzoeksfonds.

Artikel 6, § 1, en artikel 8, 7° zijn niet van toepassing op de Methusalem-financiering.

§ 6. Voor de uitvoering van de Methusalem-financiering kunnen de universiteiten overheadkosten aanrekenen tot een maximum van 10 %.

[[De overheadkosten kunnen worden besteed aan de vergoeding van kosten (werkingskosten en loonkosten) die rechtstreeks verbonden zijn aan het beheer van de ten laste van de Methusalemmiddelen bekostigde onderzoeksprojecten, of aan de vergoeding van centrale beheerskosten en algemene exploitatiekosten van de universiteit.]]

Afdeling 3. - Voorwaarden voor de financiering

Art. 14quater.

§ 1. De Vlaamse universiteiten zijn belast met het operationeel en financieel beheer van de Methusalem-financiering.

§ 2. Elke universiteit legt de voorwaarden van de Methusalem-financiering in een reglement vast. Dit reglement werkt de nadere regelen uit met betrekking tot :

1° de organisatie van de oproep, als bedoeld in artikel 14quinquies ;

2° de eisen waaraan kandidaten moeten voldoen, als bedoeld in artikel 14sexies ;

3° de selectieprocedure, als bedoeld in artikel 14septies ;


103

4° de evaluatie, als bedoeld in artikel 14octies ;

5° de procedure voor beëindiging, als bedoeld in artikel 14novies.

Art. 14quinquies.

§ 1. De universiteit die de procedure start voor de toekenning van Methusalem-financiering door middel van het lanceren van een oproep, deelt dit aan de andere Vlaamse universiteiten mee in het kader van een mogelijk overleg inzake samenwerking tussen onderzoekers uit verschillende instellingen.

§ 2. Kandidaten-onderzoekers dienen hun aanvraag voor het bekomen van Methusalem-financiering in bij hun universiteitsbestuur.

In de aanvraag verklaren zij uitdrukkelijk in te stemmen met een eventuele bekendmaking conform artikel 14ter decies, § 2.

Art. 14sexies.

Kandidaten voor de Methusalem-financiering moeten :

1° aan de criteria van excellentie voldoen waaruit blijkt dat ze substantieel bijdragen aan de ontwikkeling van hun vakgebied en hiervoor internationale erkenning genieten;

2° bewijzen dat zij meer dan andere onderzoekers bestaande financieringskanalen, zoals GOA-, IUAP-, EU-, FWO- en IWT-financiering, hebben weten te benutten;

3° over een onderzoeksgroep beschikken met een voldoende kritische massa, zoals ondermeer kan blijken uit het aantal postdoctorale onderzoekers dat hiervan over een langere periode deel uitmaakt;

4° een onderzoeksplan bij de betreffende universiteit(en) indienen, dat een begroting bevat met een indicatieve verdeling van de geplande uitgaven over een periode van zeven jaar.

Art. 14septies.

§ 1. Voor de beoordeling van de kandidaten stelt elke universiteit internationale panels samen. De leden van deze panels zijn niet in België werkzaam en genieten een internationale erkenning. Bij de samenstelling van de panels wordt rekening gehouden met de discipline of, in geval van interdisciplinair onderzoek, met de disciplines waarin de kandidaten actief zijn. In een panel dient de universiteit er naar te streven dat ten hoogsten 2/3den van het totaal aantal leden behoren tot hetzelfde geslacht. In het geval van een samenwerkingsverband tussen twee of meer universiteiten, zoals bedoeld in § 7, stellen de betrokken universiteiten één enkel panel samen.

§ 2. Gemiddeld over alle panels, die een universiteit instelt, vanaf de inwerkingtreding van deze bepaling tot eind 2009, kan ten hoogste 2/3den van het totaal aantal leden tot hetzelfde geslacht behoren. Panels die door twee of meer universiteiten samen worden ingesteld, worden bij deze berekening aan elk van deze universiteiten toegewezen.

- Annex V -

104

Indien een universiteit niet voldoet aan de in het eerste lid bedoelde regel, wordt voor het eerst vanaf 2011 de overheidsbijdrage aan het BOF verminderd met 0,25 % en dit tot het jaar t waarbij in het jaar (t-2) de instelling aan deze voorwaarde voldoet.

§ 3. De universiteit legt de samenstelling van de panels voor voorafgaand advies voor aan het FWO. Het FWO voert een meta-beoordeling van de internationale wetenschappelijke erkenning van de panelleden door en formuleert op grond daarvan een gemotiveerd advies. Indien het advies afwijzend is, geeft het FWO aan op welke wijze de vastgestelde gebreken geremedieerd kunnen worden. Slechts na positief advies van het FWO kan het panel worden ingesteld.

§ 4. Bij de beoordeling van een aanvraag past het panel de in artikel 14quater, § 2, 2°, bedoelde eisen toe, rekening houdend met de specificiteit van het betrokken vakgebied en onderzoeksdomein.

Het panel maakt de wijze van toetsing inzichtelijk.

Het panel gaat tevens na of met het aangevraagde bedrag van de Methusalem-financiering de onderzoeksgroep verder uitgebouwd kan worden tot een internationale referentiepositie. Het panel kan in dit verband bijsturingen voorstellen.

§ 5. Het panel legt zijn bevindingen neer in een omstandig geargumenteerd advies.

§ 6. Op advies van de onderzoeksraad en eventueel andere door het universiteitsbestuur aangeduide instanties beslist het universiteitsbestuur rekening houdend met het globale onderzoeksbeleid van de universiteit welke kandidaten die door een panel positief werden beoordeeld, financiering zullen ontvangen. Indien het aangevraagde bedrag aan financiering wordt aangepast dient het instellingsbestuur rekening te houden met het advies van het panel ter zake en zijn beslissing om hier eventueel van af te wijken te onderbouwen.

§ 7. Als twee of meer universiteiten beslissen samen financiering toe te kennen, sluiten ze een overeenkomst af, waarin het volgende bepaald wordt :

1° de getroffen regeling voor het functioneren van het geheel;

2° het aandeel van elke instelling in de financiering;

3° de modaliteiten inzake beëindiging van de financiering overeenkomstig artikel 14octies.

Afdeling 4. - Evaluatie

Art. 14octies.

§ 1. De onderzoeker die financiering ontvangt, wordt om de zeven jaar door een panel, dat aan de in artikel 14septies bedoelde voorwaarden voldoet, geëvalueerd.

Dit panel beoordeelt :

1° of het verrichte werk internationaal toonaangevend is en aan de verwachtingen voldoet;


105

2° het human resources beleid en in het bijzonder de mate waarin post-doctorale onderzoekers die werken in onderzoeksgroepen van ZAP-leden die Methusalem-financiering ontvangen, worden gestimuleerd ervaring op te doen met het opzetten van zelfstandig onderzoek;

3° of het onderzoeksplan voor de volgende zeven jaar en de aangevraagde financiering adequaat zijn.

Het panel kan suggesties voor de ontwikkeling van het onderzoek doen.

In het geval van een samenwerkingverband tussen twee of meer universiteiten, zoals bedoeld in artikel 14septies, § 7, wordt door de betrokken universiteiten één enkel evaluatiepanel samengesteld.

§ 2. Op basis van de in § 1 beschreven tussentijdse evaluatie beslist het universiteitsbestuur over de voortzetting van de financiering.

Afdeling 5. - Beëindiging van de financiering

Art. 14novies.

§ 1. Als de financiering wordt beëindigd op grond van een negatieve tussentijdse evaluatie, worden de toegekende middelen vanaf het jaar dat de beslissing is genomen, jaarlijks verminderd met 25 %.

Als de financiering wordt beëindigd omdat het ZAP-lid het emeritaat bereikt, worden de toegekende middelen [[vanaf het derde jaar]] voor de beëindiging jaarlijks verminderd met 25 %.

Indien een onderzoeker, die financiering ontvangt, om andere redenen dan het emeritaat de universiteit verlaat, duidt het instellingsbestuur een gewoon hoogleraar aan om tijdelijk als wetenschappelijk directeur op te treden en wordt de regeling betreffende de afbouw van de financiering, vermeld in het tweede lid, van toepassing.

§ 2. Als gevolg van de toepassing van de in § 1 beschreven geleidelijke beëindiging, wordt een nieuwe financiering stapsgewijs opgebouwd. Met de vrijgekomen middelen kan vervolgens een nieuwe kandidaat voor de Methusalem-financiering geselecteerd worden.

§ 3. Het bereiken van het emeritaat houdt niet in dat de betrokken universiteit de financiering niet aan een andere onderzoeker kan toekennen, op voorwaarde dat conform artikel 14septies blijkt dat deze aan de in artikel 14sexies vermelde criteria voldoet.

Afdeling 6. - Organisatorische elementen

Art. 14decies.

§ 1. Het ZAP-lid ontvangt, behoudens in het geval van artikel 14novies, § 1, financiering tot aan het emeritaat. Het ZAP-lid treedt op als wetenschappelijk directeur en draagt de eindverantwoordelijkheid voor de besteding van de onderzoeksmiddelen, het onderzoeksbeleid en het dagelijks bestuur van de onderzoeksgroep.

- Annex V -

106

Bij een samenwerkingsverband tussen twee of meer universiteiten fungeert het ene ZAP-lid als directeur en de andere(n) als codirecteur(s).

§ 2. De omvang van de middelen is afhankelijk van de discipline en bedraagt over de periode van zeven jaar jaarlijks gemiddeld minstens viermaal het bedrag als bedoeld in artikel 8, eerste lid, 2, en maximaal 2.000.000 euro per jaar.

In het geval van een samenwerkingsverband tussen twee of meer universiteiten, zoals bedoeld in artikel 14septies, § 7, gelden bovenstaande minimum- en maximumbedragen voor de financiering die de universiteiten samen toekennen.

§ 3. Het ZAP-lid kan de middelen besteden aan werking, personeel, uitgezonderd de salariskosten bedoeld in § 5, en uitrusting.

§ 4. De universiteit stelt aan het ZAP-lid en zijn/haar onderzoeksgroep de nodige lokalen en basisvoorzieningen ter beschikking.

§ 5. De universiteit betaalt de salariskosten van het ZAP-lid en eventuele andere aan de onderzoeksgroep verbonden ZAP-leden.

Art. 14undecies.

Het toekennen van een Methusalem-financiering aan ZAP-leden sluit niet uit dat onderzoekers die verbonden zijn aan de onderzoeksgroep van betrokken ZAP-leden middelen verwerven van andere financieringsbronnen, in het bijzonder de middelen vermeld in artikel 1bis.

Art. 14duodecies.

§ 1. In de schoot van de onderzoeksgroep van het ZAP-lid waaraan een Methusalem-financiering wordt toegekend, wordt een beheerscomité ingesteld. Hierin zetelen minstens de ZAP-leden die verbonden zijn aan de onderzoeksgroep. Het ZAP-lid waaraan de financiering wordt toegekend, fungeert als voorzitter. In het geval van een samenwerkingsverband tussen twee of meer universiteiten, zoals bedoeld in artikel 14septies, § 7, wordt één enkel beheerscomité ingesteld. Eén van de ZAP-leden waaraan financiering wordt toegekend, fungeert als voorzitter en de/het andere ZAP-lid/leden waaraan financiering wordt toegekend als co-voorzitter.

§ 2. Het beheerscomité staat in voor het bestuur van de onderzoeksgroep(en), inzonderheid voor het uitstippelen van het wetenschappelijk beleid van de onderzoeksgroep(en).

§ 3. De onderzoeksgroep of, in geval van een samenwerkingsverband, de onderzoeksgroepen, stelt/stellen eveneens een adviesraad in, waarin onderzoekers die in het betrokken vakgebied internationale erkenning genieten zetelen. Deze adviesraad geeft onder meer ondersteuning bij het uitstippelen van het langetermijnonderzoeksbeleid en het vaststellen van prioriteiten in de onderzoeksagenda.

Afdeling 7. - Rapportering

Art. 14ter decies.


107

§ 1. Artikel 12, § 1, § 2 en § 3 is van toepassing op de Methusalem-financiering.

Het jaarverslag bevat voor wat betreft de Methusalem-financiering minstens :

1° een overzicht van de gefinancierde initiatieven;

2° een toetsing van de stand van uitvoering van de gefinancierde initiatieven;

3° de eventuele bijsturing van de gefinancierde initiatieven.

§ 2. Het universiteitsbestuur publiceert op haar website de gemotiveerde beslissing van het universiteitsbestuur, bedoeld in artikel 14septies, § 7, ten aanzien van de geselecteerde kandidaat.

Tevens worden de beslissingen over de voortzetting van de financiering, bedoeld in artikel 14octies, § 2, gepubliceerd op de website van de universiteit.

In geval van een samenwerkingsovereenkomst wordt deze eveneens op de website van de betrokken universiteiten gepubliceerd. Ter zake kunnen de universiteiten beslissen om een gemeenschappelijke website te gebruiken.

Art. 14quater decies.

Om het verloop van de Methusalem-financiering systematisch te volgen, zullen de universiteiten jaarlijks aan de Minister, bevoegd voor het wetenschappelijk onderzoek en het technologisch innovatiebeleid, rapporteren over de volgende set van statistische parameters :

1° de verhouding tussen het aantal ingediende en gehonoreerde aanvragen (in aantal en in budget, wetenschapsgebied, nationaliteit (Belgisch, EU, niet-EU) en geslacht;

2° de verhouding tussen de aangevraagde en de toegekende kredieten bij geselecteerde voorstellen.]

B.Vl.R. 8-12-2006; [[ ]] B.Vl.R. 12-12-2008

- Annex V -

108


109

10.6 ANNEX VI: Personnel list anno 2010 Nr Naam Label Level FTE Affiliation

1 Adriaenssens,Niels BAP predoc 1.00 LMM

2 Aerts Marc ZAP gewoon hoogleraar

1.00 CenStat

3 Alonso Abad Ariel BAP postdoc 1.00 CenStat 4 Amadeo,Brice BAP predoc NA LMM 5 Andraud Mathieu BAP postdoc nav 1.00 CEV 6 Anguille,Sébastien BAP predoc 1.00 LEH 7 Anthierens,Sibyl BAP postdoc nav 0.80 LMM 8 Azmon, Amin BAP predoc 1.00 CenStat 9 Bergwerf,Irene BAP predoc 1.00 LEH

10 Berneman,Zwi ZAP gew.hoogl. 1.00 LEH 11 Beutels,Philippe ZAPBOF hfd.docent 1.00 CEV 12 Bilcke,Joke BAP predoc 0.90 CEV 13 Blommaert, Adriaan BAP predoc 1.00 CEV 14 Bontenakel,Aline ATP technician 1.00 CEV 15 Braeckman,Tessa BAP predoc 1.00 CEV 16 Broodhaers,Serge ATP technician 1.00 CEV 17 Bruckers Liesbeth BAP predoc 1.00 CenStat 18 Bruynseels,An ATP technician 0.75 CEV 19 Bryssinck,Liesbeth ATP technician 1.00 LMM 20 Burzykowski Tomasz ZAP hoofddocent 0.70 CenStat 21 Callaert Kris ATP admin 0.70 CenStat 22 Castro Sanchez Yovanna BAP predoc 1.00 CenStat 23 Chapelle,Sabine ATP technician 0.50 LMM 24 Claesen Jurgen BAP predoc 1.00 CenStat 25 Coenen,Samuel BAP postdoc nav 1.00 LMM 26 Cools,Nathalie BAP postdoc FWO 1.00 LEH 27 Cortiñas Abrahantes José BAP postdoc 1.00 CenStat 28 Creemers An AAP predoc 1.00 CenStat 29 Daans,Jasmijn ATP technician 0.80 LEH 30 De Knop, Kathleen BAP predoc 1.00 LEH 31 De Coster, Ilse BAP scient pers 0.80 CEV 32 De Vocht, Nathalie BAP predoc 0.50 LEH 33 Del Fava Emanuele BAP predoc 1.00 CenStat 34 Devos Beatrice BAP predoc NA CEV 35 Desloovere,Hilde ATP admin 1.00 CEV 36 Dighou,Naïma ATP technician 1.00 CEV 37 Drapier Nico BAP consultant 1.00 LMM 38 Engelen,Emmy ATP admin 1.00 CEV 39 Ensoy, Chellafe BAP predoc 1.00 CenStat 40 Faes Christel ZAP docent 1.00 CenStat 41 Gaddah Auguste BAP predoc 1.00 CenStat 42 Gadisseur,Alain BAP gastprof 1.00 LEH 43 Gazin,Muriel BAP predoc 1.00 LMM 44 Geerdens Candida AAP predoc 1.00 CenStat 45 Gitome Arthur BAP predoc 1.00 CenStat 46 Goeyvaerts Nele BAP predoc 1.00 CenStat 47 Goossens,Herman ZAP gew.hoogl. 1.00 LMM 48 Grouwels Yves BAP predoc 1.00 CenStat

- Annex VI -

110

Nr Naam Label Level FTE Affiliation 49 Guerti Khadija BAP predoc 1.00 LEH 50 Habteab Ghebretinsae Aklilu BAP predoc 1.00 CenStat 51 Haldermans Philippe AAP predoc 1.00 CenStat 52 Hanquet, Germaine BAP predoc 1.00 CEV 53 Hendrickx,Greet ATP admin 1.00 CEV 54 Hens Niel BAP docent‐gastprof 0,50‐0,50 CenStat‐CEV 55 Hens,Annick BAP scient pers 1.00 CEV 56 Hutse, Veronik BAP predoc 1.00 CEV 57 Ieven,Margareta ZAP hfd.docent 0.10 LMM 58 Jans, Béatrice BAP scient pers 1.00 LMM 59 Kafeja,Froukje BAP scient pers 0.90 CEV 60 Kasim Adetayo BAP predoc 1.00 CenStat 61 Khamiakova Tatsiana BAP predoc 1.00 CenStat 62 Laenen Annouschka BAP postdoc 1.00 CenStat 63 Lammens,Christine ATP technician 1.00 LMM 64 Lejeune,Olivier BAP postdoc nav 1.00 CEV 65 Lenders,Kevin ATP technician 1.00 LEH 66 Leten,Gert ATP technician 1.00 LMM 67 Leuridan,Elke AAP predoc 1.00 CEV 68 Lin Dan BAP postdoc 1.00 CenStat 69 Lion,Eva BAP predoc 1.00 LEH 70 Litiere Saskia BAP postdoc 1.00 CenStat 71 Loens,Katherine BAP postdoc nav 0.80 LMM 72 Luyten,Jeroen BAP predoc 1.00 CEV 73 Malhotra,Surbhi BAP postdoc nav 1.00 LMM 74 Marais,Christiaan BAP predoc 1.00 CEV 75 Martin,Manuella BAP lesgever 1.00 LMM 76 Micalessi, Maria Isabel BAP predoc 1.00 CEV 77 Milanzi Elasma BAP predoc 1.00 CenStat 78 Minalu Ayele Girma BAP predoc 1.00 CenStat

79 Molenberghs Geert ZAP gewoon hoogleraar

0.70 CenStat

80 Muller,Arno BAP postdoc.sub 1.00 LMM 81 Mutambanengwe, Chenjerai BAP predoc 1.00 CenStat 82 Muylle,Ludo M M A BAP gastprof 0.25 LEH 83 Neels, Pieter BAP postdoc 1.00 CEV 84 Neyens Thomas BAP predoc 1.00 CenStat 85 Nijs Griet ATP technician 1.00 LEH 86 Njagi Edmund BAP predoc 1.00 CenStat 87 Nuyts,Amber BAP predoc 1.00 LEH 88 Nys,Sophie ATP admin 0.80 LMM 89 Nysen Ruth AAP predoc 1.00 CenStat 90 Ogunjimi, Benson BAP predoc 1.00 CEV 91 Paasch, Fabienne BAP predoc 1.00 LMM 92 Panis,Thomas BAP predoc 1.00 CEV 93 Ponsaerts,Peter BAP postdoc FWO 1.00 LEH 94 Pramana Setia BAP predoc 1.00 CenStat 95 Praet Jelle BAP predoc 0.50 LEH 96 Prenen Leen AAP predoc 1.00 CenStat 97 Quisquater Charlotte ATP technician 1.00 LEH 98 Reekmans,Kristien BAP predoc 1.00 LEH


111

Nr Naam Label Level FTE Affiliation 99 Sabbe, Martine BAP predoc 1.00 CEV 100 Schroyens,Wilfried ZAP hfd.docent 0.10 LEH 101 Shkedy Ziv ZAP docent 1.00 CenStat 102 Smits,Evelien BAP postdoc nav 1.00 LEH 103 Sotto Cristina AAP postdoc 1.00 CenStat 104 Stein Barbara ATP technician 1.00 LEH 105 Stroobants Rudi BAP consultant 0.50 LMM 106 Struyven,Anne ATP admin 1.00 LMM 107 Suykens,Leen BAP scient pers 1.00 CEV 108 Tack,Sue ATP admin 0.60 CEV 109 Tambuyzer,Bart BAP postdoc 1.00 LEH 110 Teshome Ayele Birhanu BAP predoc 1.00 CenStat 111 Theeten,Heidi AAP predoc 1.00 CEV 112 Thijs Herbert BAP postdoc 1.00 CenStat 113 Vael,Carl BAP predoc 1.00 LMM 114 Van Bockstaele,Dirk R BAP gastprof 1.00 LEH 115 Van Camp,Kirsten ATP technician 1.00 LEH 116 Van Damme,Pierre ZAP hoogleraar 1.00 CEV 117 Van de Velde,Ann BAP lesgever 1.00 LEH 118 Van Der Planken,Marc BAP lesgever 1.00 LEH 119 Van Driessche Ann BAP predoc 1.00 LEH 120 Van Heirstraeten,Liesbet BAP predoc 1.00 LMM 121 Van Herck Koen ZAP docent 0.10 CEV 122 Van Kerckhove, Kim AAP predoc 1.00 CenStat 123 Van kerckhoven,Margaretha ATP admin 0.70 LMM 124 Van Tendeloo,Vigor ZAPBOF docent 1.00 LEH 125 Van Winckel,Anna ATP technician 1.00 CEV 126 Van den Eynde Sandy ATP technician 1.00 LEH 127 Vanderstraeten,Anouk ATP technician 1.00 LMM 128 Vanhommerig,Evelyn AAP predoc 1.00 LMM 129 Vankerckhoven,Vanessa BAP postdoc nav 1.00 Vaxinfectio 130 Van Sanden, Suzy AAP postdoc 1.00 CenStat 131 Vercauteren,Greetje ATP technician 1.00 LMM 132 Vermeulen,Katrien BAP postdoc nav 1.00 LEH 133 Versporten, Ann BAP predoc 1.00 LMM 134 Vervoort,Jascha BAP predoc 1.00 LMM 135 Verwimp Gino ATP admin 1.00 CEV 136 Vorsters,Alex ATP admin 1.00 CEV 137 Wijdooghe,Monique ATP technician 0.52 LMM 138 Willem, Lander BAP predoc 1.00 CEV 139 Willemen, Yannick BAP predoc 1.00 LEH 140 Zarb Peter BAP predoc 0.50 LMM 141 Zhu Qi BAP predoc 1.00 CenStat

methusalem report 2010 final - universiteit hasselt · headed: samuel coenen (100% bap research...

Documents